{
    "questions": [
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19587630",
                "http://www.ncbi.nlm.nih.gov/pubmed/14692188",
                "http://www.ncbi.nlm.nih.gov/pubmed/23425047",
                "http://www.ncbi.nlm.nih.gov/pubmed/1600579",
                "http://www.ncbi.nlm.nih.gov/pubmed/29478615",
                "http://www.ncbi.nlm.nih.gov/pubmed/32657748",
                "http://www.ncbi.nlm.nih.gov/pubmed/22041820",
                "http://www.ncbi.nlm.nih.gov/pubmed/26854064",
                "http://www.ncbi.nlm.nih.gov/pubmed/20082463",
                "http://www.ncbi.nlm.nih.gov/pubmed/8880865"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19587630",
                    "offsetInBeginSection": 235,
                    "offsetInEndSection": 317,
                    "text": "NF1 is the most common neurogenetic disorder, with a birth incidence of 1 in 3000.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14692188",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 191,
                    "text": "Neurofibromatosis (NF) type I (NF1) is the most common familial cancer-predisposing syndrome in humans, while type 2 (NF2) accounts for an extremely small percentage of the total cases of NF.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23425047",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 232,
                    "text": "The neurofibromatoses (neurofibromatosis type 1, NF1 and neurofibromatosis type 2, NF2) comprise the most common inherited conditions in which affected children and adults develop tumors of the central and peripheral nervous system.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1600579",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 186,
                    "text": "Neurofibromatosis (NF) is a serious, common, genetically determined neurological disorder; with a prevalence of about 1:4000 births it affects both sexes and all races and ethnic groups.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29478615",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 328,
                    "text": "The neurofibromatoses are a group of three heterogeneous disorders that include neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis. NF1 is the most common of these three conditions, and represents one of the most frequently diagnosed cancer predisposition disorders involving the nervous system.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32657748",
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 269,
                    "text": "With respective incidences of 1 in 3000, 1 in 33 000, and 1 in 60 000 births, they form part of the group of rare tumor-suppressor syndromes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22041820",
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 191,
                    "text": "NF1 has a birth incidence of one in 2500, and NF2 one in 25000.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26854064",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 181,
                    "text": "The neurofibromatoses (NF) are a group of rare genetic disorders that can affect all races equally at an incidence from 1:3000 (NF1) to a log unit lower for NF2 and schwannomatosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20082463",
                    "offsetInBeginSection": 618,
                    "offsetInEndSection": 710,
                    "text": "Disease prevalence in order of frequency were for neurofibromatosis type 1 (NF1): 1 in 4,560",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8880865",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 244,
                    "text": "Neurofibromatosis 1 and 2 (NF1 and NF2) are autosomal dominantly inherited disorders with close to 100% penetrance. NF1 is one of the most frequent human genetic diseases with an incidence of 1:3000. The incidence of NF2 is about 10 fold lower.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the prevalence of neurofibromatosis?",
            "type": "factoid",
            "id": "6616547dfdcbea915f00004f",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/32447296",
                "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
                "http://www.ncbi.nlm.nih.gov/pubmed/37445743",
                "http://www.ncbi.nlm.nih.gov/pubmed/35854236",
                "http://www.ncbi.nlm.nih.gov/pubmed/37593242",
                "http://www.ncbi.nlm.nih.gov/pubmed/36878562",
                "http://www.ncbi.nlm.nih.gov/pubmed/34717193",
                "http://www.ncbi.nlm.nih.gov/pubmed/35688951",
                "http://www.ncbi.nlm.nih.gov/pubmed/37559727",
                "http://www.ncbi.nlm.nih.gov/pubmed/36759214"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32447296",
                    "offsetInBeginSection": 383,
                    "offsetInEndSection": 654,
                    "text": "The CALLA trial is designed to determine the efficacy and safety of the programmed cell death-ligand 1 blocking antibody, durvalumab, with and following concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in women with locally advanced cervical cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
                    "offsetInBeginSection": 323,
                    "offsetInEndSection": 461,
                    "text": "We assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
                    "offsetInBeginSection": 2555,
                    "offsetInEndSection": 2912,
                    "text": "Durvalumab concurrent with chemoradiotherapy was well tolerated in participants with locally advanced cervical cancer, however it did not significantly improve progression-free survival in a biomarker unselected, all-comers population. Concurrent durvalumab plus chemoradiotherapy warrants further exploration in patients with high tumoral PD-L1 expression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37445743",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "text": "We conducted a phase Ib study to examine the safety of a combination of carbon-ion RT (CIRT) with durvalumab (MEDI4736; AstraZeneca) in patients with locally advanced cervical cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35854236",
                    "offsetInBeginSection": 309,
                    "offsetInEndSection": 502,
                    "text": "This single-arm phase II study aims to explore the efficacy and tolerability of combining PD-L1 inhibitor with concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37593242",
                    "offsetInBeginSection": 445,
                    "offsetInEndSection": 548,
                    "text": "Immune checkpoint inhibitors are a promising therapeutic strategy for locally advanced cervical cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36878562",
                    "offsetInBeginSection": 585,
                    "offsetInEndSection": 803,
                    "text": "Interestingly, the clinical development of immunotherapy in cervical cancer is currently advancing to the locally advanced setting, although preliminary efficacy outcomes in this setting have been disappointing so far.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34717193",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 352,
                    "text": "Cervical cancer is the fourth most common malignant tumor in the world, for advanced cervical cancer, more than 30% of patients continue to have tumor and relapse or metastasis after the traditional treatment (concurrent chemoradiotherapy), and the response rate of immune checkpoint inhibitor (PD-1) is less 15%, so additional approaches are required.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35688951",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "text": "PD-1/PD-L1 inhibitor treatments are relatively inefficacious in advanced cervical cancer patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37559727",
                    "offsetInBeginSection": 596,
                    "offsetInEndSection": 774,
                    "text": "Therefore, multiple types of anti-PD-1 have entered clinical trials successively and evaluated the efficacy in combination with chemotherapy, targeted therapy, and immunotherapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is Durvalumab effective for locally advanced cervical cancer?",
            "type": "yesno",
            "id": "65d3715b1930410b13000046",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21353345",
                "http://www.ncbi.nlm.nih.gov/pubmed/7813093",
                "http://www.ncbi.nlm.nih.gov/pubmed/33243685",
                "http://www.ncbi.nlm.nih.gov/pubmed/34513391",
                "http://www.ncbi.nlm.nih.gov/pubmed/21341220",
                "http://www.ncbi.nlm.nih.gov/pubmed/19081517",
                "http://www.ncbi.nlm.nih.gov/pubmed/34315269",
                "http://www.ncbi.nlm.nih.gov/pubmed/28689466",
                "http://www.ncbi.nlm.nih.gov/pubmed/21348771",
                "http://www.ncbi.nlm.nih.gov/pubmed/9429127"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21353345",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 272,
                    "text": "The Lennox-Gastaut syndrome (LGS) is one of the most severe epileptic encephalopathies of childhood, characterized by electro-clinical triad of generalized spike-wave activity, slow (POL) in the electroencephalogram (EEG), multiple types of seizures and development delay.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7813093",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "text": "The Lennox-Gastaut syndrome (LGS) is an electro-clinical syndrome of early childhood that consists of mental retardation, intractable generalized epilepsy with multiple seizure types, and typical EEG findings.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33243685",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 240,
                    "text": "Lennox-Gastaut syndrome (LGS) is a childhood-onset epileptic encephalopathy characterized by multiple types of medically intractable seizures, cognitive impairment, and generalized slow spike-wave discharges in electroencephalography (EEG).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34513391",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 307,
                    "text": "Lennox-Gastaut syndrome (LGS) is a childhood epilepsy disorder seen between the ages of one to eight years with the electroencephalogram (EEG) changes showing slow spiked-wave complex bursts or paroxysms of generalized fast activity and intellectual disability and often needing multiple lines of treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21341220",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "text": "Lennox-Gastaut syndrome (LGS) is an epileptic encephalopathy that starts in childhood and has an unknown pathophysiological mechanism.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19081517",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "text": "Lennox-Gastaut syndrome is one of the most severe epileptic encephalopathies of childhood onset.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19081517",
                    "offsetInBeginSection": 97,
                    "offsetInEndSection": 231,
                    "text": "The cause of this syndrome can be symptomatic (ie, secondary to an underlying brain disorder) or cryptogenic (ie, has no known cause).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19081517",
                    "offsetInBeginSection": 232,
                    "offsetInEndSection": 547,
                    "text": "Although Lennox-Gastaut syndrome is commonly characterised by a triad of signs, which include multiple seizure types, slow spike-wave complexes on electroencephalographic (EEG) recordings, and impairment of cognitive function, there is debate with regard to the precise limits, cause, and diagnosis of the syndrome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19081517",
                    "offsetInBeginSection": 548,
                    "offsetInEndSection": 722,
                    "text": "Tonic seizures, which are thought to be a characteristic sign of Lennox-Gastaut syndrome, are not present at onset and the EEG features are not pathognomonic of the disorder.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19081517",
                    "offsetInBeginSection": 723,
                    "offsetInEndSection": 862,
                    "text": "There are few effective treatment options for the multiple seizures and comorbidities, and the long-term outlook is poor for most patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is Lennox-Gastaut syndrome?",
            "type": "summary",
            "id": "661be07748a2c27714000002",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
                "http://www.ncbi.nlm.nih.gov/pubmed/19995375",
                "http://www.ncbi.nlm.nih.gov/pubmed/9500554",
                "http://www.ncbi.nlm.nih.gov/pubmed/12235125",
                "http://www.ncbi.nlm.nih.gov/pubmed/17000761",
                "http://www.ncbi.nlm.nih.gov/pubmed/33940580",
                "http://www.ncbi.nlm.nih.gov/pubmed/16757562",
                "http://www.ncbi.nlm.nih.gov/pubmed/10707962",
                "http://www.ncbi.nlm.nih.gov/pubmed/12519122",
                "http://www.ncbi.nlm.nih.gov/pubmed/18628967"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
                    "offsetInBeginSection": 141,
                    "offsetInEndSection": 272,
                    "text": "Microphthalmia-associated transcription factor (MITF) is a key transcription factor for melanocyte development and differentiation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19995375",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 276,
                    "text": "Microphthalmia-associated transcription factor (MITF) was initially shown to play a key role in melanocyte differentiation through the direct transcriptional control of TYROSINASE, TYRP1 and DCT genes, encoding the three enzymes involved in melanin synthesis or melanogenesis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9500554",
                    "offsetInBeginSection": 355,
                    "offsetInEndSection": 519,
                    "text": "We have previously shown that MITF transactivates the gene for tyrosinase, a key enzyme for melanogenesis, and is critically involved in melanocyte differentiation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12235125",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "text": "The transcription factor Microphthalmia-associated transcription factor (MITF) is a lineage-determination factor, which modulates melanocyte differentiation and pigmentation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17000761",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 302,
                    "text": "Commitment to the melanocyte lineage is characterized by the onset of expression of the microphthalmia-associated transcription factor (Mitf). This transcription factor plays a fundamental role in melanocyte development and maintenance and seems to be crucial for the survival of malignant melanocytes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33940580",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "text": "Although microphthalmia-associated transcription factor (MITF) has been known for decades as a key regulator for melanocytic differentiation",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16757562",
                    "offsetInBeginSection": 274,
                    "offsetInEndSection": 520,
                    "text": "In both zebrafish and mice, one transcription factor, SOX10, controls the expression of another, MITF (microphthalmia-associated transcription factor), which in turn regulates a set of genes critical for pigment cell development and pigmentation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10707962",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 258,
                    "text": "Microphthalmia gene encodes a basic helix-loop-helix-leucine zipper (bHLH-Zip) transcription factor involved in the development of the melanocyte lineage and plays a key role in the transcriptional regulation of the melanogenic enzymes, tyrosinase and TyrpI.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12519122",
                    "offsetInBeginSection": 530,
                    "offsetInEndSection": 904,
                    "text": "In this study, we utilized primary cultures of neural crest cells and an immortalized melanocyte cell line (DMEL-2) which proliferates in the absence of TPA, to explore the effects of TPA on key melanogenic effectors. In neural crest cells, TPA was found to be necessary for both microphthalmia associated transcription factor (Mitf) up-regulation and for melanin synthesis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18628967",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 340,
                    "text": "The Microphthalmia-associated transcription factor (MITF) is an important regulator of cell-type specific functions in melanocytic cells. MITF is essential for the survival of pigmented cells, but whereas high levels of MITF drive melanocyte differentiation, lower levels are required to permit proliferation and survival of melanoma cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the key transcription factor for melanocyte development and differentiation?",
            "type": "factoid",
            "id": "661d96c9eac11fad33000028",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [],
            "snippets": [],
            "body": "Why does rectal cancer have worse prognosis than other colon tumors?",
            "type": "summary",
            "id": "660998ecfdcbea915f000014",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/9276706",
                "http://www.ncbi.nlm.nih.gov/pubmed/12772515",
                "http://www.ncbi.nlm.nih.gov/pubmed/11521792",
                "http://www.ncbi.nlm.nih.gov/pubmed/18019695",
                "http://www.ncbi.nlm.nih.gov/pubmed/16965660",
                "http://www.ncbi.nlm.nih.gov/pubmed/18069642",
                "http://www.ncbi.nlm.nih.gov/pubmed/16734265",
                "http://www.ncbi.nlm.nih.gov/pubmed/30820266",
                "http://www.ncbi.nlm.nih.gov/pubmed/20945037",
                "http://www.ncbi.nlm.nih.gov/pubmed/11066136"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9276706",
                    "offsetInBeginSection": 81,
                    "offsetInEndSection": 638,
                    "text": "The present review revealed that hepatic resection is the best treatment modality, although the overall survival rate after hepatectomy for metastatic colorectal cancer is still low (20-40%). Various prognostic factors analyzed by many authors are controversial. The number of hepatic metastases and the surgical margin were the most important prognostic factors, as seen in 10 papers previously reported including our data. A clear surgical margin is achievable, but the prognosis of patients with four or more metastatic nodules in the liver remains poor.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12772515",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 77,
                    "text": "Liver metastases develop in 50% to 60% of patients with colorectal carcinoma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11521792",
                    "offsetInBeginSection": 582,
                    "offsetInEndSection": 970,
                    "text": "The five-year survival rate after surgical resection varies from 20% to 45% according to several prognostic factors. The longer survival is observed in patients with fewer than four lesions, with lesions smaller than 4 cm, without extra-hepatic disease, with lesions that appeared more than two years after the resection of a stage I or II colorectal cancer and whose CEA level is normal.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18019695",
                    "offsetInBeginSection": 73,
                    "offsetInEndSection": 188,
                    "text": "The efficacy of resection of metastatic lesions in liver metastasis of colorectal cancer is also widely recognized.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16965660",
                    "offsetInBeginSection": 666,
                    "offsetInEndSection": 1088,
                    "text": "Univariate analysis revealed that extrahepatic invasion, primary tumor resection, liver metastasis resection, type of primary tumor, serum CEA concentration, number and size of liver metastases, and distribution of liver metastases were associated with prognosis. Multivariate analysis identified that the resection of liver metastases, serum CEA concentration, number and size of liver metastases were prognostic factors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18069642",
                    "offsetInBeginSection": 899,
                    "offsetInEndSection": 1070,
                    "text": "Multivariate analysis showed that liver metastasis resection, abdominal carcinomatosis, chemotherapy and intervention treatment were the most important prognostic factors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16734265",
                    "offsetInBeginSection": 838,
                    "offsetInEndSection": 1271,
                    "text": "Favorable patient selection criteria for liver resection are: 1) medical fitness for hepatectomy; 2) radical resection of the primary colorectal lesion; 3) metastatic tumors anatomically confined within the liver allowing adequate preservation of the liver parenchyma; 4) no signs of disseminated disease; 5) no signs of hepatic lymph node metastases; 6) four or fewer metastatic tumors; and 7) resection margins of 10 mm or greater.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30820266",
                    "offsetInBeginSection": 389,
                    "offsetInEndSection": 459,
                    "text": "Surgical resection is the only treatment modality for curative intent.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30820266",
                    "offsetInBeginSection": 929,
                    "offsetInEndSection": 996,
                    "text": "The role of neoadjuvant and adjuvant chemotherapy is still debated.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20945037",
                    "offsetInBeginSection": 765,
                    "offsetInEndSection": 1170,
                    "text": "Univariate analysis indicated that degree of primary tumor differentiation, resection margin, preoperative carcinoembryonic antigen (CEA) level, number of liver metastases, and resection of liver metastases were associated with prognosis (P < 0.05). In multivariate analysis, the last three factors were found to be independent prognostic factors. The resection of liver metastases was a favorable factor.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What clinical conditions influence the prognostic after the liver metastasis resection from colorectal cancer patients?",
            "type": "list",
            "id": "66099c57fdcbea915f000025",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [],
            "snippets": [],
            "body": "What is borderline personality disorder?",
            "type": "summary",
            "id": "66150366fdcbea915f000046",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27175306",
                "http://www.ncbi.nlm.nih.gov/pubmed/18566668",
                "http://www.ncbi.nlm.nih.gov/pubmed/35405047",
                "http://www.ncbi.nlm.nih.gov/pubmed/10527663",
                "http://www.ncbi.nlm.nih.gov/pubmed/28182360",
                "http://www.ncbi.nlm.nih.gov/pubmed/19629656",
                "http://www.ncbi.nlm.nih.gov/pubmed/32039316",
                "http://www.ncbi.nlm.nih.gov/pubmed/14726806",
                "http://www.ncbi.nlm.nih.gov/pubmed/35854334",
                "http://www.ncbi.nlm.nih.gov/pubmed/33970801"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27175306",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 158,
                    "text": "Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine metabolism, which is caused by mutation in phenylalanine hydroxylase (PAH) gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18566668",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 270,
                    "text": "Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine (Phe) metabolism resulting from deficiency of phenylalanine hydroxylase (PAH). Most forms of PKU and hyperphenylalaninaemia (HPA) are caused by mutations in the PAH gene on chromosome 12q23.2.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35405047",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 121,
                    "text": "Phenylketonuria (PKU) is an autosomal recessive disorder of phenylalanine metabolism, mostly caused by PAH gene variants.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10527663",
                    "offsetInBeginSection": 446,
                    "offsetInEndSection": 591,
                    "text": "The autosomal recessive disease phenylketonuria (PKU) is the result of a deficiency of PheOH enzymatic activity due to mutations in the PAH gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28182360",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "text": "Deficiency of phenylalanine hydroxylase (PAH) enzyme and elevation of phenylalanine in body fluids cause phenylketonuria (PKU).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19629656",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "text": "Phenylketonuria (PKU), the most frequent disorder of amino acid metabolism, is caused by mutations in human phenylalanine hydroxylase gene (PAH), leading to deficient enzyme activity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32039316",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 81,
                    "text": "Phenylketonuria (PKU) is caused by phenylalanine hydroxylase (PAH) gene variants.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14726806",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 121,
                    "text": "Phenylketonuria (PKU) is an autosomal recessive disorder caused by mutations in the phenylalanine hydroxylase (PAH) gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35854334",
                    "offsetInBeginSection": 116,
                    "offsetInEndSection": 280,
                    "text": "PKU, an autosomal recessive disease, is an inborn error of phenylalanine (Phe) metabolism caused by pathogenic variants in the phenylalanine hydroxylase (PAH) gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33970801",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "text": "Phenylketonuria is an autosomal recessive disorder caused by mutations in the phenylalanine hydroxylase gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the cause of Phenylketonuria (PKU)?",
            "type": "factoid",
            "id": "661d48a2eac11fad33000018",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/38032456",
                "http://www.ncbi.nlm.nih.gov/pubmed/34937485",
                "http://www.ncbi.nlm.nih.gov/pubmed/37095249",
                "http://www.ncbi.nlm.nih.gov/pubmed/37616235",
                "http://www.ncbi.nlm.nih.gov/pubmed/38070539",
                "http://www.ncbi.nlm.nih.gov/pubmed/37082704",
                "http://www.ncbi.nlm.nih.gov/pubmed/32726528",
                "http://www.ncbi.nlm.nih.gov/pubmed/37641189",
                "http://www.ncbi.nlm.nih.gov/pubmed/37824423",
                "http://www.ncbi.nlm.nih.gov/pubmed/38085019"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38032456",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 203,
                    "text": "Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34937485",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "text": "Respiratory syncytial virus (RSV) is a leading cause of serious lower respiratory tract infection (LRTI) in infants and young children.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34937485",
                    "offsetInBeginSection": 357,
                    "offsetInEndSection": 504,
                    "text": "Nirsevimab (MEDI8897) is a monoclonal antibody with an extended half-life developed to protect infants for an entire RSV season with a single dose.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34937485",
                    "offsetInBeginSection": 856,
                    "offsetInEndSection": 1035,
                    "text": "Nirsevimab (MEDI8897) is an RSV F protein monoclonal antibody and the next-generation RSV medicine having an extended half-life developed for the prevention of LRTI caused by RSV.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37095249",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "text": "Nirsevimab is an extended half-life monoclonal antibody specific for the prefusion conformation of the respiratory syncytial virus (RSV) F protein",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37616235",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 315,
                    "text": "Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting monoclonal antibody, for passive immunization to prevent RSV-associated lower respiratory tract infection among infants and young children.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38070539",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "text": "Respiratory syncytial virus (RSV) infects nearly all infants in their first year of life and is the leading cause of hospitalization for infants younger than 1 year of age in the United States.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38070539",
                    "offsetInBeginSection": 376,
                    "offsetInEndSection": 536,
                    "text": "In July 2023, the U.S. Food and Drug Administration approved nirsevimab for the prevention of RSV-associated lower respiratory tract infections for all infants.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37082704",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 155,
                    "text": "Respiratory syncytial virus (RSV) is a leading cause of morbidity and mortality among infants with a global incidence of 9.5% and a mortality rate of 2.2%.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32726528",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 332,
                    "text": "Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention of RSV in healthy infants. Nirsevimab is a monoclonal antibody with an extended half-life that is being developed to protect infants for an entire RSV season with a single intramuscular dose.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which disease is treated with nirsevimab?",
            "type": "factoid",
            "id": "65cebc0c1930410b13000003",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27125181",
                "http://www.ncbi.nlm.nih.gov/pubmed/29687491",
                "http://www.ncbi.nlm.nih.gov/pubmed/30833837",
                "http://www.ncbi.nlm.nih.gov/pubmed/31085000",
                "http://www.ncbi.nlm.nih.gov/pubmed/26652537",
                "http://www.ncbi.nlm.nih.gov/pubmed/26290839",
                "http://www.ncbi.nlm.nih.gov/pubmed/26131745",
                "http://www.ncbi.nlm.nih.gov/pubmed/26617788",
                "http://www.ncbi.nlm.nih.gov/pubmed/22563345",
                "http://www.ncbi.nlm.nih.gov/pubmed/28252349"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27125181",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "text": "Loeys-Dietz syndrome due to mutations in TGFBR1 and 2 is associated with early and aggressive aortic aneurysm and branch vessel disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29687491",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 192,
                    "text": "Aortic aneurysms in childhood are rare disease entities and are usually seen in patients with genetic connective tissue disorders such as Marfans, Ehler-Danlos, and Loeys-Dietz syndrome (LDS).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30833837",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 202,
                    "text": "Loeys-Dietz syndrome is a genetic disorder that predisposes patients to aortic aneurysms. If left untreated, the natural history of the associated aortopathy often culminates in fatal aortic dissection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31085000",
                    "offsetInBeginSection": 154,
                    "offsetInEndSection": 376,
                    "text": "Loeys-Dietz syndrome is a connective tissue disorder characterized by aortic aneurysms, arterial tortuosity, and aortic dissections. It is caused by mutations in the genes affecting the transforming growth factor  pathway.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26652537",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 95,
                    "text": "Loeys-Dietz syndrome presents early in life with rapidly progressive aortic aneurysmal disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26290839",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 194,
                    "text": "Loeys-Dietz syndrome (LDS) is an autosomal dominant connective tissue disorder that is characterized by aggressive arterial and aortic disease, often involving the formation of aortic aneurysms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26131745",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "Loeys-Dietz syndrome is a connective tissue disorder accompanied by life-threatening vascular abnormalities such as aneurysms and dissections.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26617788",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "text": "Loeys-Dietz syndrome (LDS) is an autosomal dominant genetic connective tissue disorder, and most of LDS patients will develop into aortic aneurysm.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22563345",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 304,
                    "text": "Loeys-Dietz syndrome is a recently described autosomal dominant disorder caused by mutations in the genes for transforming growth factor-beta receptor type 1 or 2 (TGF-R 1/2). The syndrome predisposes patients to aortic aneurysm and dissections, along with craniofacial and musculoskeletal abnormalities.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28252349",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 168,
                    "text": "Loeys-Dietz syndrome (LDS) is characterised by a mutation in the transforming growth factor beta receptor, and is strongly associated with aortic aneurysms and rupture.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is Loeys-Dietz syndrome (LDS) associated with Aortic Aneurysm?",
            "type": "yesno",
            "id": "661a6733fdcbea915f00005c",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23205026",
                "http://www.ncbi.nlm.nih.gov/pubmed/23904181",
                "http://www.ncbi.nlm.nih.gov/pubmed/8308357",
                "http://www.ncbi.nlm.nih.gov/pubmed/35322345"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23205026",
                    "offsetInBeginSection": 1162,
                    "offsetInEndSection": 1341,
                    "text": "Two tests are used - the burrow ink test and handheld dermatoscopy. The burrow ink test is a simple, rapid, noninvasive test that can be used to screen a large number of patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23904181",
                    "offsetInBeginSection": 443,
                    "offsetInEndSection": 656,
                    "text": "The diagnosis is based mainly on history and physical examination, but definitive diagnosis depends on direct visualization of the mites under microscopy. Alternative diagnostic methods include the burrow ink test",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8308357",
                    "offsetInBeginSection": 879,
                    "offsetInEndSection": 942,
                    "text": "Burrow Ink Test was positive among 85% of patients with burrows",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35322345",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 73,
                    "text": "The Burrow Ink Test: a Simple Method to Improve the Diagnosis of Scabies.",
                    "beginSection": "title",
                    "endSection": "title"
                }
            ],
            "body": "Burrow Ink Test can be used to diagnose which disease?",
            "type": "factoid",
            "id": "65cfcd541930410b13000019",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [],
            "snippets": [],
            "body": "How is Huntington's Disease inherited?",
            "type": "summary",
            "id": "661d62dceac11fad33000026",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21503684",
                "http://www.ncbi.nlm.nih.gov/pubmed/22649425",
                "http://www.ncbi.nlm.nih.gov/pubmed/22476979",
                "http://www.ncbi.nlm.nih.gov/pubmed/27062924",
                "http://www.ncbi.nlm.nih.gov/pubmed/17163418",
                "http://www.ncbi.nlm.nih.gov/pubmed/22115363",
                "http://www.ncbi.nlm.nih.gov/pubmed/22313737",
                "http://www.ncbi.nlm.nih.gov/pubmed/27791031",
                "http://www.ncbi.nlm.nih.gov/pubmed/30206966",
                "http://www.ncbi.nlm.nih.gov/pubmed/26541755"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21503684",
                    "offsetInBeginSection": 133,
                    "offsetInEndSection": 247,
                    "text": "FOXA1 expression correlates with estrogen receptor (ER)-positivity especially in luminal subtype A breast cancers.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22649425",
                    "offsetInBeginSection": 120,
                    "offsetInEndSection": 298,
                    "text": "FoxA1 acts as a pioneer factor for both androgen receptor (AR) and estrogen receptor- (ER), dictating the binding location, and therefore function of these transcription factors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22649425",
                    "offsetInBeginSection": 299,
                    "offsetInEndSection": 445,
                    "text": "It is an essential protein for the transcriptional activity of both ER and AR, yet it has distinct roles with the two different nuclear receptors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22649425",
                    "offsetInBeginSection": 446,
                    "offsetInEndSection": 568,
                    "text": "In both malignancies, FoxA1 plays a pivotal role from early stage cancer through to drug resistant and metastatic disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22649425",
                    "offsetInBeginSection": 569,
                    "offsetInEndSection": 726,
                    "text": "Due to this key role in mediating ER and AR function, FoxA1 is not only an attractive therapeutic target but could potentially function as a novel biomarker.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22476979",
                    "offsetInBeginSection": 1056,
                    "offsetInEndSection": 1395,
                    "text": "The nuclear immunoreactivity of FOXA1 was detected in 80 (74%) of 108 human invasive breast cancers and was negatively correlated with tumor grade and positively correlated with hormone receptor status, including ER and progesterone receptor, pathological tumor size, and immunoreactivity of FOXP1, another FOX family transcription factor.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22476979",
                    "offsetInBeginSection": 1396,
                    "offsetInEndSection": 1512,
                    "text": "FOXA1 immunoreactivity was significantly elevated in the relapse-free breast cancer patients treated with tamoxifen.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27062924",
                    "offsetInBeginSection": 147,
                    "offsetInEndSection": 264,
                    "text": "FoxA1 has been implicated in establishing ER-binding patterns though its unique ability to serve as a pioneer factor.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17163418",
                    "offsetInBeginSection": 348,
                    "offsetInEndSection": 486,
                    "text": "Forced expression of FOXA1 inhibited clonal growth of breast cancer cell lines, and FOXA1 levels inversely correlated with growth stimuli.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17163418",
                    "offsetInBeginSection": 487,
                    "offsetInEndSection": 615,
                    "text": "In the estrogen receptor (ER)-positive MCF-7 cells, FOXA1 increased p27 promoter activity and inhibited the ER pathway activity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the role of the FOXA1 transcription factor in estrogen-receptor-positive (ER+) breast cancer?",
            "type": "summary",
            "id": "661d9cc3eac11fad33000029",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37426456",
                "http://www.ncbi.nlm.nih.gov/pubmed/35536244"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37426456",
                    "offsetInBeginSection": 821,
                    "offsetInEndSection": 1454,
                    "text": "Recently, Hyena, a large language model based on implicit convolutions was shown to match attention in quality while allowing longer context lengths and lower time complexity. Leveraging Hyena's new long-range capabilities, we present HyenaDNA, a genomic foundation model pretrained on the human reference genome with context lengths of up to 1 million tokens at the single nucleotide-level - an up to 500x increase over previous dense attention-based models. HyenaDNA scales sub-quadratically in sequence length (training up to 160x faster than Transformer), uses single nucleotide tokens, and has full global context at each layer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35536244",
                    "offsetInBeginSection": 281,
                    "offsetInEndSection": 617,
                    "text": "Here, we present LOGO (Language of Genome), a self-attention based contextualized pre-trained language model containing only two self-attention layers with 1 million parameters as a substantially light architecture that applies self-supervision techniques to learn bidirectional representations of the unlabelled human reference genome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which DNA language models currently exist to model the human genome?",
            "type": "list",
            "id": "661c41d448a2c27714000009",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19452131",
                "http://www.ncbi.nlm.nih.gov/pubmed/24347989",
                "http://www.ncbi.nlm.nih.gov/pubmed/17239286",
                "http://www.ncbi.nlm.nih.gov/pubmed/34362003",
                "http://www.ncbi.nlm.nih.gov/pubmed/33378750",
                "http://www.ncbi.nlm.nih.gov/pubmed/31803963",
                "http://www.ncbi.nlm.nih.gov/pubmed/22250636",
                "http://www.ncbi.nlm.nih.gov/pubmed/33028137",
                "http://www.ncbi.nlm.nih.gov/pubmed/25037801",
                "http://www.ncbi.nlm.nih.gov/pubmed/33910927"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19452131",
                    "offsetInBeginSection": 823,
                    "offsetInEndSection": 1919,
                    "text": "The goal of managing EGFR inhibitor-associated skin toxicity is to minimize the detrimental effects of the rash on patients' quality of life and treatment course without antagonizing the clinical efficacy of EGFR inhibitors. There is currently no evidence-based treatment guideline to prevent or treat the EGFR inhibitor-associated skin toxicities. Expert panels recommend a proactive, multidisciplinary approach that includes patient education and the use of a grade-based treatment algorithm. Elucidation of the mechanisms of EGFR inhibitor-associated skin toxicity and development of mechanism-based novel therapies are urgently needed. Preclinical data suggest topical application of a potent phosphatase inhibitor menadione (Vitamin K3) can rescue the inhibition of EGFR and downstream signaling molecules in the skin of mice receiving systemic EGFR inhibitor erlotinib or cetuximab. A randomized, double-blinded, placebo-controlled study has been initiated to evaluate the clinical efficacy of menadione topical cream, in the treatment or prevention of EGFR inhibitor-induced skin toxicity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24347989",
                    "offsetInBeginSection": 1220,
                    "offsetInEndSection": 1502,
                    "text": "Based on randomized data, recent guidelines established by the Multinational Association for Supportive Care in Cancer Skin Toxicity Study Group suggest that prophylactic use of oral doxycycline or minocycline reduces the risk and severity of skin rash, improving clinical outcomes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17239286",
                    "offsetInBeginSection": 633,
                    "offsetInEndSection": 1608,
                    "text": "Several trials evaluating anti-EGFR therapies have reported a positive correlation between rash and response and even rash and survival. If rash is truly a predictor of outcome, it becomes imperative that clinicians identify effective methods for managing this toxicity to avoid unwanted dose reduction, therapy interruption, delay, or discontinuation in patients experiencing a therapeutic benefit. Unfortunately, because of a lack of well-defined rash etiology, variability of use, and interpretation of rash grading scales, as well as a lack of clinical trials evaluating approaches to rash management, we are left without systematic, evidence-based guidelines for treatment. Preliminary results of a prospective study evaluating a rash treatment algorithm developed at the University of Texas M. D. Anderson Cancer Center have been positive, and there is universal agreement that initiation of more prospective trials to evaluate EGFR-inhibitor rash management is needed.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34362003",
                    "offsetInBeginSection": 387,
                    "offsetInEndSection": 588,
                    "text": "The cutaneous adverse reactions induced by EGFR inhibitors, particularly papulopustular rash, often require long-term antibiotic treatment with tetracycline agents (mostly minocycline and doxycycline).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33378750",
                    "offsetInBeginSection": 1332,
                    "offsetInEndSection": 1462,
                    "text": "Prophylactic topical CHL-PRED was efficacious when compared to AQUA, in the treatment of EGFRI-induced facial papulopustular rash.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31803963",
                    "offsetInBeginSection": 1127,
                    "offsetInEndSection": 1286,
                    "text": "After treatment with topical and/or oral antibiotics without topical corticosteroids, the papulopustular rash rapidly improved by an average of 2.9  3.4 weeks.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22250636",
                    "offsetInBeginSection": 772,
                    "offsetInEndSection": 1008,
                    "text": "The treatment modalities prescribed were doxycycline and topical antibiotics for the papulopustular rash; topical high potency steroids, tacrolimus, pimecrolimus, and moisturizers for xerosis and eczema; and cetirizine for the pruritus.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33028137",
                    "offsetInBeginSection": 1799,
                    "offsetInEndSection": 2059,
                    "text": "In 22 patients, PPL side effects were observed in the skin; it was G1 in 19 patients and G2 in three patients. In seven patients who developed acneiform side effects, systemic doxycycline was used, and in others, topical tetracycline and clindamycin were used.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25037801",
                    "offsetInBeginSection": 306,
                    "offsetInEndSection": 577,
                    "text": "Tyrosine kinase inhibitors can cause edema and macular rash, whereas papulopustular rash, paronychia, regulatory changes in hair, itching, and dryness caused by epidermal growth factor receptor inhibitors (PRIDE) syndrome can be seen in patients treated with these drugs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33910927",
                    "offsetInBeginSection": 256,
                    "offsetInEndSection": 952,
                    "text": "We then conducted a phase I clinical trial testing the hypothesis that topical therapy with the BRAF inhibitor LUT014 could improve skin toxicities induced by EGFR inhibitors. Ten patients with metastatic colorectal cancer who had developed acneiform rash while being treated with cetuximab or panitumumab were enrolled in three cohorts. LUT014 was well tolerated, and there were no dose-limiting toxicities. The acneiform rash improved in the 6 patients who started with grade 2 rash in the low and intermediate cohorts. We conclude that topical LUT014 is safe and efficacious in improving rash from EGFR inhibitors, consistent with the mechanism of action inducting paradoxical MAPK activation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What drugs are effective for the treatment of EGFR inhibitors skin rash?",
            "type": "list",
            "id": "6609994bfdcbea915f000017",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36881966",
                "http://www.ncbi.nlm.nih.gov/pubmed/29078501",
                "http://www.ncbi.nlm.nih.gov/pubmed/31734479",
                "http://www.ncbi.nlm.nih.gov/pubmed/14579027",
                "http://www.ncbi.nlm.nih.gov/pubmed/27407553",
                "http://www.ncbi.nlm.nih.gov/pubmed/15318043",
                "http://www.ncbi.nlm.nih.gov/pubmed/36935229",
                "http://www.ncbi.nlm.nih.gov/pubmed/16982197",
                "http://www.ncbi.nlm.nih.gov/pubmed/35096458",
                "http://www.ncbi.nlm.nih.gov/pubmed/23816675"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36881966",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "text": "The minimally invasive repair of pectus excavatum (MIRPE), or Nuss procedure, is regarded as the gold standard technique for the treatment of symptomatic pectus excavatum.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078501",
                    "offsetInBeginSection": 477,
                    "offsetInEndSection": 970,
                    "text": "In the late 1990's, the operative approach was challenged with a new minimally invasive technique described by Dr. Donald Nuss. This approach utilizes thoracoscopic visualization with small incisions and placement of a temporary metal bar positioned behind the sternum for support it while the costal cartilages remodel. Since introduction, the minimally invasive repair of pectus excavatum (MIRPE) has become accepted in many centers as the procedure of choice for repair of pectus excavatum.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31734479",
                    "offsetInBeginSection": 69,
                    "offsetInEndSection": 186,
                    "text": "The minimally invasive repair of pectus excavatum (MIRPE) is the most commonly practiced method of surgical treatment",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14579027",
                    "offsetInBeginSection": 298,
                    "offsetInEndSection": 427,
                    "text": "This procedure was originally developed only for children and is based on the fact that the growing chest wall is still flexible.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27407553",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 245,
                    "text": "The technique of minimally invasive repair of pectus excavatum is a new operation that allows for repair of this deformity without any cartilage resection or sternal osteotomy. The procedure has revolutionized the management of pectus excavatum.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15318043",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "Surgical correction of pectus excavatum in children has gained new momentum since the introduction of the new minimally invasive repair by Nuss.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15318043",
                    "offsetInBeginSection": 259,
                    "offsetInEndSection": 466,
                    "text": "From 2000 to 2002, 28 patients underwent pectus excavatum correction in the authors' hospital. Twenty-one were treated by minimally invasive repair of pectus excavatum and seven patients had open correction.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15318043",
                    "offsetInBeginSection": 574,
                    "offsetInEndSection": 871,
                    "text": "In the minimally invasive repair of pectus excavatum group, the children were younger (14.4 +/- 2.9 versus 17.8 +/- 3.2 years), had shorter operation times (53 +/- 18 versus 125 +/- 6 minutes), and had less blood loss (minimal versus 380 +/- 175 ml). No intraoperative complications were recorded.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15318043",
                    "offsetInBeginSection": 1515,
                    "offsetInEndSection": 1650,
                    "text": "Minimally invasive repair of pectus excavatum is a novel method with clear advantages, such as limited surgical trauma and small scars.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36935229",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 199,
                    "text": "We aimed to determine the longitudinal changes in pulmonary functions of adolescents with Pectus Excavatum who underwent the Nuss procedure, the minimally invasive repair of pectus excavatum (MIRPE).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is MIRPE, also known as the Nuss procedure, considered to be an very invasive form of surgical treatment?",
            "type": "yesno",
            "id": "660810a0fdcbea915f000005",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12927292",
                "http://www.ncbi.nlm.nih.gov/pubmed/32073562",
                "http://www.ncbi.nlm.nih.gov/pubmed/9849684",
                "http://www.ncbi.nlm.nih.gov/pubmed/32152042",
                "http://www.ncbi.nlm.nih.gov/pubmed/11045383",
                "http://www.ncbi.nlm.nih.gov/pubmed/30056031",
                "http://www.ncbi.nlm.nih.gov/pubmed/15756796",
                "http://www.ncbi.nlm.nih.gov/pubmed/15602861",
                "http://www.ncbi.nlm.nih.gov/pubmed/12464851",
                "http://www.ncbi.nlm.nih.gov/pubmed/17493691"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12927292",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 289,
                    "text": "Before the antibiotic era, lateral sinus thrombosis (LST) was the most frequent complication of otitis media. With the widespread usage of antibiotics, its occurrence is rare. Nevertheless, it is still a major complication of middle ear disease. LST mortality fluctuates between 5 and 35%.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32073562",
                    "offsetInBeginSection": 846,
                    "offsetInEndSection": 1107,
                    "text": "The complications can be extracranial (subperiosteal abscess, Bezold's abscess); intratemporal (facial nerve palsy, labyrinthitis) and intracranial (subdural abscess). The complications have often a very serious clinical course and potentially life-threatening.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9849684",
                    "offsetInBeginSection": 130,
                    "offsetInEndSection": 353,
                    "text": "Acute mastoiditis is a serious complication of acute otitis media with potentially grave consequences and the epidural abscess constitutes the commonest of all intracranial complications, arising from middle ear infections.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32152042",
                    "offsetInBeginSection": 841,
                    "offsetInEndSection": 1035,
                    "text": "The incidence of brain abscess and acute mastoiditis following AOM were 0.03 (95% confidence interval [CI] = 0.01 to 0.20) and 5.62 (95% CI = 4.81 to 6.56) per 10 000 AOM episodes, respectively.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11045383",
                    "offsetInBeginSection": 802,
                    "offsetInEndSection": 986,
                    "text": "The most common complication of acute mastoiditis was hearing loss (31.6%); the second was meningitis (21.1%). Subperiosteal abscess was found in two patients and brain abscess in one.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30056031",
                    "offsetInBeginSection": 1405,
                    "offsetInEndSection": 1882,
                    "text": "The main points of the management protocol are: initiate a broad-spectrum intravenous antibiotic treatment; mastoidectomy should be performed if the infection fails to be controlled after 48h of administering intravenous antibiotic therapy. We believe that early mastoidectomy prevents serious complications, and our initial observation is that by performing broad mastoidectomy with posterior attic and facial recess exposure, recurrence of acute mastoiditis can be prevented.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15756796",
                    "offsetInBeginSection": 860,
                    "offsetInEndSection": 1059,
                    "text": "Early diagnosis and adequate treatment (surgery combined with an effective antibiotics therapy) is most important to prevent a serious complications of mastoiditis (extracranial and/or intracranial).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15602861",
                    "offsetInBeginSection": 494,
                    "offsetInEndSection": 598,
                    "text": "Despite its rarity, diagnosis of TAM is often delayed, with potentially danger for severe complications.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12464851",
                    "offsetInBeginSection": 638,
                    "offsetInEndSection": 733,
                    "text": "Lateral sinus thrombophlebitis was the most frequent complication, observed in 3 children (8%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17493691",
                    "offsetInBeginSection": 851,
                    "offsetInEndSection": 2107,
                    "text": "The percentage of surgical treatment grew from 4.3% to 33% in the last years and to 70% in 2005. Most cases (80%) have received prior antibacterial agent therapy, but individual pathogens and current complications of periostitis or subperiosteal abscess formation were equally distributed between the two groups. We have detected a 28.57% of Streptococcus pneumoniae and a significative high rate of Staphylococcus aureus (16.32%). A 53.68% of cases had negative cultures. There is a progressive increase in the incidence of acute mastoiditis in our medium, and an increase of the surgical treatments. Ten years ago the process was controlled with antibiotic therapy only, but now the number of interventions has been eight times the previous years. Most cases of acute mastoiditis have responded well to medical management alone. But if higher levels of resistance predominate, more severe forms of pneumococcal or other pathogen like S. aureus disease are likely to be seen, these would be less likely to respond to oral or parenteral antibiotic therapy, so, tympanocentesis for middle ear culture may become more valuable and more frequently used in cases of antibiotic treatment failures, and surgical therapy may be necessary more often in the future.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are major complications of mastoiditis?",
            "type": "list",
            "id": "66154a32fdcbea915f00004b",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36467887",
                "http://www.ncbi.nlm.nih.gov/pubmed/33419284",
                "http://www.ncbi.nlm.nih.gov/pubmed/23056680",
                "http://www.ncbi.nlm.nih.gov/pubmed/35637988",
                "http://www.ncbi.nlm.nih.gov/pubmed/28738231",
                "http://www.ncbi.nlm.nih.gov/pubmed/33879942",
                "http://www.ncbi.nlm.nih.gov/pubmed/32190434",
                "http://www.ncbi.nlm.nih.gov/pubmed/34899922",
                "http://www.ncbi.nlm.nih.gov/pubmed/11765663",
                "http://www.ncbi.nlm.nih.gov/pubmed/22421936"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36467887",
                    "offsetInBeginSection": 684,
                    "offsetInEndSection": 988,
                    "text": "The area under the receiver operating characteristic curve (AUROC) of the commonly opted biomarker tests [distribution width of red blood cells (RDW) and platelets(PDW), mean platelet volume(MPV), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR)] was compared to the culture-confirmed case.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33419284",
                    "offsetInBeginSection": 399,
                    "offsetInEndSection": 637,
                    "text": "Currently, there are several markers used for sepsis evaluation, such as hematological indices, acute phase reactants, cytokines, which by themselves do not show acceptable sensitivity and specificity for the diagnosis of EOS in neonates.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23056680",
                    "offsetInBeginSection": 141,
                    "offsetInEndSection": 342,
                    "text": "In this study, we evaluated whether clinical characteristics, laboratory parameters and measurements of serum interleukin-8 (IL-8) are able to discriminate between late neonatal sepsis and normal baby.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35637988",
                    "offsetInBeginSection": 454,
                    "offsetInEndSection": 2662,
                    "text": "A combination of haematological parameters like total leucocyte count (TLC), immature to total neutrophil ratio (I/T ratio), absolute neutrophil count (ANC), platelet count and C-reactive protein (CRP) estimation provide an early diagnosis of bacteremia. This study was undertaken to evaluate the usefulness of the above mentioned parameters as indicators for early diagnosis of neonatal sepsis. In the present cross-sectional study, we intent to analyse various hematologic parameters in 160 neonates admitted in the neonatal care unit of a tertiary care hospital in Delhi. We obtained data from the records of blood culture and complete blood counts of neonates from pathology and microbiology departments of the hospital. Out of 160 admitted neonates, 80 were taken as cases and remaining 80 were taken as controls. Medical records were studied to identify infants born at  34 weeks gestation. CBCs was analysed, blood cultures and CRP were done in department of Microbiology. CBC, CRP and Blood culture was done as per standard protocols and clinical assesment by paediatrician. The statistical analyses were performed using SPSS version 22 for windows. Among 80 neonates, who were in early neonatal sepsis, 44 cases (55%) were females, and 36 (45%) were males. The Microbiological profile of 80 septic neonates was analysed. The I/T value, ANC and CRP values were significantly higher in the neonates suffering from sepsis as compared to the control group. Among 80 septic neonates (cases), 30 (37.5%) were having normal ANC while 50 (62.5%) were having increased ANC and 34 (42.5%) were having normal I:T ratio while 46 (57.5%) were having increased I:T ratio. Out of 80 septic neonates (cases), 18 (22.5%) were having normal CRP while 62 (77.5%) were having increased CRP. ANC, I/T Ratio and CRP are quick, simple and cost-effective routine laboratory tests which help in early diagnosis of neonatal sepsis. Although there are many serological markers available, ANC and I/T Ratio serves as a reliable predictor of neonatal sepsis. With a good sensitivity, high specificity and a good negative predictive value these parameters can therefore help in timely and early identification of neonatal sepsis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28738231",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1140,
                    "text": "This article describes a 3D microfluidic paper-based analytical device that can be used to conduct an enzyme-linked immunosorbent assay (ELISA). The device comprises two parts: a sliding strip (which contains the active sensing area) and a structure surrounding the sliding strip (which holds stored reagents-buffers, antibodies, and enzymatic substrate-and distributes fluid). Running an ELISA involves adding sample (e.g. blood) and water, moving the sliding strip at scheduled times, and analyzing the resulting color in the sensing area visually or using a flatbed scanner. We demonstrate that this device can be used to detect C-reactive protein (CRP)-a biomarker for neonatal sepsis, pelvic inflammatory disease, and inflammatory bowel diseases-at a concentration range of 1-100ng/mL in 1000-fold diluted blood (1-100g/mL in undiluted blood). The accuracy of the device (as characterized by the area under the receiver operator characteristics curve) is 89% and 83% for cut-offs of 10ng/mL (for neonatal sepsis and pelvic inflammatory disease) and 30ng/mL (for inflammatory bowel diseases) CRP in 1000-fold diluted blood respectively.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33879942",
                    "offsetInBeginSection": 146,
                    "offsetInEndSection": 441,
                    "text": "The present, cross-sectional, hospital-based, study was conducted to evaluate the association of red cell distribution width (RDW) with neonatal sepsis and its role as a predictive marker in the diagnosis of neonatal sepsis at Soba University Hospital, during the period July 2018 to April 2019.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32190434",
                    "offsetInBeginSection": 769,
                    "offsetInEndSection": 878,
                    "text": "Demographic features, signs of sepsis, blood culture results, and laboratory markers of sepsis were recorded.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34899922",
                    "offsetInBeginSection": 905,
                    "offsetInEndSection": 1544,
                    "text": "The statistical evaluation was done using Fisher, and ANOVA tests using SPSS 20.0 version. Sixty children were included in the study with forty as the referred ones. Most of them had tachypnea (45%). CRP showed high sensitivity, whereas micro-ESR and gastric aspirate for polymorphs showed high specificity. Neonatal sepsis screening is required for the detection of infection as the blood culture report may not be positive in all the cases, and even if positive, the result takes few hours. CRP showed high sensitivity, whereas micro-ESR and gastric aspirate for polymorphs showed high specificity independently as well as when combined.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11765663",
                    "offsetInBeginSection": 579,
                    "offsetInEndSection": 816,
                    "text": "Knowledge of neonatal risk factors, together with cytokines evaluation as early markers of sepsis and laboratory tests such as polymerase chain reaction, have allowed us to accelerate the diagnosis of sepsis with prognostic improvements.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22421936",
                    "offsetInBeginSection": 537,
                    "offsetInEndSection": 871,
                    "text": "The overall magnitude of UTI was 6%. The urine culture positivity in the early onset sepsis group was 1.83% and in the late onset group was 10.98% (p <0.05). Urine culture positivity in proven sepsis was 6.32% and in suspected sepsis group was 5.78%. The sensitivity of bacteriuria in neonatal UTI was 91.6% and specificity was 97.8%.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What biomarkers are used for the identification of neonatal sepsis in low-income countries?",
            "type": "list",
            "id": "661d1d2deac11fad33000015",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37069321",
                "http://www.ncbi.nlm.nih.gov/pubmed/37594044",
                "http://www.ncbi.nlm.nih.gov/pubmed/37001911",
                "http://www.ncbi.nlm.nih.gov/pubmed/36881820",
                "http://www.ncbi.nlm.nih.gov/pubmed/37465925",
                "http://www.ncbi.nlm.nih.gov/pubmed/33105016",
                "http://www.ncbi.nlm.nih.gov/pubmed/35553661",
                "http://www.ncbi.nlm.nih.gov/pubmed/32570252",
                "http://www.ncbi.nlm.nih.gov/pubmed/36777426",
                "http://www.ncbi.nlm.nih.gov/pubmed/30215632"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37069321",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 736,
                    "text": "Interleukin-12 (IL-12) and interleukin-23 (IL-23), which belong to the IL-12 family of cytokines, have a key role in intestinal homeostasis and inflammation and are implicated in the pathogenesis of inflammatory bowel disease. Upon their secretion by antigen-presenting cells, they exert both pro-inflammatory and anti-inflammatory receptor-mediated effects. An increased understanding of these biological effects, particularly the pro-inflammatory effects mediated by IL-12 and IL-23, has led to the development of monoclonal antibodies that target a subunit common to IL-12 and IL-23 (p40; targeted by ustekinumab and briakinumab), or the IL-23-specific subunit (p19; targeted by risankizumab, guselkumab, brazikumab and mirikizumab).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37594044",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 186,
                    "text": "Mirikizumab, an anti-interleukin-23p19 monoclonal antibody, demonstrated efficacy in phase 2 and 3 randomized clinical trials of patients with moderate-to-severe ulcerative colitis (UC).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37001911",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 181,
                    "text": "Mirikizumab, a monoclonal antibody targeting the interleukin-23 p19 subunit, was effective in a Phase 2 study (NCT02589665) of moderately-to-severely active ulcerative colitis (UC).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36881820",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 243,
                    "text": "Mirikizumab, a monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, demonstrated efficacy and was well-tolerated in a phase 2 randomized clinical trial in patients with moderate-to-severe ulcerative colitis (UC) (NCT02589665).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37465925",
                    "offsetInBeginSection": 289,
                    "offsetInEndSection": 626,
                    "text": "Mirikizumab is a humanized IgG4 monoclonal antibody against the p19 subunit of IL-23, dosed intravenously during induction and subcutaneously during maintenance. It is effective for the induction and maintenance of remission in moderately to severely active UC, including patients with prior failure of biological or tofacitinib therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33105016",
                    "offsetInBeginSection": 444,
                    "offsetInEndSection": 932,
                    "text": "The interleukin (IL)-23 pathway plays a key role in IBD pathogenesis through promoting a pathological Th17 response. Targeting IL-23 is effective in the treatment of IBD. Ustekinumab, a monoclonal antibody targeting the shared p40 subunit of IL-12/23, is approved for treatment of moderate-to-severe CD and UC. Specific IL-23p19 antagonists are in development and promising results from phase II trials of mirikizumab and risankizumab underscore the potential for this class of treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35553661",
                    "offsetInBeginSection": 179,
                    "offsetInEndSection": 428,
                    "text": "IL-23 is an inflammatory cytokine involved in both innate and adaptive immunity, which has been identified as a therapeutic target in Crohn's disease [CD] and ulcerative colitis [UC] through its upstream inhibition of the T helper 17 [Th17] pathway.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32570252",
                    "offsetInBeginSection": 388,
                    "offsetInEndSection": 734,
                    "text": "Besides tumor necrosis factor, interleukin (IL)-23 is a promising drug target, and antibodies for the combined inhibition of IL-23 and IL-12 (ustekinumab and briakinumab) or selective IL-23 inhibition (brazikumab, risankizumab, and mirikizumab) seem to be effective in Crohn's disease (CD) with emerging evidence also for ulcerative colitis (UC).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36777426",
                    "offsetInBeginSection": 148,
                    "offsetInEndSection": 398,
                    "text": "Mirikizumab, a humanized monoclonal antibody directed against the p19 subunit of IL-23, significantly reduced bowel urgency in a double-blind, randomized, placebo-controlled Phase 2 clinical trial in patients with moderate-to-severe UC (NCT02589665).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30215632",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 322,
                    "text": "Since the identification of high levels of interleukin 23 (IL- 23) in psoriasis lesional skin, as well as finding that IL-23 was the most important source of the p40 subunit shared by IL-12 and IL-23, significant effort has been made in identifying potential new drugs that specifically block the unique IL-23 p19 subunit.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the mechanism of action of Mirikizumab?",
            "type": "summary",
            "id": "65cfdd9c1930410b13000027",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/32167939",
                "http://www.ncbi.nlm.nih.gov/pubmed/26560097",
                "http://www.ncbi.nlm.nih.gov/pubmed/10741926",
                "http://www.ncbi.nlm.nih.gov/pubmed/31523592",
                "http://www.ncbi.nlm.nih.gov/pubmed/30926204",
                "http://www.ncbi.nlm.nih.gov/pubmed/25743791",
                "http://www.ncbi.nlm.nih.gov/pubmed/18924330",
                "http://www.ncbi.nlm.nih.gov/pubmed/18385822",
                "http://www.ncbi.nlm.nih.gov/pubmed/34226290",
                "http://www.ncbi.nlm.nih.gov/pubmed/29852782"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32167939",
                    "offsetInBeginSection": 142,
                    "offsetInEndSection": 255,
                    "text": "Proton pump inhibitor exposure for 10 or more years was not associated with any increased risk of gastric cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26560097",
                    "offsetInBeginSection": 664,
                    "offsetInEndSection": 1068,
                    "text": "PPIs cause a hypergastrinemic state, increasing enterochromaffin-like cell dysplasia and risk of gastric NET development, increasing gastritis severity in the context of Helicobacter pylori infection, and progression of carcinogenesis in a certain predisposed subset of Barrett's esophagus patients. There are case reports of PPI-induced gastric NETs and adenocarcinomas as consequences of these effects.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10741926",
                    "offsetInBeginSection": 207,
                    "offsetInEndSection": 663,
                    "text": "Although the mechanism of gastric carcinogenesis is not known, the model proposed by Correa has provided the most attractive explanation to date. The suggestion is that prolonged hypochlorhydria predisposes to gastric carcinoma by an increase in the production of carcinogenic N-nitroso compounds. This hypothesis has led to concerns about the safety of long-term acid suppression in the management of a variety of acid-related gastrointestinal conditions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31523592",
                    "offsetInBeginSection": 140,
                    "offsetInEndSection": 279,
                    "text": "However, doubts have arisen about its safety in long term use and have been associated with an increased risk of developing gastric cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31523592",
                    "offsetInBeginSection": 280,
                    "offsetInEndSection": 378,
                    "text": "We aim to study if there is an association between chronic PPI use and the risk of gastric cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31523592",
                    "offsetInBeginSection": 1071,
                    "offsetInEndSection": 1212,
                    "text": "PPI users had a hazard ratio of 2.44 (95% confidence interval [CI] 1.42-4.20), and the risk of cancer increased with the duration of PPI use.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31523592",
                    "offsetInBeginSection": 1320,
                    "offsetInEndSection": 1478,
                    "text": "The standardized incidence ratio of gastric cancer among PPI users was 3.38 (95% CI 3.23-3.53), and the risk of cancer increased with the duration of PPI use.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31523592",
                    "offsetInBeginSection": 1479,
                    "offsetInEndSection": 1631,
                    "text": "Therefore, chronic PPI use is associated with an increase in the risk of gastric cancer. It might also be an independent risk factor for gastric cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30926204",
                    "offsetInBeginSection": 598,
                    "offsetInEndSection": 708,
                    "text": "Long-term PPIs may be responsible for an increased risk of gastric cancer according to several recent studies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25743791",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 341,
                    "text": "The fact that long-term use of proton pump inhibitors (PPIs) aggravates corpus atrophic gastritis in patients with Helicobacter pylori infection has been proven clinically and experimentally. Corpus atrophic gastritis is a known risk factor for gastric cancer. Therefore, gastric neoplasia might be associated with the long-term use of PPIs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Do PPIs increase the risk of gastric cancer?",
            "type": "yesno",
            "id": "6616a250fdcbea915f000059",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/3141147",
                "http://www.ncbi.nlm.nih.gov/pubmed/28936977",
                "http://www.ncbi.nlm.nih.gov/pubmed/37059094",
                "http://www.ncbi.nlm.nih.gov/pubmed/9159075",
                "http://www.ncbi.nlm.nih.gov/pubmed/15342512",
                "http://www.ncbi.nlm.nih.gov/pubmed/9671818",
                "http://www.ncbi.nlm.nih.gov/pubmed/31402173",
                "http://www.ncbi.nlm.nih.gov/pubmed/6235875",
                "http://www.ncbi.nlm.nih.gov/pubmed/25403490",
                "http://www.ncbi.nlm.nih.gov/pubmed/35451484"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3141147",
                    "offsetInBeginSection": 998,
                    "offsetInEndSection": 1186,
                    "text": "Thus, the same nuclear factor can act as a positive activator of both enhancer and promoter function, suggesting that the two functions involve similar events in the transcription process.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28936977",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "text": "Enhancers are key cis-acting gene regulatory elements in eukaryotes, which can effectively promote the expression of target genes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059094",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 304,
                    "text": "The spatiotemporal control of gene expression is dependent on the activity of cis-acting regulatory sequences, called enhancers, which regulate target genes over variable genomic distances and, often, by skipping intermediate promoters, suggesting mechanisms that control enhancer-promoter communication.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9159075",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 197,
                    "text": "Regulation of both transcription and RNA splicing requires enhancer elements, that is, cis-acting DNA or RNA sequences that promote the activities of linked promoters or splice sites, respectively.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15342512",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 112,
                    "text": "Eukaryotic enhancers act over very long distances, yet still show remarkable specificity for their own promoter.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9671818",
                    "offsetInBeginSection": 525,
                    "offsetInEndSection": 668,
                    "text": "This role in enhancement is distinct from that at the promoter and does not involve translocation of UBF from enhancer repeats to the promoter.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31402173",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1134,
                    "text": "While Mediator plays a key role in eukaryotic transcription, little is known about its mechanism of action. This study combines CRISPR-Cas9 genetic screens, degron assays, Hi-C, and cryoelectron microscopy (cryo-EM) to dissect the function and structure of mammalian Mediator (mMED). Deletion analyses in B, T, and embryonic stem cells (ESC) identified a core of essential subunits required for Pol II recruitment genome-wide. Conversely, loss of non-essential subunits mostly affects promoters linked to multiple enhancers. Contrary to current models, however, mMED and Pol II are dispensable to physically tether regulatory DNA, a topological activity requiring architectural proteins. Cryo-EM analysis revealed a conserved core, with non-essential subunits increasing structural complexity of the tail module, a primary transcription factor target. Changes in tail structure markedly increase Pol II and kinase module interactions. We propose that Mediator's structural pliability enables it to integrate and transmit regulatory signals and act as a functional, rather than an architectural bridge, between promoters and enhancers.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6235875",
                    "offsetInBeginSection": 512,
                    "offsetInEndSection": 718,
                    "text": "Transcription of cellular genes can be stimulated by viral or cellular short DNA elements named enhancers. These elements acting in cis, can be placed 5' or 3' to the gene and function in both orientations.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25403490",
                    "offsetInBeginSection": 1490,
                    "offsetInEndSection": 1802,
                    "text": "Although MUNC overlaps with the DRR enhancer, our results suggest that MUNC is not a classic cis-acting enhancer RNA (e-RNA) acting exclusively by stimulating the neighboring MyoD gene but more like a promyogenic lncRNA that acts directly or indirectly on multiple promoters to increase myogenic gene expression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35451484",
                    "offsetInBeginSection": 628,
                    "offsetInEndSection": 741,
                    "text": "Notably, we found that MER57E3 functionally acted as proximal regulatory element to activate respective ZNF gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can enhancers act as promoters?",
            "type": "yesno",
            "id": "661c414d48a2c27714000007",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
                "http://www.ncbi.nlm.nih.gov/pubmed/11367532",
                "http://www.ncbi.nlm.nih.gov/pubmed/10809953",
                "http://www.ncbi.nlm.nih.gov/pubmed/8996252",
                "http://www.ncbi.nlm.nih.gov/pubmed/7858501",
                "http://www.ncbi.nlm.nih.gov/pubmed/29202042",
                "http://www.ncbi.nlm.nih.gov/pubmed/31732528",
                "http://www.ncbi.nlm.nih.gov/pubmed/11312253",
                "http://www.ncbi.nlm.nih.gov/pubmed/1849806",
                "http://www.ncbi.nlm.nih.gov/pubmed/11091285"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 535,
                    "text": "CD21, the complement receptor type 2 (CR2), binds the complement fragments iC3b, C3dg and C3d, interacts with CD23 (the low-affinity receptor for IgE), and binds IFN-alpha. This 145 kDa glycoprotein merits particular interest because it plays a pivotal role in the activation and proliferation of B cells by lowering the signal threshold. In human disease CD21 is important as a receptor for Epstein-Barr virus and HIV. CD21 is primarily expressed on B lymphocytes and follicular dendritic cells, but has also been reported on T cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11367532",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 242,
                    "text": "The Complement Receptor Type 2 (Cr2-145,CR2, CD21) is an important receptor in the innate and acquired immune response. CD21 is produced by B cells and follicular dendritic cells, where it binds cleavage products of the C3 complement protein.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10809953",
                    "offsetInBeginSection": 138,
                    "offsetInEndSection": 358,
                    "text": "The primary function of complement, in this regard, is to opsonize antigen or immune complexes for uptake by complement receptor type 2 (CR2, CD21) expressed on B cells, follicular dendritic cells (FDC) and some T cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8996252",
                    "offsetInBeginSection": 113,
                    "offsetInEndSection": 255,
                    "text": "By expression cloning, a cDNA clone encoding for the long human CR2/ CD21 isoform (CD21L) that contains an additional exon (10a) was isolated.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8996252",
                    "offsetInBeginSection": 256,
                    "offsetInEndSection": 387,
                    "text": "We demonstrated that FDCs selectively express CD21L, while B cells selectively express the short CR2/CD21 lacking exon 10a (CD21S).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8996252",
                    "offsetInBeginSection": 545,
                    "offsetInEndSection": 694,
                    "text": "Thus, CD21L represents the first characterized human FDC-specific molecule, which may confer unique functions of FDCs in germinal center development.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7858501",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 662,
                    "text": "Follicular dendritic cells (FDC) are restricted to the B-cell regions of secondary lymphoid tissue and to non-Hodgkin's lymphomas derived from the follicular center or the mantle zone. With their cytoplasmic ramifications they form a dense network which contains the B-lymphocytes. In situ, FDC are only detectable at the ultrastructural level or when stained with anti FDC-reagents. On the surface of their dendritic extensions they express transferrin receptors (CD71), the B-cell epitope CD20, class II antigens, the myelomonocytic molecule CD14, the glycoprotein gp50 (CD40), and several receptors for components of the complement system (CD11b, CD21, CD35).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29202042",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 333,
                    "text": "Complement receptors 1 and 2 (CR1/2 or CD35/CD21) recognize complement-opsonized antigens to initiate innate and adaptive immunity, respectively. CD35 stimulates phagocytosis on macrophages and antigen presentation on follicular dendritic cells (FDCs). CD21 helps activate B cells as part of the B cell coreceptor with CD19 and CD81.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31732528",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 454,
                    "text": "Humoral autoimmunity is central to the development of systemic lupus erythematosus (SLE). Complement receptor type 2 (CR2)/CD21 plays a key role in the development of high-affinity Abs and long-lasting memory to foreign Ags. When CR2 is bound by its primary C3 activation fragment-derived ligand, designated C3d, it coassociates with CD19 on B cells to amplify BCR signaling. C3d and CR2 also mediate immune complex binding to follicular dendritic cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11312253",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 131,
                    "text": "Expression of human complement receptor type 2 (CR2/CD21) is primarily restricted to mature B cells and follicular dendritic cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "List the cells which have CD21 on the surface.",
            "type": "list",
            "id": "661a624bfdcbea915f00005b",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20703837",
                "http://www.ncbi.nlm.nih.gov/pubmed/27652303",
                "http://www.ncbi.nlm.nih.gov/pubmed/28100994",
                "http://www.ncbi.nlm.nih.gov/pubmed/26064818",
                "http://www.ncbi.nlm.nih.gov/pubmed/30918585",
                "http://www.ncbi.nlm.nih.gov/pubmed/28325090",
                "http://www.ncbi.nlm.nih.gov/pubmed/31949937",
                "http://www.ncbi.nlm.nih.gov/pubmed/35434862",
                "http://www.ncbi.nlm.nih.gov/pubmed/32456396",
                "http://www.ncbi.nlm.nih.gov/pubmed/24506142"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20703837",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 150,
                    "text": "Self-expandable metal stent (SEMS) placement is a minimally invasive option for achieving acute colonic decompression in obstructed colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20703837",
                    "offsetInBeginSection": 151,
                    "offsetInEndSection": 302,
                    "text": "Colorectal stenting offers nonoperative, immediate, and effective colon decompression and allows bowel preparation for an elective oncologic resection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20703837",
                    "offsetInBeginSection": 303,
                    "offsetInEndSection": 504,
                    "text": "Patients who benefit the most are high-risk surgical patients and candidates for laparoscopic resection with complete obstruction, because emergency surgery can be avoided in more than 90% of patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20703837",
                    "offsetInBeginSection": 505,
                    "offsetInEndSection": 647,
                    "text": "Colonic stent placement also offers effective palliation of malignant colonic obstruction, although it carries risks of delayed complications.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20703837",
                    "offsetInBeginSection": 648,
                    "offsetInEndSection": 767,
                    "text": "When performed by experienced endoscopists, the technical success rate is high with a low procedural complication rate.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20703837",
                    "offsetInBeginSection": 768,
                    "offsetInEndSection": 1027,
                    "text": "Despite concerns of tumor seeding following endoscopic colorectal stent placement, no difference exists in oncologic long-term survival between patients who undergo stent placement followed by elective resection and those undergoing emergency bowel resection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20703837",
                    "offsetInBeginSection": 1028,
                    "offsetInEndSection": 1118,
                    "text": "Colorectal stents have also been used in selected patients with benign colonic strictures.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27652303",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 296,
                    "text": "The feasibility of endoscopic resection for synchronous early colon cancer after placement of self-expandable metallic stents (SEMS) for malignant colorectal obstruction is unknown. Herein we evaluated 3 cases of endoscopic resection for synchronous early colorectal cancers after SEMS placement.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28100994",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "text": "Self-expandable metallic stent (SEMS) placement has been practiced in several hospitals in Japan, including ours, since January 2012.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28100994",
                    "offsetInBeginSection": 453,
                    "offsetInEndSection": 528,
                    "text": "We performed SEMS placement because the patient refused to undergo surgery.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What clinical indications does the self-expanding colon stent have in colorectal cancer patients?",
            "type": "list",
            "id": "66099c30fdcbea915f000024",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37610655",
                "http://www.ncbi.nlm.nih.gov/pubmed/19707427",
                "http://www.ncbi.nlm.nih.gov/pubmed/24143206",
                "http://www.ncbi.nlm.nih.gov/pubmed/26857924",
                "http://www.ncbi.nlm.nih.gov/pubmed/18472617",
                "http://www.ncbi.nlm.nih.gov/pubmed/26549053",
                "http://www.ncbi.nlm.nih.gov/pubmed/25585649",
                "http://www.ncbi.nlm.nih.gov/pubmed/19192669",
                "http://www.ncbi.nlm.nih.gov/pubmed/32318348",
                "http://www.ncbi.nlm.nih.gov/pubmed/32516590"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37610655",
                    "offsetInBeginSection": 454,
                    "offsetInEndSection": 846,
                    "text": "Evaluation of paired pre- and posttreatment samples of liver metastases from 20 colorectal cancer patients treated with combination bevacizumab therapy, including 10 responders and 10 nonresponders, indicated that ECM deposition in liver metastases and a highly activated fatty acid oxidation (FAO) pathway were elevated in nonresponders after antiangiogenic therapy compared with responders.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37610655",
                    "offsetInBeginSection": 847,
                    "offsetInEndSection": 1074,
                    "text": "In mouse models of liver metastatic colorectal cancer (mCRC), anti-VEGF increased ECM deposition and FAO in colorectal cancer cells, and treatment with the FAO inhibitor etomoxir enhanced the efficacy of antiangiogenic therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37610655",
                    "offsetInBeginSection": 1075,
                    "offsetInEndSection": 1411,
                    "text": "Hepatic stellate cells (HSC) were essential for matrix stiffness-mediated FAO in colon cancer cells. Matrix stiffness activated lipolysis in HSCs via the focal adhesion kinase (FAK)/yes-associated protein (YAP) pathway, and free fatty acids secreted by HSCs were absorbed as metabolic substrates and activated FAO in colon cancer cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37610655",
                    "offsetInBeginSection": 1511,
                    "offsetInEndSection": 2061,
                    "text": "Together, these results indicate that bevacizumab-induced ECM remodeling triggers lipid metabolic cross-talk between colon cancer cells and HSCs. This metabolic mechanism of bevacizumab resistance mediated by the physical tumor microenvironment represents a potential therapeutic target for reversing drug resistance. Extracellular matrix stiffening drives bevacizumab resistance by stimulating hepatic stellate cells to provide fuel for mCRC cells in the liver, indicating a potential metabolism-based therapeutic strategy for overcoming resistance.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19707427",
                    "offsetInBeginSection": 609,
                    "offsetInEndSection": 707,
                    "text": "The mechanism by which colorectal cancer may become resistant to bevacizumab is poorly understood.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24143206",
                    "offsetInBeginSection": 566,
                    "offsetInEndSection": 810,
                    "text": "In the discovery cohort, VEGF-C was increased prior to progression and at progression (+49% and +95%, respectively, p<0.01), consistent with previously reported elevations in PlGF. Levels of VEGF-D were increased (+23%) at progression (p=0.05).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24143206",
                    "offsetInBeginSection": 811,
                    "offsetInEndSection": 1101,
                    "text": "In the validation cohort, samples obtained from patients after progression on a regimen with bevacizumab had higher levels of PlGF and VEGF-D (+43% and +6%, p=0.02, p=0.01, respectively) compared to untreated patients, but failed to validate the increase in VEGF-C seen in the first cohort.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24143206",
                    "offsetInBeginSection": 1102,
                    "offsetInEndSection": 1287,
                    "text": "Patients who progressed on chemotherapy with bevacizumab had significantly elevated levels of PlGF (+88%) but not VEGF-C and VEGF-D compared to patients treated with chemotherapy alone.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24143206",
                    "offsetInBeginSection": 1391,
                    "offsetInEndSection": 1686,
                    "text": "Increases in PlGF and VEGF-D were observed after progression on chemotherapy with bevacizumab. These changes appear to be reversible after discontinuing therapy. These ligands are associated with resistance to bevacizumab-containing chemotherapy in mCRC, but causation remains to be established.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26857924",
                    "offsetInBeginSection": 530,
                    "offsetInEndSection": 740,
                    "text": "Efforts are ongoing to understand the better way to combine bevacizumab and chemotherapy, and to identify valid predictive biomarkers of benefit to avoid unnecessary and costly therapy to nonresponder patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients?",
            "type": "list",
            "id": "65f77a32c4010b4d7800003a",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/32785879",
                "http://www.ncbi.nlm.nih.gov/pubmed/37456349",
                "http://www.ncbi.nlm.nih.gov/pubmed/36336119",
                "http://www.ncbi.nlm.nih.gov/pubmed/35592550",
                "http://www.ncbi.nlm.nih.gov/pubmed/37843599",
                "http://www.ncbi.nlm.nih.gov/pubmed/35322226",
                "http://www.ncbi.nlm.nih.gov/pubmed/35419654",
                "http://www.ncbi.nlm.nih.gov/pubmed/32328845",
                "http://www.ncbi.nlm.nih.gov/pubmed/31912620",
                "http://www.ncbi.nlm.nih.gov/pubmed/31111153"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32785879",
                    "offsetInBeginSection": 462,
                    "offsetInEndSection": 673,
                    "text": "Patisiran, a novel drug, is a liposomal siRNA against TTR that specifically targets this protein, reducing the accumulation of TTR in tissues, with subsequent improvement in both neuropathy and cardiac function.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37456349",
                    "offsetInBeginSection": 479,
                    "offsetInEndSection": 671,
                    "text": "Patisiran is a small interfering RNA that disrupts the complimentary mRNA and inhibits TTR synthesis, and is the first gene-silencing medication licensed for the treatment of ATTR amyloidosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37456349",
                    "offsetInBeginSection": 672,
                    "offsetInEndSection": 861,
                    "text": "After encouraging results following the use of patisiran for the treatment of patients with ATTR-PN, there has been increasing interest in the use of patisiran for the treatment of ATTR-CM.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37456349",
                    "offsetInBeginSection": 862,
                    "offsetInEndSection": 1128,
                    "text": "Various studies have demonstrated improvements across a wide range of cardiac biomarkers following treatment with patisiran, and have changed the perception of ATTR-CM from being thought of as a terminal disease process, to now being regarded as a treatable disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36336119",
                    "offsetInBeginSection": 555,
                    "offsetInEndSection": 675,
                    "text": "New RNA-interfering drugs (such as patisiran) have been devised and are effective in the treatment of ATTRh amyloidosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36336119",
                    "offsetInBeginSection": 973,
                    "offsetInEndSection": 1048,
                    "text": "Patisiran should be considered in ATTRh cardiomyopathy with polyneuropathy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35592550",
                    "offsetInBeginSection": 740,
                    "offsetInEndSection": 1328,
                    "text": "Literature data, as well as the above presented case reports, show that this drug is effective and safe in improving both neurological and cardiovascular symptoms of ATTRv amyloidosis, and to maintain a good QoL, independently form the stage of the disease and the involved mutation. Recent studies correlated improved functional and biochemical outcomes with a regression of amyloid burden, especially at the cardiac level. Today, patisiran can be considered a valid therapeutic option for the management of patients with ATTRv amyloidosis and polyneuropathy and cardiovascular symptoms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37843599",
                    "offsetInBeginSection": 159,
                    "offsetInEndSection": 476,
                    "text": "This study aims to evaluate changes in cardiac tracer uptake on bone scintigraphy in ATTRv amyloidosis patients on different treatments. In this retrospective cohort study, outcomes of 20 patients treated with the transthyretin (TTR) gene silencer patisiran were compared to 12 patients treated with a TTR-stabilizer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35322226",
                    "offsetInBeginSection": 654,
                    "offsetInEndSection": 1154,
                    "text": "The siRNA patisiran and the ASO inotersen have been approved for the treatment of patients with ATTR variant polyneuropathy, regardless of the presence and severity of ATTR cardiomyopathy. Preliminary data show that therapy with patisiran improves the cardiac phenotype rather than only inducing disease stabilization in patients with ATTR variant polyneuropathy and concomitant ATTR cardiomyopathy, and this drug is being evaluated in a phase III clinical trial in patients with ATTR cardiomyopathy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35419654",
                    "offsetInBeginSection": 538,
                    "offsetInEndSection": 1559,
                    "text": "Treatment options consist of TTR stabilizing drugs, such as tafamidis and active agents that selectively interfere at the mRNA level, the so-called gene silencers patisiran and inotersen. All forms of treatment aim to prevent amyloid tissue deposition in tissues and organ dysfunction. Patisiran works by RNA interference on endogenous mechanisms of gene expression. It results in the cleavage of TTR-mRNA using the cytoplasmatic RNA-induced silencing complex. Inotersen, an antisense oligonucleotide, degrades TTR-mRNA via activation of nuclear RNase H. Both mechanisms result in a significant reduction of TTR protein serum levels. The efficacy could be demonstrated by slowing or improving neuropathy progression in the phase III study APOLLO (patisiran) or the NEURO-TTR study (inotersen). Furthermore, the use of both agents led to an improvement in the quality of life in patients with ATTRv. Both forms of treatment are approved in Germany since August 2018 for polyneuropathy stages 1 and 2 according to Coutinho.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is Patisiran used for Transthyretin Cardiac Amyloidosis?",
            "type": "yesno",
            "id": "65cfa6201930410b1300000e",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26306491",
                "http://www.ncbi.nlm.nih.gov/pubmed/21035601",
                "http://www.ncbi.nlm.nih.gov/pubmed/8699569",
                "http://www.ncbi.nlm.nih.gov/pubmed/35088057",
                "http://www.ncbi.nlm.nih.gov/pubmed/29344239",
                "http://www.ncbi.nlm.nih.gov/pubmed/34758935",
                "http://www.ncbi.nlm.nih.gov/pubmed/33187950",
                "http://www.ncbi.nlm.nih.gov/pubmed/27994410",
                "http://www.ncbi.nlm.nih.gov/pubmed/29034276",
                "http://www.ncbi.nlm.nih.gov/pubmed/22349276"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26306491",
                    "offsetInBeginSection": 84,
                    "offsetInEndSection": 161,
                    "text": "In general, patients diagnosed with small tumors have a fairly good prognosis",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21035601",
                    "offsetInBeginSection": 987,
                    "offsetInEndSection": 1105,
                    "text": "The increase in salivary transferrin levels in OSCC patients strongly correlated with the size and stage of the tumor.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8699569",
                    "offsetInBeginSection": 1049,
                    "offsetInEndSection": 1311,
                    "text": "The 5-year survival rates were 62% for patients with stage I disease, 80% for patients with stage II disease, 42% for patients with stage III, and 19% for patients with stage IV disease. Stage at initial presentation was an important factor influencing survival.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35088057",
                    "offsetInBeginSection": 244,
                    "offsetInEndSection": 331,
                    "text": "Diagnosis at an early-stage is important for better prognosis, treatment, and survival.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29344239",
                    "offsetInBeginSection": 626,
                    "offsetInEndSection": 792,
                    "text": "In the clinical stage I/II patients, disease-free survival (DFS) was demonstrated to be higher in patients with negative SNB compared with patients with positive SNB.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29344239",
                    "offsetInBeginSection": 1036,
                    "offsetInEndSection": 1181,
                    "text": "Of these 40 patients, DFS of the patients with low serum IL-6 was significantly higher compared with the patients with high serum IL-6 (P=0.012).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29344239",
                    "offsetInBeginSection": 1182,
                    "offsetInEndSection": 1266,
                    "text": "In 19 patients with negative SNB and low serum IL-6, the disease-free rate was 100%.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34758935",
                    "offsetInBeginSection": 746,
                    "offsetInEndSection": 870,
                    "text": "Overall 2-year survival was significantly poorer in patients with close/positive margin status and free flap reconstruction.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33187950",
                    "offsetInBeginSection": 748,
                    "offsetInEndSection": 833,
                    "text": "Five-year OS and DSS for patients with stage I SCC were 79.7% and 93.4%, respectively",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27994410",
                    "offsetInBeginSection": 193,
                    "offsetInEndSection": 333,
                    "text": "Diagnosing oral cancers at an early stage is critical in improving the survival rate and reducing the morbidity associated with the disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Does early stage oral squamous cell carcinoma have  good survival rates?",
            "type": "yesno",
            "id": "661a6a67fdcbea915f00005d",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28186390",
                "http://www.ncbi.nlm.nih.gov/pubmed/36124037",
                "http://www.ncbi.nlm.nih.gov/pubmed/36305215",
                "http://www.ncbi.nlm.nih.gov/pubmed/37637226",
                "http://www.ncbi.nlm.nih.gov/pubmed/37745744",
                "http://www.ncbi.nlm.nih.gov/pubmed/34124258",
                "http://www.ncbi.nlm.nih.gov/pubmed/27695362",
                "http://www.ncbi.nlm.nih.gov/pubmed/28967365",
                "http://www.ncbi.nlm.nih.gov/pubmed/34301703",
                "http://www.ncbi.nlm.nih.gov/pubmed/30512708"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28186390",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1223,
                    "text": "Chronic pain in the Ehlers-Danlos syndromes (EDS) is common and may be severe. According to one study, nearly 90% of patients report some form of chronic pain. Pain, which is often one of the first symptoms to occur, may be widespread or localized to one region such as an arm or a leg. Studies on treatment modalities are few and insufficient to guide management. The following is a discussion of the evidence regarding the underlying mechanisms of pain in EDS. The causes of pain in this condition are multifactorial and include joint subluxations and dislocations, previous surgery, muscle weakness, proprioceptive disorders, and vertebral instability. Affected persons may also present with generalized body pain, fatigue, headaches, gastrointestinal pain, temporomandibular joint pain, dysmenorrhea, and vulvodynia. Pain management strategies may be focused around treating the cause of the pain (e.g., dislocation of a joint, proprioceptive disorder) and minimizing the sensation of pain. Management strategies for chronic pain in EDS includes physical therapy, medications, as well as durable medical equipment such as cushions, compressive garments, and braces. The different modalities are discussed in this paper.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36124037",
                    "offsetInBeginSection": 491,
                    "offsetInEndSection": 988,
                    "text": "Pain is one of the most common symptoms of EDS, leading to disability and decreased quality of life. Current guidelines for treating chronic pain in EDS are lacking. Clinicians focus on a conservative multidisciplinary approach in patients with EDS, which avoids surgical interventions and its accompanying risks of morbidity and mortality. The multidisciplinary approach includes physiotherapy, occupational therapy, cognitive behavioral therapy, and pharmacologic interventions to decrease pain.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36305215",
                    "offsetInBeginSection": 594,
                    "offsetInEndSection": 920,
                    "text": "Since hEDS associated chronic pain is multifactorial in origin, treatment requires a multidisciplinary approach which includes physical therapy, psychotherapy, pharmacotherapy and interventional pain procedures such as trigger point injections, peripheral nerve block, radiofrequency ablation and peripheral nerve stimulation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37637226",
                    "offsetInBeginSection": 749,
                    "offsetInEndSection": 1228,
                    "text": "Treatment relies on management strategies for other chronic pain syndromes with a multidisciplinary approach likely optimal. Lifestyle modifications focus on weight loss and exercise. Physical therapy helps strengthen periarticular muscles, improving mobility. Pharmacologic therapies focus on judicious use of non-steroidal anti-inflammatory drugs and acetaminophen. Serotonin and norepinephrine reuptake inhibitor may help widespread pain. Avoidance of opioids remains prudent.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37745744",
                    "offsetInBeginSection": 958,
                    "offsetInEndSection": 1078,
                    "text": "The essential components of pain management include non-opioid medications, physical therapy, and psychological support.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37745744",
                    "offsetInBeginSection": 1079,
                    "offsetInEndSection": 1201,
                    "text": "Opioids should be used cautiously in EDS patients because of connective tissue vulnerabilities and potential side effects.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37745744",
                    "offsetInBeginSection": 1202,
                    "offsetInEndSection": 1298,
                    "text": "Personalized plans for opioid tapering may be appropriate for those on long-term opioid therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37745744",
                    "offsetInBeginSection": 1299,
                    "offsetInEndSection": 1381,
                    "text": "Managing EDS-related chronic pain requires a tailored, multidisciplinary approach.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37745744",
                    "offsetInBeginSection": 1382,
                    "offsetInEndSection": 1508,
                    "text": "Early and accurate diagnosis and specialized healthcare providers familiar with EDS are crucial for effective pain management.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37745744",
                    "offsetInBeginSection": 1509,
                    "offsetInEndSection": 1679,
                    "text": "Ongoing research and evidence-based pain management approaches are vital to address the unique needs of EDS patients, promoting better pain relief and overall well-being.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "How is pain treated in patients with Ehlers-Danlos Syndrome?",
            "type": "summary",
            "id": "661d575eeac11fad33000020",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37125467"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37125467",
                    "offsetInBeginSection": 841,
                    "offsetInEndSection": 862,
                    "text": "sulbactam-durlobactam",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are active ingredients of Xacduro?",
            "type": "list",
            "id": "65d1369c1930410b1300003b",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33030865",
                "http://www.ncbi.nlm.nih.gov/pubmed/9599531",
                "http://www.ncbi.nlm.nih.gov/pubmed/23122448",
                "http://www.ncbi.nlm.nih.gov/pubmed/3308246",
                "http://www.ncbi.nlm.nih.gov/pubmed/24834708",
                "http://www.ncbi.nlm.nih.gov/pubmed/22926273",
                "http://www.ncbi.nlm.nih.gov/pubmed/28078171",
                "http://www.ncbi.nlm.nih.gov/pubmed/11227314",
                "http://www.ncbi.nlm.nih.gov/pubmed/9740929",
                "http://www.ncbi.nlm.nih.gov/pubmed/9746844"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33030865",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "text": "In this Commentary, we explain the case for a standardized cesarean delivery surgical technique.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9599531",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 335,
                    "text": "The literature was reviewed in order to find clinical-epidemiological and physiological evidence for which surgical techniques should be preferred when performing Caesarean section. We found reasonable evidence for the following procedure: spontaneous placenta detachment, uterine repair in one layer and non-closure of the peritoneum.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23122448",
                    "offsetInBeginSection": 364,
                    "offsetInEndSection": 530,
                    "text": "When possible, spinal anesthesia is the technique of choice for elective repeat cesarean delivery even in case of morbidly adherent placenta (professional agreement).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3308246",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 99,
                    "text": "The available options for cesarean section anesthesia are spinal, epidural, and general anesthesia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24834708",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 74,
                    "text": "Regional anesthesia is considered a 'gold standard' for cesarean sections.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22926273",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "text": "Cesarean delivery is the most common surgical procedure performed in the United States, yet the techniques used during this procedure often vary significantly among providers.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28078171",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 88,
                    "text": "Until today, there is no standardized Cesarean Section method and many variations exist.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11227314",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 112,
                    "text": "In the community hospital of Konstanz, spinal block is the standard method of anaesthesia for caesarean section.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9740929",
                    "offsetInBeginSection": 444,
                    "offsetInEndSection": 667,
                    "text": "The mean general anaesthesia rate for elective caesarean sections was 66.5%, for non-elective sections 90.8%. The mean epidural anaesthesia rate for caesarean section was 22.6% and the mean spinal anaesthesia rate was 9.8%.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9746844",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 310,
                    "text": "A survey of all German hospitals providing obstetric anaesthesia in 1997 (n = 1061, recovery rate 82% comprising 115,000 Caesarean sections revealed that most Caesarean sections (CS) are performed under general anaesthesia (GA). For elective CS, the average was 63%, and 82% for urgent (non-emergency) section.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the technique of choice to perform a caesarean section?",
            "type": "factoid",
            "id": "65f85fdbc4010b4d78000054",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35810190",
                "http://www.ncbi.nlm.nih.gov/pubmed/37268606",
                "http://www.ncbi.nlm.nih.gov/pubmed/31833956",
                "http://www.ncbi.nlm.nih.gov/pubmed/34874265",
                "http://www.ncbi.nlm.nih.gov/pubmed/24771846",
                "http://www.ncbi.nlm.nih.gov/pubmed/7448792",
                "http://www.ncbi.nlm.nih.gov/pubmed/32553158",
                "http://www.ncbi.nlm.nih.gov/pubmed/33914706",
                "http://www.ncbi.nlm.nih.gov/pubmed/36425754",
                "http://www.ncbi.nlm.nih.gov/pubmed/28649789"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35810190",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 60,
                    "text": "Melanoma cells display distinct intrinsic phenotypic states.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37268606",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "Melanoma exhibits numerous transcriptional cell states including neural crest-like cells as well as pigmented melanocytic cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31833956",
                    "offsetInBeginSection": 661,
                    "offsetInEndSection": 821,
                    "text": "Melanoma cells are also capable of rapidly switching their molecular and cellular phenotype, leading to an initial drug-tolerant favorizing melanoma resistance.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34874265",
                    "offsetInBeginSection": 160,
                    "offsetInEndSection": 353,
                    "text": "In melanoma, the melanocytic (MEL) and the mesenchymal-like (MES) states present themselves with different responses to therapy, making the identification of specific enhancers highly relevant.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24771846",
                    "offsetInBeginSection": 405,
                    "offsetInEndSection": 706,
                    "text": "Whereas most drug-sensitive cell lines and patient biopsies showed high expression and activity of the melanocytic lineage transcription factor MITF, intrinsically resistant cell lines and biopsies displayed low MITF expression but higher levels of NF-B signaling and the receptor tyrosine kinase AXL.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7448792",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 303,
                    "text": "Cultured human melanoma cells M10 harvested from cultures in different phases of their growth show significant changes in the expression of melanoma-associated antigens (MAA), but they do not vary in susceptibility to lysis mediated by anti-MAA xenoantisera and effected by complement or lymphoid cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32553158",
                    "offsetInBeginSection": 524,
                    "offsetInEndSection": 720,
                    "text": "We identify melanoma cells in intravascular niches of various metastatic organs. These cells are quiescent, are negative for characteristic melanoma markers, and acquire endothelial cell features.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33914706",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 186,
                    "text": "Melanoma dedifferentiation has been reported to be a state of cellular resistance to targeted therapies and immunotherapies as cancer cells revert to a more primitive cellular phenotype.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36425754",
                    "offsetInBeginSection": 130,
                    "offsetInEndSection": 258,
                    "text": "Dedifferentiation, a common mechanism of non-genetic resistance in melanoma is characterized by the loss of melanocytic markers.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28649789",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 297,
                    "text": "MITF governs multiple steps in the development of melanocytes, including specification from neural crest, growth, survival, and terminal differentiation. In addition, the level of MITF activity determines the phenotype adopted by melanoma cells, whether invasive, proliferative, or differentiated.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which cell states can exist in melanomas?",
            "type": "list",
            "id": "661d9e79fe9d0b3967000001",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/14968944",
                "http://www.ncbi.nlm.nih.gov/pubmed/16291583",
                "http://www.ncbi.nlm.nih.gov/pubmed/19238627",
                "http://www.ncbi.nlm.nih.gov/pubmed/37013782",
                "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
                "http://www.ncbi.nlm.nih.gov/pubmed/37525581",
                "http://www.ncbi.nlm.nih.gov/pubmed/32594093",
                "http://www.ncbi.nlm.nih.gov/pubmed/10668856",
                "http://www.ncbi.nlm.nih.gov/pubmed/10829050",
                "http://www.ncbi.nlm.nih.gov/pubmed/32514617"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14968944",
                    "offsetInBeginSection": 87,
                    "offsetInEndSection": 472,
                    "text": "The incidence of this side effect is claimed to dependent on infusion rate and therefore a 2-h infusion is often recommended. For practical reasons and for the convenience of the patient, we used XELOX (Xeloda 2000 mg/m2 orally on days 1-14 and oxaliplatin 130 mg/m2 as a 30-min infusion on day 1) in patients with advanced colorectal cancer resistant to irinotecan and 5-fluorouracil.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16291583",
                    "offsetInBeginSection": 255,
                    "offsetInEndSection": 636,
                    "text": "The incidence is claimed to be infusion rate-dependent and therefore a 2-h infusion is recommended. For practical and economic reasons, but also for patient's convenience, we performed a phase II study to examine XELOX30 (capecitabine 1000 mg/m2 orally twice daily on days 1-14 and oxaliplatin 130 mg/m2 as a 30 min infusion on day 1) in patients with ACRC resistant to irinotecan.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19238627",
                    "offsetInBeginSection": 251,
                    "offsetInEndSection": 577,
                    "text": "Dose-limiting toxicity of oxaliplatin is peripheral sensory neuropathy and it is recommended to give oxaliplatin as a 120 min infusion. However, in patients with colorectal cancer a 30 min infusion of oxaliplatin can safely be administered without increasing neurotoxicity, standard infusion time is 30 min at our departments.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37013782",
                    "offsetInBeginSection": 1063,
                    "offsetInEndSection": 1189,
                    "text": "Prolongation of the infusion time was effective in the re-administration of oxaliplatin in six of the hypersensitive patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1553,
                    "text": "Oxaliplatin at a dose of 85 mg/m(2) traditionally has been administered over 120 min in the standard FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) regimen. CapeOx (capecitabine plus oxaliplatin), in which the dose of oxaliplatin is 130 mg/m(2), has also been infused over 120 min. Maintenance of a prolonged infusion time has been largely based on the concern for a potential hypersensitivity reaction (HSR) if administered too quickly. We first performed a retrospective review of our institutional experience to assess whether HSR rates were similar in FOLFOX and CapeOx by using computerized pharmacy records between January 1, 2011, and December 31, 2013. We then instituted a new policy to infuse all nonresearch doses of oxaliplatin at a set rate of 1 mg/m(2)/min (85 mg/m(2) given over 85 min; 68 mg/m(2) over 68 min, etc). The incidence of HSRs with the new infusion rate was actively monitored. Of 2,097 patients who previously received oxaliplatin over 120 min, 1,936 received a dose of 85 mg/m(2) ( 10%), and 161 received a dose of 130 mg/m(2). The incidence of HSRs in the 85 mg/m(2) group was 11% versus 7% in the 130 mg/m(2) group (P = .13). Then between December 1, 2014, and June 4, 2015, 667 patients received oxaliplatin at a rate of 1 mg/m(2)/min for all doses. The incidence of HSRs in patients treated at this fixed infusion rate was 8%. Infusing oxaliplatin at a rate of 1 mg/m(2)/min does not increase the rate of HSRs and does not compromise patient safety. This infusion rate is safe for use in routine practice.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37525581",
                    "offsetInBeginSection": 728,
                    "offsetInEndSection": 878,
                    "text": "Rapid-rate oxaliplatin was not associated with increased HSR or difference in toxicity requiring dose reduction, delayed dose, or slowed infusion rate",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32594093",
                    "offsetInBeginSection": 1367,
                    "offsetInEndSection": 1452,
                    "text": "Increased infusion time effectively prevented dysarthria during subsequent infusions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10668856",
                    "offsetInBeginSection": 2189,
                    "offsetInEndSection": 2416,
                    "text": "The prolonged stability of oxaliplatin makes it suitable for continuous infusions over 4 to 5 days, with a delivery rate which can be either constant or chronomodulated (peak rate at 1600h), using programmable ambulatory pumps.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10829050",
                    "offsetInBeginSection": 343,
                    "offsetInEndSection": 478,
                    "text": "Raltitrexed was administered as a 15-minute infusion followed by oxaliplatin as a 2-hour infusion 1 hour later, repeated every 3 weeks.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32514617",
                    "offsetInBeginSection": 1025,
                    "offsetInEndSection": 1105,
                    "text": "The mean dose of oxaliplatin administered was 162 mg per cure over 6.7-h course.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the faster length time for oxaliplatin infusion?",
            "type": "factoid",
            "id": "66099967fdcbea915f000018",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7806786",
                "http://www.ncbi.nlm.nih.gov/pubmed/31835250",
                "http://www.ncbi.nlm.nih.gov/pubmed/36600777",
                "http://www.ncbi.nlm.nih.gov/pubmed/27237542",
                "http://www.ncbi.nlm.nih.gov/pubmed/20384766",
                "http://www.ncbi.nlm.nih.gov/pubmed/16552568",
                "http://www.ncbi.nlm.nih.gov/pubmed/10449075",
                "http://www.ncbi.nlm.nih.gov/pubmed/27923529",
                "http://www.ncbi.nlm.nih.gov/pubmed/32280261",
                "http://www.ncbi.nlm.nih.gov/pubmed/7631070"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7806786",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 497,
                    "text": "Although corpus callosotomy has been used since 1940 to treat severe, medically intractable seizure disorders, controversy remains as to when, or even if, the surgery should be performed. Unlike other types of surgical therapy of epilepsy where the epileptic focus is identified and removed, corpus callosotomy is used to interrupt the propagation of epileptic discharges. The procedure is primarily used in patients with secondarily generalized seizures in whom focal resections are not possible.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31835250",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "text": "Corpus callosotomy is a palliative procedure that is effective at reducing seizure burden in patients with medically refractory epilepsy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36600777",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 260,
                    "text": "Medically refractory epilepsy constitutes up to one-third of the epilepsy pediatric patients. Corpus callosotomy (CC) has been used for the treatment of medically refractory epilepsy in children with atonic seizures and generalized tonic-clonic (GTC) seizures.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27237542",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 157,
                    "text": "Corpus callosotomy is a palliative neurosurgical treatment for patients with either generalized or multifocal refractory epilepsy and injurious drop attacks.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20384766",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 355,
                    "text": "Although many patients with medically refractory focal epilepsy are candidates for resective surgery, patients with multifocal epilepsy and symptomatic generalized epilepsy remain difficult to treat medically and surgically. Corpus callosotomy has been utilized since 1940 for the treatment of seizures, with reports of efficacy in multiple seizure types.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16552568",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "Epilepsy surgery is a standard of care in the treatment of medically intractable epilepsy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16552568",
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 340,
                    "text": "Corpus callosotomy is a surgical treatment option for patients with potentially injurious drop attacks and disabling generalized seizures.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10449075",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 112,
                    "text": "Corpus callosotomy is a surgical option for medically uncontrolled generalized epilepsy in appropriate patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27923529",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "text": "Corpus callosotomy is a palliative therapy for refractory epilepsy, including West syndrome, without a resectable epileptic focus.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32280261",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "text": "Corpus callosotomy (CCT) is a palliative procedure to treat injurious drop attacks or multifocal/generalized seizures in which resection of the epileptogenic focus is not feasible.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What disease is treated by Callosotomy",
            "type": "factoid",
            "id": "661be55f48a2c27714000003",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/34555028",
                "http://www.ncbi.nlm.nih.gov/pubmed/37201742",
                "http://www.ncbi.nlm.nih.gov/pubmed/33491921",
                "http://www.ncbi.nlm.nih.gov/pubmed/36213653",
                "http://www.ncbi.nlm.nih.gov/pubmed/26624960",
                "http://www.ncbi.nlm.nih.gov/pubmed/28702195",
                "http://www.ncbi.nlm.nih.gov/pubmed/17662560",
                "http://www.ncbi.nlm.nih.gov/pubmed/26558692",
                "http://www.ncbi.nlm.nih.gov/pubmed/37890901",
                "http://www.ncbi.nlm.nih.gov/pubmed/17577816"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34555028",
                    "offsetInBeginSection": 434,
                    "offsetInEndSection": 1480,
                    "text": "In this paper, we aimed to evaluate the potential of a selection of genes that have been considered biomarkers in humans, to differentially diagnose bacterial from viral infections in the pig. First porcine PBMC were induced with six toll-like receptor (TLR) agonists (FliC, LPS, ODN 2216, Pam3CSK4, poly I:C, R848) to mimic host gene expression induced by bacterial or viral pathogens, or exposed to heat-killed Actinobacillus pleuropneumoniae or a split influenza virus. Genes that were differentially expressed between bacterial and viral inducers were further evaluated on clinical material comprising eleven healthy pigs, and six pigs infected with A. pleuropneumoniae. This comprised three virally upregulated genes (IFI44L, MxA, RSAD2) and four bacterially upregulated genes (IL-1, IL-8, FAM89A, S100PBP). All six infected pigs could be differentially diagnosed to healthy pigs using a host gene transcription assay based on the geometric average of the bacterially induced genes IL-8 and S100PBP over that of the virally induced gene MxA.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37201742",
                    "offsetInBeginSection": 169,
                    "offsetInEndSection": 339,
                    "text": "Recently, FDA cleared a multivariate index test called MeMed-BV that distinguishes viral and bacterial infections based on the differential expression of 3 host proteins.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37201742",
                    "offsetInBeginSection": 1103,
                    "offsetInEndSection": 1238,
                    "text": "Diagnostic accuracy studies revealed a sensitivity of 94% and specificity of 88% for identifying bacterial infections or co-infections.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37201742",
                    "offsetInBeginSection": 1531,
                    "offsetInEndSection": 1735,
                    "text": "Importantly, the MeMed-BV test performed better than routinely measured infection-related biomarkers like white blood cell counts, procalcitonin and C-reactive protein in classifying bacterial infections.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33491921",
                    "offsetInBeginSection": 981,
                    "offsetInEndSection": 1381,
                    "text": "mCD169 was elevated in patients with viral infections, with a majority of Flu A virus or Respiratory Syncytial Virus, while nCD64 was elevated in subjects with bacterial infections, with a majority of Streptococcus pneumoniae and Escherichia coli. nCD64 and mCD169 showed 90% and 80% sensitivity, and 78% and 91% specificity, respectively, for identifying patients with bacterial or viral infections.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36213653",
                    "offsetInBeginSection": 267,
                    "offsetInEndSection": 671,
                    "text": "Recent data suggest that CD169 may represent a promising new biomarker in acute respiratory and non-respiratory viral infections, such as SARS-CoV-2, Respiratory syncytial virus (RSV) and Human immunodeficiency virus (HIV). Therein lies a great potential to sufficiently differentiate viral from bacterial infection, which has been an incessant challenge in the clinical management of infectious disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26624960",
                    "offsetInBeginSection": 337,
                    "offsetInEndSection": 688,
                    "text": "Assessment of areas under the receiver-operator characteristic curves revealed that 2-5AS and CRP levels and the age of the patient differentiated between viral and bacterial infections, 2-5AS levels differentiated between viral infection and non-infectious disease and PCT levels differentiated between bacterial infection and non-infectious disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28702195",
                    "offsetInBeginSection": 1119,
                    "offsetInEndSection": 1387,
                    "text": "We present the discovery and validation of salmon host transcriptional biomarkers capable of distinguishing fish in an active viral disease state [viral disease development (VDD)] from those carrying a latent viral infection, and viral versus bacterial disease states.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17662560",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 222,
                    "text": "The values of procalcitonin (PCT), neopterin, and C-reactive protein (CRP) alone and in combination to differentiate bacterial from viral etiology in patients with lower respiratory tract infections (LRTIs) were evaluated.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17662560",
                    "offsetInBeginSection": 474,
                    "offsetInEndSection": 662,
                    "text": "The area under the receiver operating characteristic (ROC) curve (area under curve [AUC]) for distinguishing bacterial from viral infections was 0.838 for CRP and 0.770 for PCT (P < 0.05).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Are there any molecular signatures identified for the differentiation between bacterial and viral infections?",
            "type": "yesno",
            "id": "661d1c3ceac11fad33000012",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29897831",
                "http://www.ncbi.nlm.nih.gov/pubmed/35746442",
                "http://www.ncbi.nlm.nih.gov/pubmed/32082265",
                "http://www.ncbi.nlm.nih.gov/pubmed/30852345",
                "http://www.ncbi.nlm.nih.gov/pubmed/29300166",
                "http://www.ncbi.nlm.nih.gov/pubmed/36541807",
                "http://www.ncbi.nlm.nih.gov/pubmed/35834540",
                "http://www.ncbi.nlm.nih.gov/pubmed/28758019",
                "http://www.ncbi.nlm.nih.gov/pubmed/32669655",
                "http://www.ncbi.nlm.nih.gov/pubmed/32194996"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29897831",
                    "offsetInBeginSection": 238,
                    "offsetInEndSection": 310,
                    "text": "There is no licensed vaccine or drug to prevent or treat ZIKV infection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35746442",
                    "offsetInBeginSection": 579,
                    "offsetInEndSection": 861,
                    "text": "To date, there are no approved DENV and ZIKA vaccines available, except a Dengue vaccine (Dengvaxia, Sanofi Pasteur Inc., Lyon, France) recently approved to be used only for 9-16 years of age groups living in endemic areas and having a previous record of confirmed dengue infection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32082265",
                    "offsetInBeginSection": 192,
                    "offsetInEndSection": 298,
                    "text": "Currently, there are no vaccines or therapeutic drugs clinically approved for treatments of ZIKV infection",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30852345",
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 221,
                    "text": "No clinically approved vaccine or drug is currently available for ZIKV.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29300166",
                    "offsetInBeginSection": 195,
                    "offsetInEndSection": 303,
                    "text": "To date, no approved antiviral therapeutics to treat, nor vaccines to prevent, ZIKV infection are available.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36541807",
                    "offsetInBeginSection": 272,
                    "offsetInEndSection": 395,
                    "text": "Although different types of vaccine antigens have been investigated, there is still no approved vaccine that prevents ZIKV.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35834540",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "text": "There are currently no approved drugs to treat Zika virus (ZIKV) infection during pregnancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28758019",
                    "offsetInBeginSection": 499,
                    "offsetInEndSection": 548,
                    "text": "No licensed prophylactic vaccine is yet available",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32669655",
                    "offsetInBeginSection": 262,
                    "offsetInEndSection": 382,
                    "text": "However, there are currently no approved vaccines or specific antiviral drugs for preventing or treating ZIKV infection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32194996",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 487,
                    "text": "The recent spread of Zika virus (ZIKV) through the Americas and Caribbean and its devastating consequences for pregnant women and their babies have driven the search for a safe and efficacious ZIKV vaccine. Among the vaccine candidates, a first-generation ZIKV purified inactivated vaccine (ZPIV), adjuvanted with aluminum hydroxide, developed by the Walter Reed Army Institute of Research (WRAIR), has elicited high seroconversion rates in participants in three phase-I clinical trials.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is there an approved vaccine to prevent Zika virus infection during pregnancy?",
            "type": "yesno",
            "id": "6614fe3dfdcbea915f000045",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36453510",
                "http://www.ncbi.nlm.nih.gov/pubmed/27355333",
                "http://www.ncbi.nlm.nih.gov/pubmed/36698225",
                "http://www.ncbi.nlm.nih.gov/pubmed/31768950"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36453510",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 508,
                    "text": "Heterozygous mutations in the cytoplasmic and mitochondrial isoforms of isocitrate dehydrogenase enzymes 1 and 2 subtypes have been extensively exploited as viable druggable targets, as they decrease the affinity of isocitrate and higher affinity of D-2-hydroxyglutarate, an oncometabolite. Vorasidenib (AG-881) has recently been reported as a promising dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 with the ability to penetrate the blood-brain barrier towards the treatment of low-grade glioma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27355333",
                    "offsetInBeginSection": 801,
                    "offsetInEndSection": 993,
                    "text": "Current targeted inhibitors of IDH1 (AG120, IDH305), IDH2 (AG221), and pan-IDH1/2 (AG881) selectively inhibit mutant IDH protein and induce cell differentiation in in vitro and in vivo models.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36698225",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 229,
                    "text": "Targeting mutated isocitrate dehydrogenase 1 (mIDH1) is one of the key therapeutic strategies for the treatment of glioma. Few inhibitors, such as ivosidenib and vorasidenib, have been identified as selective inhibitors of mIDH1.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27355333",
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 273,
                    "text": "Recurrent mutations in IDH1 or IDH2 are prevalent in several cancers including glioma, acute myeloid leukemia (AML), cholangiocarcinoma and chondrosarcoma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27355333",
                    "offsetInBeginSection": 274,
                    "offsetInEndSection": 442,
                    "text": "The mutated IDH1 and IDH2 proteins have a gain-of-function, neomorphic activity, catalyzing the reduction of -ketoglutarate (-KG) to 2-hydroxyglutarate (2-HG) by NADPH.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31768950",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1038,
                    "text": "Mutations in the isocitrate dehydrogenase (IDH) 1 gene are commonly found in human glioma, with the majority of low-grade gliomas harboring a recurrent point mutation (IDH1 R132H). Mutant IDH reveals an altered enzymatic activity leading to the synthesis of 2-hydroxyglutarate, which has been implicated in epigenetic mechanisms of oncogenesis. Nevertheless, it is unclear exactly how IDH mutations drive glioma initiation and progression, and it is also not clear why tumors with this mutation generally have a better prognosis than IDH wild-type tumors. Recognition of the high frequency of IDH mutations in glioma [and also in other malignancies, including acute myeloid leukemia (AML) and cholangiocarcinoma] have led to the development of a number of targeted agents that can inhibit these enzymes. Enasidenib and ivosidenib have both gained regulatory approval for IDH mutant AML. Both agents are still in early clinical phases for glioma therapy, as are a number of additional candidates (including AG-881, BAY1436032, and DS1001).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What enzymes are inhibited by Vorasidenib?",
            "type": "list",
            "id": "65cfcb4c1930410b13000017",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [],
            "snippets": [],
            "body": "What is acupotomy?",
            "type": "summary",
            "id": "65f03bf8c4010b4d78000003",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23016620",
                "http://www.ncbi.nlm.nih.gov/pubmed/16615961",
                "http://www.ncbi.nlm.nih.gov/pubmed/17661570",
                "http://www.ncbi.nlm.nih.gov/pubmed/21247481",
                "http://www.ncbi.nlm.nih.gov/pubmed/15750102",
                "http://www.ncbi.nlm.nih.gov/pubmed/26845714",
                "http://www.ncbi.nlm.nih.gov/pubmed/11427433",
                "http://www.ncbi.nlm.nih.gov/pubmed/32708203",
                "http://www.ncbi.nlm.nih.gov/pubmed/14762453",
                "http://www.ncbi.nlm.nih.gov/pubmed/24172840"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23016620",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 252,
                    "text": "Perinatal transmission of human cytomegalovirus (HCMV) infection in very low birth weight (VLBW) premature infants can lead to serious clinical symptoms and it has ben increasingly recognized that breast milk is the most frequent route of transmission.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23016620",
                    "offsetInBeginSection": 430,
                    "offsetInEndSection": 556,
                    "text": "The majority of HCMV seropositive mothers shed the virus into their breast milk and can transmit infection to their offspring.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23016620",
                    "offsetInBeginSection": 1088,
                    "offsetInEndSection": 1268,
                    "text": "Preterm infants with a gestational age <30 weeks, or with a birth weight <1000 g, are at greater risk of severe postnatal symptomatic HCMV infection, transmitted via maternal milk.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16615961",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 184,
                    "text": "Preterm infants are at risk of acquiring human cytomegalovirus (CMV) infection through breast milk transmission, possibly leading to serious symptoms, as suggested by previous studies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17661570",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 80,
                    "text": "Human cytomegalovirus (HCMV) can be transmitted through breast milk to neonates.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17661570",
                    "offsetInBeginSection": 81,
                    "offsetInEndSection": 261,
                    "text": "Although healthy full-term infants rarely develop symptoms of CMV infection; premature or low-birth-weight infants can experience symptomatic infection that is occasionally severe.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21247481",
                    "offsetInBeginSection": 822,
                    "offsetInEndSection": 1164,
                    "text": "70.2% of tested mothers showed reactivation of the infection, and CMV-positive breast milk during the six weeks postpartum has been found. However, only one infant was infected by CMV, developing hepatic affection concomitantly with a multi-system involvement, as shown CMV DNA detection in urine, saliva, blood, gastric aspirate, and stools.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15750102",
                    "offsetInBeginSection": 353,
                    "offsetInEndSection": 1359,
                    "text": "Of the 73 mothers, 48 (66%) were positive for HCMV DNA in the lactating breast. HCMV reactivation could be confirmed for 19 of 20 (95%) immunoglobulin G-positive mothers. Of the eight immunoglobulin G-negative mothers one was positive for HCMV DNA in breast milk. In only 2 out of 13 seropositive mothers with HCMV DNA in breast milk could viral DNA be detected in the peripheral blood. HCMV mother-to-child transmission was concluded for 20 of the 48 (42%) mothers positive for DNA or 7 of 19 (37%) seropositive for HCMV and positive for HCMV DNA in breast milk and one of one mother seronegative for HCMV but positive for HCMV DNA in breast milk. One mother transmitted the virus to her twins. In addition, one infant acquired postnatal HCMV infection despite the mother's being negative for HCMV DNA in breast milk; altogether, we found 22 infants with HCMV infection. In 13 of these 22 infants, virus infection occurred definitively postnatally; two of them developed severe symptomatic HCMV infection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26845714",
                    "offsetInBeginSection": 496,
                    "offsetInEndSection": 666,
                    "text": "Among the 1236 preterm neonates included, 10 had a congenital infection (0.8%) and 49 had an acquired infection (4.0%) (82% demonstrated positive PCR-CMV in breast milk).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26845714",
                    "offsetInBeginSection": 667,
                    "offsetInEndSection": 837,
                    "text": "The neonates who received only frozen milk presented less frequently with acquired infection (1.2%) than those fed fresh milk (5.5%) (RR=0.22; 95% CI 0.05-0.90; P=0.017).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can cytomegalovirus (CMV) be transmitted via breast milk to premature infants?",
            "type": "yesno",
            "id": "661d20b7eac11fad33000016",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37193451",
                "http://www.ncbi.nlm.nih.gov/pubmed/32968365",
                "http://www.ncbi.nlm.nih.gov/pubmed/32095167",
                "http://www.ncbi.nlm.nih.gov/pubmed/24887789",
                "http://www.ncbi.nlm.nih.gov/pubmed/33769894",
                "http://www.ncbi.nlm.nih.gov/pubmed/34546622",
                "http://www.ncbi.nlm.nih.gov/pubmed/24882440",
                "http://www.ncbi.nlm.nih.gov/pubmed/22272666",
                "http://www.ncbi.nlm.nih.gov/pubmed/33919428",
                "http://www.ncbi.nlm.nih.gov/pubmed/29458155"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37193451",
                    "offsetInBeginSection": 207,
                    "offsetInEndSection": 338,
                    "text": "Routine CRC screening is advised for people with average risk starting at age 45 because it is a common and preventable malignancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32968365",
                    "offsetInBeginSection": 534,
                    "offsetInEndSection": 646,
                    "text": "new screening recommendations have recently lowered the age for screening average-risk individuals from 50 to 45",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32095167",
                    "offsetInBeginSection": 1311,
                    "offsetInEndSection": 1700,
                    "text": "Although Multi-Society Task Force (MSTF) and American College of Physicians (ACP) recommend initiating screening colonoscopy at age 50 years in all individuals except African Americans who should begin screening colonoscopy at age 45 years, the American Cancer Society (ACS) recommends initiating screening colonoscopy at age 45 years in all individuals irrespective of race and ethnicity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24887789",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "text": "The U.S. Preventive Services Task Force (USPSTF) recommends screening for colorectal cancer (CRC) in adults, beginning at age 50 years and continuing until age 75 years.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33769894",
                    "offsetInBeginSection": 531,
                    "offsetInEndSection": 655,
                    "text": "Screening strategies were simulated for individuals without CRC at age 40 and screened from ages 50 to 75 or 45 to 75 years.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34546622",
                    "offsetInBeginSection": 816,
                    "offsetInEndSection": 897,
                    "text": "36% correctly identified the current age of recommended CRC screening initiation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24882440",
                    "offsetInBeginSection": 700,
                    "offsetInEndSection": 805,
                    "text": "A third of the HCPs (30%) knew the recommended age to begin CRC screening for patients with average risk.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22272666",
                    "offsetInBeginSection": 933,
                    "offsetInEndSection": 1167,
                    "text": "Only 28% of physicians correctly identified the screening initiation point for African-Americans while only 12% of physicians correctly identified the screening initiation point and interval for a patient with a family history of CRC.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33919428",
                    "offsetInBeginSection": 120,
                    "offsetInEndSection": 649,
                    "text": "Organized screening programs targeting Canadians aged 50 to 74 at average risk of developing the disease have contributed to decreased rates of CRC, improved patient outcomes and reduced healthcare costs. However, data shows that recent incidence reductions are unique to the screening-age population, while rates in people under-50 are on the rise. Similar incidence patterns in the United States prompted the American Cancer Society and U.S. Preventive Services Task Force to recommend screening begin at age 45 rather than 50.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29458155",
                    "offsetInBeginSection": 1973,
                    "offsetInEndSection": 2248,
                    "text": "Although screening is recommended to begin at age 50 years for individuals with no family history of CRC, starting ages calculated based on combined E-score and G-score differed by 12 years for men and 14 for women, for individuals with the highest vs the lowest 10% of risk.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "From what age is it recommended to start population screening for colorectal cancer?",
            "type": "factoid",
            "id": "66099a03fdcbea915f00001d",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15043803",
                "http://www.ncbi.nlm.nih.gov/pubmed/23209063",
                "http://www.ncbi.nlm.nih.gov/pubmed/19733364",
                "http://www.ncbi.nlm.nih.gov/pubmed/24450147",
                "http://www.ncbi.nlm.nih.gov/pubmed/28725699",
                "http://www.ncbi.nlm.nih.gov/pubmed/18989112",
                "http://www.ncbi.nlm.nih.gov/pubmed/24687897",
                "http://www.ncbi.nlm.nih.gov/pubmed/25890772",
                "http://www.ncbi.nlm.nih.gov/pubmed/25656841",
                "http://www.ncbi.nlm.nih.gov/pubmed/20522090"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15043803",
                    "offsetInBeginSection": 343,
                    "offsetInEndSection": 422,
                    "text": "Prevalence studies suggest that up to 30% of patients with PD develop dementia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23209063",
                    "offsetInBeginSection": 501,
                    "offsetInEndSection": 552,
                    "text": "The point prevalence of dementia in PD is about 30%",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19733364",
                    "offsetInBeginSection": 173,
                    "offsetInEndSection": 424,
                    "text": "The point prevalence of dementia in PD is close to 30% and the incidence rate is increased 4-6 times as compared to controls. The cumulative prevalence is very high, at least 75% of PD patients who survive for more than 10 years will develop dementia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24450147",
                    "offsetInBeginSection": 1181,
                    "offsetInEndSection": 1338,
                    "text": "Cross-sectional studies have commonly reported dementia in 20-30% of PD patients, although the 8-year cumulative incidence of dementia may be as high as 78%.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28725699",
                    "offsetInBeginSection": 130,
                    "offsetInEndSection": 267,
                    "text": "PD-MCI is six times more likely than age-matched controls to develop dementia and the PDD prevalence is 80% after 15-20 years of disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18989112",
                    "offsetInBeginSection": 337,
                    "offsetInEndSection": 458,
                    "text": "A very high cumulative prevalence of dementia in Parkinson's disease has been shown in two independent long-term cohorts.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24687897",
                    "offsetInBeginSection": 1187,
                    "offsetInEndSection": 1275,
                    "text": "Dementia developed in 13 patients with an incidence rate of 35.7 per 1,000 person-years.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25890772",
                    "offsetInBeginSection": 640,
                    "offsetInEndSection": 785,
                    "text": "According to the Movement Disorder Society Task Force consensus criteria, up to 29.1% of PD patients were classified as PD-MCI and 32.1% as PD-D.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25656841",
                    "offsetInBeginSection": 708,
                    "offsetInEndSection": 841,
                    "text": "Cognitive impairment was frequent in patients with PD; MCI was found in 38.9% of patients, whereas dementia was in 38.3% of patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20522090",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "text": "The prevalence of cognitive impairment and dementia in Parkinson's disease (PD) is high and can potentially occur as the result of multiple differing pathologies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "How many people affected by Parkinson's Disease develop dementia?",
            "type": "factoid",
            "id": "660d7324fdcbea915f000040",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35121725",
                "http://www.ncbi.nlm.nih.gov/pubmed/32616859",
                "http://www.ncbi.nlm.nih.gov/pubmed/23595227",
                "http://www.ncbi.nlm.nih.gov/pubmed/30917778",
                "http://www.ncbi.nlm.nih.gov/pubmed/30587130",
                "http://www.ncbi.nlm.nih.gov/pubmed/29498679",
                "http://www.ncbi.nlm.nih.gov/pubmed/35580127",
                "http://www.ncbi.nlm.nih.gov/pubmed/32669118",
                "http://www.ncbi.nlm.nih.gov/pubmed/30130256",
                "http://www.ncbi.nlm.nih.gov/pubmed/36889906"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35121725",
                    "offsetInBeginSection": 245,
                    "offsetInEndSection": 394,
                    "text": "H3K27ac is a characteristic marker for identifying active enhancers and even indicates chromatin accessibility associated with super-enhancers (SEs).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32616859",
                    "offsetInBeginSection": 757,
                    "offsetInEndSection": 839,
                    "text": "H3K4me1 and H3K4me3, which are indicators of active enhancers and active promoters",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23595227",
                    "offsetInBeginSection": 742,
                    "offsetInEndSection": 1456,
                    "text": "The preferentially bound chromatin states of regulators were enriched for sequence motifs of regulators relative to all states, suggesting that these preferences are at least partly encoded by the genomic sequence. Relative to all regions bound by a regulator, however, regulatory motifs were surprisingly depleted in the regulator's preferentially bound states, suggesting additional non-sequence-specific binding beyond the level predicted by the regulatory motifs. Such permissive binding was largely restricted to open-chromatin regions showing histone modification marks characteristic of active enhancer and promoter regions, whereas open-chromatin regions lacking such marks did not show permissive binding.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30917778",
                    "offsetInBeginSection": 995,
                    "offsetInEndSection": 1251,
                    "text": "We developed enhancer HMM (eHMM), a supervised hidden Markov model designed to learn the molecular structure of promoters and enhancers. Both consist of a central stretch of accessible DNA flanked by nucleosomes with distinct histone modification patterns.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30917778",
                    "offsetInBeginSection": 1538,
                    "offsetInEndSection": 1682,
                    "text": "eHMM predicts active enhancers based on data from chromatin accessibility assays and a minimal set of histone modification ChIP-seq experiments.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30587130",
                    "offsetInBeginSection": 471,
                    "offsetInEndSection": 688,
                    "text": "Here, we report genome-wide changes of the H3K27ac mark, characteristic of activated enhancers and promoters, after stimulation of nasopharyngeal epithelial cells with the bacterial endotoxin Lipopolysaccharide (LPS).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30587130",
                    "offsetInBeginSection": 689,
                    "offsetInEndSection": 831,
                    "text": "In this study, we have identified 626 regions where the H3K27ac mark showed reproducible increase following LPS induction in epithelial cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30587130",
                    "offsetInBeginSection": 1050,
                    "offsetInEndSection": 1223,
                    "text": "As expected, LPS-increased H3K27ac regions were found in the vicinity of genes relevant for LPS response and these changes correlated with up-regulation of their expression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30587130",
                    "offsetInBeginSection": 1224,
                    "offsetInEndSection": 1409,
                    "text": "In addition, we found the induction of H3K27ac mark to overlap with the binding of one of the NF-kB members and key regulator of the innate immune response, RELA, following LPS sensing.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29498679",
                    "offsetInBeginSection": 819,
                    "offsetInEndSection": 990,
                    "text": "While mono-methylation of H3K4 (H3K4me1) is located preferentially at active enhancers, tri-methylation (H3K4me3) is a mark found at open and potentially active promoters.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What chromatin signatures are characteristic of active enhancers?",
            "type": "list",
            "id": "661c3d1448a2c27714000005",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24674738",
                "http://www.ncbi.nlm.nih.gov/pubmed/31106290",
                "http://www.ncbi.nlm.nih.gov/pubmed/29951530",
                "http://www.ncbi.nlm.nih.gov/pubmed/33870423",
                "http://www.ncbi.nlm.nih.gov/pubmed/29138457",
                "http://www.ncbi.nlm.nih.gov/pubmed/28533025",
                "http://www.ncbi.nlm.nih.gov/pubmed/34539983",
                "http://www.ncbi.nlm.nih.gov/pubmed/28936977",
                "http://www.ncbi.nlm.nih.gov/pubmed/37537618",
                "http://www.ncbi.nlm.nih.gov/pubmed/33034351"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24674738",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "text": "A large portion of the human genome is transcribed into RNAs without known protein-coding functions, far outnumbering coding transcription units.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24674738",
                    "offsetInBeginSection": 373,
                    "offsetInEndSection": 504,
                    "text": "More recently, enhancers have been found to be broadly transcribed, resulting in the production of enhancer-derived RNAs, or eRNAs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24674738",
                    "offsetInBeginSection": 505,
                    "offsetInEndSection": 607,
                    "text": "Here, we review emerging evidence suggesting that at least some eRNAs contribute to enhancer function.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24674738",
                    "offsetInBeginSection": 608,
                    "offsetInEndSection": 736,
                    "text": "We discuss these findings with respect to potential mechanisms of action of eRNAs and other ncRNAs in regulated gene expression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31106290",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 231,
                    "text": "Enhancers play a central role in the transcriptional regulation of metazoans. Almost a decade ago, the discovery of their pervasive transcription into noncoding RNAs, termed enhancer RNAs (eRNAs), opened a whole new field of study.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31106290",
                    "offsetInBeginSection": 232,
                    "offsetInEndSection": 361,
                    "text": "The presence of eRNAs correlates with enhancer activity; however, whether they act as functional molecules remains controversial.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31106290",
                    "offsetInBeginSection": 362,
                    "offsetInEndSection": 586,
                    "text": "Here we review direct experimental evidence supporting a functional role of eRNAs in transcription and provide a general pipeline that could help in the design of experimental approaches to investigate the function of eRNAs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31106290",
                    "offsetInBeginSection": 587,
                    "offsetInEndSection": 829,
                    "text": "We propose that induction of transcriptional activity at enhancers promotes an increase in its activity by an RNA-mediated titration of regulatory proteins that can impact different processes like chromatin accessibility or chromatin looping.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31106290",
                    "offsetInBeginSection": 830,
                    "offsetInEndSection": 1089,
                    "text": "In a few cases, transcripts originating from enhancers have acquired specific molecular functions to regulate gene expression. We speculate that these transcripts are either nonannotated long noncoding RNAs (lncRNAs) or are evolving toward functional lncRNAs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29951530",
                    "offsetInBeginSection": 413,
                    "offsetInEndSection": 570,
                    "text": "These eRNAs can promote enhancer-promoter (E-P) looping formation by binding to other protein factors or propel expression of downstream protein-coding gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are eRNAs and what is their function?",
            "type": "summary",
            "id": "661c416048a2c27714000008",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30858776",
                "http://www.ncbi.nlm.nih.gov/pubmed/35396906",
                "http://www.ncbi.nlm.nih.gov/pubmed/26452443",
                "http://www.ncbi.nlm.nih.gov/pubmed/30983397",
                "http://www.ncbi.nlm.nih.gov/pubmed/22781752",
                "http://www.ncbi.nlm.nih.gov/pubmed/9181775",
                "http://www.ncbi.nlm.nih.gov/pubmed/34437011",
                "http://www.ncbi.nlm.nih.gov/pubmed/11704406",
                "http://www.ncbi.nlm.nih.gov/pubmed/9557891",
                "http://www.ncbi.nlm.nih.gov/pubmed/6705261"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30858776",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 197,
                    "text": "The Ehlers-Danlos syndrome (EDS) is a non-inflammatory, heritable connective tissue disorder divided into 13 types according to the 2017 International Classification of the Ehlers-Danlos syndromes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35396906",
                    "offsetInBeginSection": 182,
                    "offsetInEndSection": 435,
                    "text": "Fourteen subtypes of Ehlers-Danlos Syndrome (EDS) have been described, each with characteristic phenotypes and associated genes. Pathogenic variants in COL5A1 and COL5A2 cause the classical EDS subtypes. Pathogenic variants in COL3A1 cause vascular EDS.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26452443",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 158,
                    "text": "Ehlers-Danlos syndrome is a heterogeneous group of heritable connective tissue disorders characterized by increased fragility of various non-ossified tissues.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30983397",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 187,
                    "text": "In this review article, the authors summarize the clinical aspects of the novel classification of Ehlers-Danlos syndrome, which is a group of rare, hereditary connective tissue disorders.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30983397",
                    "offsetInBeginSection": 188,
                    "offsetInEndSection": 325,
                    "text": "The leading symptom of the Ehlers-Danlos syndrome group is joint hypermobility, skin hyperextensibility and generalized tissue fragility.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30983397",
                    "offsetInBeginSection": 326,
                    "offsetInEndSection": 446,
                    "text": "Ehlers-Danlos syndrome displays a high clinical and genetic heterogeneity and harbors many multidisciplinary properties.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30983397",
                    "offsetInBeginSection": 447,
                    "offsetInEndSection": 583,
                    "text": "Certain subtypes only affect the quality of life, while other forms may lead to severe, even fatal vascular or intestinal complications.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30983397",
                    "offsetInBeginSection": 584,
                    "offsetInEndSection": 771,
                    "text": "Last year, based on the data of various international genotype-phenotype correlation studies of large populations, a new classification of the syndrome's clinical subtypes was introduced.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30983397",
                    "offsetInBeginSection": 772,
                    "offsetInEndSection": 983,
                    "text": "The novel international nosology of Ehlers-Danlos syndromes published in 2017 delineates 13 clinical subtypes, describes their genetic background and defines major and minor diagnostic criteria for each subtype.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22781752",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "text": "Gastrointestinal complications are common in patients with Ehlers-Danlos syndrome, affecting up to 50% of individuals depending on the subtype.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the types of Ehlers-Danlos Syndrome?",
            "type": "list",
            "id": "661d4fabeac11fad3300001c",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20519818",
                "http://www.ncbi.nlm.nih.gov/pubmed/18790253",
                "http://www.ncbi.nlm.nih.gov/pubmed/36398875",
                "http://www.ncbi.nlm.nih.gov/pubmed/23460378",
                "http://www.ncbi.nlm.nih.gov/pubmed/16317748",
                "http://www.ncbi.nlm.nih.gov/pubmed/30602365",
                "http://www.ncbi.nlm.nih.gov/pubmed/23331314",
                "http://www.ncbi.nlm.nih.gov/pubmed/28181126",
                "http://www.ncbi.nlm.nih.gov/pubmed/17110690",
                "http://www.ncbi.nlm.nih.gov/pubmed/19096887"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20519818",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "text": "Reversible posterior leukoencephalopathy syndrome (RPLS) is one of the important adverse events following organ transplantation, associated with calcineurin inhibitors (CNIs).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18790253",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "text": "Reversible posterior leukoencephalopathy syndrome (RPLS) is one of the important side effects of calcineurin inhibitors (CNIs).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18790253",
                    "offsetInBeginSection": 389,
                    "offsetInEndSection": 482,
                    "text": "Herein we have described 2 cases (1.7%) of RPLS induced by CNIs after kidney transplantation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18790253",
                    "offsetInBeginSection": 1167,
                    "offsetInEndSection": 1351,
                    "text": "In both patients, RPLS was diagnosed with neurological symptoms and MRI findings at early stage of the disease, and they recovered rapidly from the disease by the interruption of CNIs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36398875",
                    "offsetInBeginSection": 1044,
                    "offsetInEndSection": 1116,
                    "text": "Renal insufficiency and high tacrolimus levels are associated with PRES.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23460378",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "text": "Tacrolimus-associated posterior reversible encephalopathy syndrome (PRES) is a potential complication of allogeneic stem cell transplant (SCT).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23460378",
                    "offsetInBeginSection": 548,
                    "offsetInEndSection": 738,
                    "text": "Nineteen patients were identified. Altered mental status, seizures, and visual abnormalities were experienced by 78.9%, 52.6%, and 31.5% of the patients, respectively, at time of PRES onset.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16317748",
                    "offsetInBeginSection": 728,
                    "offsetInEndSection": 911,
                    "text": "Seizure activity was proximate to cytarabine and tacrolimus administration in three patients and further seizures occurred with re-administration of these medications in two patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30602365",
                    "offsetInBeginSection": 769,
                    "offsetInEndSection": 1064,
                    "text": "After several possible causes were excluded, we found that progression of underlying posterior reversible encephalopathy syndrome-induced endothelial damage by overdose of tacrolimus may have been the major cause for deteriorating hypoperfusion of the transplanted liver and fatal graft failure.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23331314",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1481,
                    "text": "Posterior reversible encephalopathy syndrome (PRES) is a disorder characterized by gray and white matter abnormalities in the temporal, parietal, and occipital lobes of the brain. Its etiology has been attributed to renal failure, immunosuppressive drugs such as cyclosporine and tacrolimus, and other potential entities leading to acute hypertension. Clinical findings include headaches, altered mental status, seizures, visual changes, and focal neurologic deficits. We report the case of a child who developed PRES with intracerebral and subarachnoid hemorrhages associated with tacrolimus exposure 10 days after heart transplantation for restrictive cardiomyopathy. The patient initially presented with complex partial seizures, headache, agitation, and hypertension. Head MRI was suggestive of PRES along with intracerebral and subarachnoid hemorrhages. Tacrolimus was discontinued and blood pressure was controlled. The patient's encephalopathy resolved, but he has had ongoing neurologic symptoms secondary to hemorrhage. Generally, PRES is less common in children than in the adult population and is a rare complication of calcineurin inhibitors (CNI). Presentation with secondary hemorrhage also can occur. In children receiving CNIs presenting with new neurologic symptoms, PRES should be considered as prompt discontinuation of the offending agent can induce resolution of symptoms. Children can develop hemorrhage in the context of PRES, leading to increased morbidity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can tacrolimus increase risk of Posterior Reversible Encephalopathy Syndrome?",
            "type": "yesno",
            "id": "65cfe0381930410b13000029",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29967698",
                "http://www.ncbi.nlm.nih.gov/pubmed/36762783",
                "http://www.ncbi.nlm.nih.gov/pubmed/36525493",
                "http://www.ncbi.nlm.nih.gov/pubmed/33535154",
                "http://www.ncbi.nlm.nih.gov/pubmed/29853159",
                "http://www.ncbi.nlm.nih.gov/pubmed/25459672",
                "http://www.ncbi.nlm.nih.gov/pubmed/32883032",
                "http://www.ncbi.nlm.nih.gov/pubmed/12697939",
                "http://www.ncbi.nlm.nih.gov/pubmed/18308150",
                "http://www.ncbi.nlm.nih.gov/pubmed/24188125"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29967698",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 85,
                    "text": "Inflammatory breast cancer (IBC) is a rare but most aggressive breast cancer subtype.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36762783",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "text": "Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer and has a high propensity for distant metastases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36525493",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "text": "Inflammatory breast cancer (IBC), the most aggressive breast cancer subtype, is driven by an immunosuppressive tumor microenvironment (TME).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33535154",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "text": "Inflammatory breast cancer (IBC) is a highly aggressive breast cancer that metastasizes largely via tumor emboli, and has a 5-year survival rate of less than 30%.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29853159",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "text": "Inflammatory Breast Cancer (IBC) is a rare and very aggressive breast cancer, still associated with poor prognosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25459672",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 80,
                    "text": "Inflammatory breast cancer (IBC) is the most aggressive entity of breast cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32883032",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "text": "Inflammatory breast cancer (IBC), although rare, is the most aggressive type of breast cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12697939",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "text": "Inflammatory breast cancer (IBC) is the most aggressive manifestation of primary breast carcinoma, with the clinical and biological characteristics of a rapidly proliferating disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18308150",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer, often presenting with distant metastasis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24188125",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 89,
                    "text": "Inflammatory breast cancer (IBC) is the most aggressive and deadly form of breast cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Inflammatory breast cancer is the most aggressive form of breast cancer.",
            "type": "yesno",
            "id": "660d1285fdcbea915f000036",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/31383813",
                "http://www.ncbi.nlm.nih.gov/pubmed/34775366",
                "http://www.ncbi.nlm.nih.gov/pubmed/33948110",
                "http://www.ncbi.nlm.nih.gov/pubmed/36998297",
                "http://www.ncbi.nlm.nih.gov/pubmed/36862965",
                "http://www.ncbi.nlm.nih.gov/pubmed/36896306",
                "http://www.ncbi.nlm.nih.gov/pubmed/37876934",
                "http://www.ncbi.nlm.nih.gov/pubmed/35340166",
                "http://www.ncbi.nlm.nih.gov/pubmed/36217119",
                "http://www.ncbi.nlm.nih.gov/pubmed/37099945"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31383813",
                    "offsetInBeginSection": 347,
                    "offsetInEndSection": 666,
                    "text": "Nivolumab and pembrolizumab, as well as nivolumab in combination with low-dose ipilimumab-all checkpoint inhibitors-are currently approved by the U.S. Food and Drug Administration (FDA) for patients with MSI-H/dMMR metastatic CRC that progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31383813",
                    "offsetInBeginSection": 2117,
                    "offsetInEndSection": 2319,
                    "text": "Combination therapy (e.g., nivolumab with low-dose ipilimumab) has demonstrated numerically higher response rates and improved long-term clinical benefit relative to anti-programmed death-1 monotherapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34775366",
                    "offsetInBeginSection": 218,
                    "offsetInEndSection": 489,
                    "text": "The use of immunotherapy, like nivolumab and pembrolizumab (which are monoclonal antibodies against programmed cell death 1) has shown prosperous outcomes in a group of CRC patients who represent mismatch-repair-deficient and microsatellite instability-high (dMMR-MSI-H).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33948110",
                    "offsetInBeginSection": 255,
                    "offsetInEndSection": 524,
                    "text": "Unfortunately, currently available immunotherapeutics only displayed significant antitumoral activity - in terms of progression free survival (PFS) and objective response rate (ORR) - in microsatellite instability-high (MSI-H)/DNA mismatch repair deficient (dMMR) CRCs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36998297",
                    "offsetInBeginSection": 646,
                    "offsetInEndSection": 750,
                    "text": "Pembrolizumab is also strongly recommended as first-line therapy for MSI-H metastatic colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36862965",
                    "offsetInBeginSection": 541,
                    "offsetInEndSection": 731,
                    "text": "Observed deep and durable responses with the use of ICIs in advanced-stage disease have stimulated the development of clinical trials with ICIs for patients with early-stage MMR-D/MSI-H CRC.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36862965",
                    "offsetInBeginSection": 732,
                    "offsetInEndSection": 962,
                    "text": "Most recently, neoadjuvant dostarlimab monotherapy for nonoperative management of MMR-D/MSI-H rectal cancer and neoadjuvant NICHE trial with nivolumab and ipilimumab for MMR-D/MSI-H colon cancer resulted in groundbreaking results.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36896306",
                    "offsetInBeginSection": 409,
                    "offsetInEndSection": 1659,
                    "text": "In this retrospective study, we enrolled 36 patients with dMMR/MSI-H gastrointestinal malignancies. All the patients received PD-1 blockade with or without chemotherapy of CapOx regime preoperatively. PD1 blockade 200 mg was given intravenously over 30 min on day 1 of each 21-d cycle. Three patients with locally advanced gastric cancer achieved pathological complete response (pCR). Three patients with locally advanced duodenal carcinoma achieved clinical complete response (cCR), followed by watch and wait. Eight of 16 patients with locally advanced colon cancer achieved pCR. All four patients with liver metastasis from colon cancer reached CR, including three with pCR and one with cCR. pCR was achieved in two of five patients with non-liver metastatic colorectal cancer. CR was achieved in four of five patients with low rectal cancer, including three with cCR and one with pCR. cCR was achieved in seven of 36 cases, among which, six were selected for watch and wait strategy. No cCR was observed in gastric or colon cancer. Preoperative PD-1 blockade immunotherapy in dMMR/MSI-H gastrointestinal malignancies can achieve a high CR, especially in patients with duodenal or low rectal cancer, and can achieve high organ function protection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37876934",
                    "offsetInBeginSection": 73,
                    "offsetInEndSection": 267,
                    "text": "However, the benefit of immunotherapy is limited to a minority of patients with mismatch-repair-deficient (dMMR) and microsatellite instability-high (MSI-H) (dMMR-MSI-H) colorectal cancer (CRC).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37876934",
                    "offsetInBeginSection": 726,
                    "offsetInEndSection": 864,
                    "text": "Identifying immune subtypes will improve understanding of complex CRC tumor heterogeneity and refine current immunotherapeutic strategies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer?",
            "type": "factoid",
            "id": "660999e7fdcbea915f00001c",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24150273",
                "http://www.ncbi.nlm.nih.gov/pubmed/29325625",
                "http://www.ncbi.nlm.nih.gov/pubmed/33499210",
                "http://www.ncbi.nlm.nih.gov/pubmed/16297602",
                "http://www.ncbi.nlm.nih.gov/pubmed/30370373",
                "http://www.ncbi.nlm.nih.gov/pubmed/22017974",
                "http://www.ncbi.nlm.nih.gov/pubmed/23405227",
                "http://www.ncbi.nlm.nih.gov/pubmed/25628642",
                "http://www.ncbi.nlm.nih.gov/pubmed/26246313",
                "http://www.ncbi.nlm.nih.gov/pubmed/11285364"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24150273",
                    "offsetInBeginSection": 607,
                    "offsetInEndSection": 705,
                    "text": "Approximately 35% of SNPs are in the coding sequence regions, and half of them are non-synonymous.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29325625",
                    "offsetInBeginSection": 327,
                    "offsetInEndSection": 737,
                    "text": "Most of what we know about genetic contributions to disease so far comes from analysis of mutations in protein-coding genes. Since most genetic variation lies in nonprotein-coding regions of the genome whose presumed function is entirely regulatory, understanding gene regulation in a cell type and developmental state-specific manner will be important to connect human genetic variation to disease mechanisms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33499210",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "text": "The majority of the human genome is comprised of non-protein-coding genes, but the relevance of non-coding RNAs in complex diseases has yet to be fully elucidated.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16297602",
                    "offsetInBeginSection": 449,
                    "offsetInEndSection": 727,
                    "text": "The proportion of these sequence variants which have any functional effect is unknown but it is likely that the majority of those which influence illness lie outside of the amino acid coding regions of genes, and affect the regulation of gene expression--these are called rSNPs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16297602",
                    "offsetInBeginSection": 728,
                    "offsetInEndSection": 904,
                    "text": "Recent research suggests that about 50% of genes have one or more common rSNPs associated with them and probably most if not all genes have an rSNP within the human population.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30370373",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 84,
                    "text": "The vast majority of somatic variants in cancer genomes occur in non-coding regions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22017974",
                    "offsetInBeginSection": 154,
                    "offsetInEndSection": 376,
                    "text": "Most organellar genes in the nucleus migrated there long ago, but transfer is ongoing and ubiquitous. It now generates mostly noncoding nuclear DNA, can also disrupt gene functions, and reshape genes by adding novel exons.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23405227",
                    "offsetInBeginSection": 100,
                    "offsetInEndSection": 577,
                    "text": "Although rDNA occurs as multiple copies, in most non-microsporidian species copies within a genome occur as tandem arrays and are homogenised by concerted evolution. In contrast, microsporidian rDNA units are dispersed throughout the genome in some species, and on this basis are predicted to undergo reduced concerted evolution. Furthermore many microsporidian species appear to be asexual and should therefore exhibit reduced genetic diversity due to a lack of recombination.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25628642",
                    "offsetInBeginSection": 895,
                    "offsetInEndSection": 1161,
                    "text": "Majority of the novel variants, 13, were mapped to intronic sequences and un-translated regions of the gene. Four of the five novel variants located in the coding region of the gene, represented missense mutations within the serine/threonine kinase catalytic domain.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26246313",
                    "offsetInBeginSection": 349,
                    "offsetInEndSection": 671,
                    "text": "Even though colony density in the study population is the same today as in the past, a major loss of haplotypic diversity occurred, indicative of a drastic mitochondrial bottleneck, caused by massive colony mortality. In contrast, nuclear genetic diversity did not change, though hundreds of genes show signs of selection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is the majority of genetic variation present in the coding regions of the genome?",
            "type": "yesno",
            "id": "661dc376fe9d0b3967000002",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
                "http://www.ncbi.nlm.nih.gov/pubmed/33792453",
                "http://www.ncbi.nlm.nih.gov/pubmed/30762205",
                "http://www.ncbi.nlm.nih.gov/pubmed/37962198",
                "http://www.ncbi.nlm.nih.gov/pubmed/32833750",
                "http://www.ncbi.nlm.nih.gov/pubmed/35639288",
                "http://www.ncbi.nlm.nih.gov/pubmed/34821184"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
                    "offsetInBeginSection": 2530,
                    "offsetInEndSection": 2739,
                    "text": "Zilucoplan treatment showed rapid and clinically meaningful improvements in myasthenia gravis-specific efficacy outcomes, had a favourable safety profile, and was well tolerated, with no major safety findings.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33792453",
                    "offsetInBeginSection": 862,
                    "offsetInEndSection": 1058,
                    "text": "In a randomized, double-blind, placebo-controlled, phase 2 clinical trial, zilucoplan demonstrated clinically meaningful complement inhibition in patients with acetylcholine receptor-positive gMG.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33792453",
                    "offsetInBeginSection": 1059,
                    "offsetInEndSection": 1327,
                    "text": "Zilucoplan, a first-of-its-kind cyclic peptide targeting C5, appears to be a therapeutic option for the treatment of gMG based on available pharmacokinetic/pharmacodynamic data and phase 1 and 2 efficacy, safety, and tolerability data with limited long-term follow-up.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30762205",
                    "offsetInBeginSection": 1980,
                    "offsetInEndSection": 2157,
                    "text": "Zilucoplan is a subcutaneously administered terminal complement inhibitor that recently demonstrated significant improvements in functional outcome measures in a phase II trial.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37962198",
                    "offsetInBeginSection": 469,
                    "offsetInEndSection": 563,
                    "text": "The phase 3 RAISE trial of zilucoplan, a self-administered complement C5 inhibitor, is covered",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32833750",
                    "offsetInBeginSection": 923,
                    "offsetInEndSection": 1095,
                    "text": "Three new biologic agents showed promising results in phase-II controlled myasthenia gravis trials: Zilucoplan, a subcutaneous macrocyclic peptide inhibiting complement C5;",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33792453",
                    "offsetInBeginSection": 679,
                    "offsetInEndSection": 861,
                    "text": "Zilucoplan is a small, subcutaneously administered, macrocyclic peptide that inhibits cleavage of complement component C5 and the subsequent formation of the membrane attack complex.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35639288",
                    "offsetInBeginSection": 1282,
                    "offsetInEndSection": 1359,
                    "text": "Zilucoplan and ravulizumab are other agents in this group in clinical trials.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34821184",
                    "offsetInBeginSection": 1292,
                    "offsetInEndSection": 1447,
                    "text": "This study analyzed the efficacy characteristics of nine drugs. The present findings provide necessary quantitative information for drug development of MG.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34821184",
                    "offsetInBeginSection": 795,
                    "offsetInEndSection": 991,
                    "text": "The pharmacodynamic model showed that eculizumab had the highest efficacy in reducing QMGs scores (3.66 points), and efgartigimod had the highest efficacy in reducing MG-ADLs scores (1.97 points).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is zilucoplan effective for myasthenia gravis?",
            "type": "yesno",
            "id": "65d1300e1930410b13000033",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25491204",
                "http://www.ncbi.nlm.nih.gov/pubmed/36469907",
                "http://www.ncbi.nlm.nih.gov/pubmed/23496908",
                "http://www.ncbi.nlm.nih.gov/pubmed/29633482",
                "http://www.ncbi.nlm.nih.gov/pubmed/24821069",
                "http://www.ncbi.nlm.nih.gov/pubmed/29860066",
                "http://www.ncbi.nlm.nih.gov/pubmed/17100995",
                "http://www.ncbi.nlm.nih.gov/pubmed/27782177",
                "http://www.ncbi.nlm.nih.gov/pubmed/31056860",
                "http://www.ncbi.nlm.nih.gov/pubmed/14993477"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25491204",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 244,
                    "text": "Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder. It is caused by mutations in the PKD1 and PKD2 genes, and manifests as progressive cyst growth and renal enlargement, resulting in renal failure.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36469907",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "text": "Autosomal dominant polycystic kidney disease (ADPKD) is a systemic, irreversible, genetic condition caused by mutations in the PKD1 and PKD2 genes",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23496908",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 348,
                    "text": "Autosomal dominant polycystic kidney disease (ADPKD) is the most common form of inherited kidney disease that results in renal failure. ADPKD is a systemic disorder with cysts and connective tissue abnormalities involving many organs. ADPKD caused by mutations in PKD1 gene is significantly more severe than the cases caused by PKD2 gene mutations.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29633482",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "text": "Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary renal disease in humans and is caused by mutations in the PKD1 or PKD2 gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821069",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 297,
                    "text": "Autosomal-dominant polycystic kidney disease (ADPKD), a heterogeneous genetic disorder characterized by massive kidney enlargement and progressive chronic kidney disease, is due to abnormal proliferation of renal tubular epithelium. ADPKD is known to be caused by mutations in PKD1 and PKD2 genes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29860066",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 284,
                    "text": "Autosomal Dominant Polycystic Kidney Disease (ADPKD), the most frequent genetic disorder of the kidneys, is characterized by a typical presenting symptoms include cysts development in different organs and a non-cysts manifestations. ADPKD is caused by mutations in PKD1 or PKD2 genes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17100995",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "text": "Autosomal dominant polycystic kidney disease (ADPKD) is genetically heterogeneous and is caused by mutations in the PKD1 or PKD2 genes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27782177",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "text": "Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder mainly caused by mutation in PKD1/PKD2.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31056860",
                    "offsetInBeginSection": 78,
                    "offsetInEndSection": 221,
                    "text": "The main mutational genes causing autosomal dominant polycystic kidney disease (ADPKD) are PKD1 and PKD2 as well as some rare pathogenic genes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14993477",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 245,
                    "text": "Autosomal dominant polycystic kidney disease (ADPKD) is genetically heterogeneous and caused by mutations in at least three different loci. Based on linkage analysis, mutations in the PKD2 gene are responsible for approximately 15% of the cases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the cause of autosomal dominant Polycystic Kidney Disease?",
            "type": "factoid",
            "id": "661d6252eac11fad33000025",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12421732",
                "http://www.ncbi.nlm.nih.gov/pubmed/9579853",
                "http://www.ncbi.nlm.nih.gov/pubmed/10645210",
                "http://www.ncbi.nlm.nih.gov/pubmed/9376636",
                "http://www.ncbi.nlm.nih.gov/pubmed/15991972",
                "http://www.ncbi.nlm.nih.gov/pubmed/7577020",
                "http://www.ncbi.nlm.nih.gov/pubmed/24093908",
                "http://www.ncbi.nlm.nih.gov/pubmed/12056700",
                "http://www.ncbi.nlm.nih.gov/pubmed/33268287",
                "http://www.ncbi.nlm.nih.gov/pubmed/10606253"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12421732",
                    "offsetInBeginSection": 334,
                    "offsetInEndSection": 509,
                    "text": "The introduction of irinotecan, oxaliplatin, oral fluoropyrimidines and raltitrexed has broadened the treatment options available for patients with advanced colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9579853",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 309,
                    "text": "Following the demonstration of efficacy, tolerability and quality-of-life benefits of raltitrexed ('Tomudex'), principally in advanced colorectal but also in other cancers, an extensive evaluation of combination therapy with other agents in patients with colorectal and other tumour types is being undertaken.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10645210",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1375,
                    "text": "Radiotherapy, either alone or in combination with chemotherapy, may reduce local recurrence of rectal cancer following surgery and improve survival of patients with operable and advanced/recurrent/inoperable disease. Chemotherapy with 5-fluorouracil in combination with radiotherapy has been used both before and after surgery; however, the optimum schedule is unclear. In addition, alternative chemotherapy with raltitrexed (Tomudex) may be more convenient and better tolerated. The preliminary results of three phase I dose-finding studies are described, combining escalating doses of raltitrexed with radiotherapy as pre- or postoperative treatment for operable rectal cancer or as treatment for advanced/inoperable/recurrent rectal cancer. The recommended dose of raltitrexed when combined with adjuvant radiotherapy is likely to be 2.6 mg/m2. This is a small dose reduction compared with the dose of raltitrexed for the treatment of advanced colorectal cancer (3.0 mg/m2); however, toxicity appears to be lower using the pre-operative approach. Neo-adjuvant therapy with raltitrexed plus radiotherapy also demonstrated clinical activity in the pre-operative study, which showed that 22% of patients achieved a complete response and 56% a partial response. Once the recommended dose has been defined in each setting, large-scale studies will be undertaken as appropriate.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9376636",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 197,
                    "text": "The efficacy and tolerability of raltitrexed ('Tomudex', formerly ZD1694) as a single agent for the treatment of advanced colorectal cancer has been established in a large clinical trial programme.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15991972",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "text": "Raltitrexed (Tomudex) is a new specific, mixed non-competitive inhibitor of thymidylate synthase indicated for use in the therapy of advanced colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15991972",
                    "offsetInBeginSection": 392,
                    "offsetInEndSection": 637,
                    "text": "Phase III studies in patients with advanced colorectal cancer indicate similar efficacy with raltitrexed monotherapy and combination therapy with 5-fluorouracil + low or high dose leucovorin (5-FU + LV) (Mayo or Machover regimens, respectively).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7577020",
                    "offsetInBeginSection": 611,
                    "offsetInEndSection": 692,
                    "text": "Treatment with 5FU/leucovorin has been shown to be effective as adjuvant therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7577020",
                    "offsetInBeginSection": 1518,
                    "offsetInEndSection": 1776,
                    "text": "Recently, two new drugs have shown efficacy in the treatment of advanced colorectal cancer. A phase II trial with Tomudex (ZD1694), a new antifolate thymidiylate synthase inhibitor, produced a response rate of 25% in patients with advanced colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24093908",
                    "offsetInBeginSection": 301,
                    "offsetInEndSection": 480,
                    "text": "Raltitrexed (Tomudex), a quinazoline analogue of folinic acid, is a selective and direct thymidylate synthase (TS) inhibitor with a convenient 3-weekly schedule of administration.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12056700",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "text": "Raltitrexed ('Tomudex') monotherapy is a conveniently administered alternative to 5-fluorouracil (5-FU) in the first-line treatment of advanced colorectal cancer (CRC)",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which are the clinical indications for the use of Raltitrexed in patients with colorectal cancer?",
            "type": "list",
            "id": "65f77618c4010b4d7800002e",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36105828",
                "http://www.ncbi.nlm.nih.gov/pubmed/29404361",
                "http://www.ncbi.nlm.nih.gov/pubmed/37425557",
                "http://www.ncbi.nlm.nih.gov/pubmed/37275090",
                "http://www.ncbi.nlm.nih.gov/pubmed/34373821",
                "http://www.ncbi.nlm.nih.gov/pubmed/15164784",
                "http://www.ncbi.nlm.nih.gov/pubmed/35698705",
                "http://www.ncbi.nlm.nih.gov/pubmed/36993088",
                "http://www.ncbi.nlm.nih.gov/pubmed/32539005",
                "http://www.ncbi.nlm.nih.gov/pubmed/7316726"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36105828",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "text": "Wallenberg syndrome is also called lateral medullary syndrome, a neurological disorder resulting from occlusion of the vertebral artery or the posterior inferior cerebellar artery.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29404361",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 333,
                    "text": "Lateral medullary syndrome (LMS), also known as Wallenberg's syndrome, PICA syndrome, results from occlusion of the posterior inferior cerebellar artery, with associated infarction of parts of medulla oblongata, and cerebellum on the ipsilateral side. It often manifests as various patterns of sensory, motor, and autonomic deficits.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37425557",
                    "offsetInBeginSection": 350,
                    "offsetInEndSection": 483,
                    "text": "common symptoms of LMS include difficulty swallowing, hoarseness, ipsilateral weakness, and ipsilateral loss of sensation or numbness",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37275090",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 249,
                    "text": "Lateral medullary syndrome/Wallenberg syndrome, is a neurological disorder occurring due to ischemia in the lateral part of medullary oblongata resulting in wide range of symptoms. Dysphagia is usually exhibited in severe and persistent form in LMS.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34373821",
                    "offsetInBeginSection": 1336,
                    "offsetInEndSection": 1625,
                    "text": "The neurological deficits associated with this disease are due to damage of the lateral medulla, inferior cerebellar peduncle, nucleus of trigeminal nerve, nucleus and fibers of vagus and glossopharyngeal nerves, descending sympathetic tract, spinothalamic tract, and/or vestibular nuclei.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15164784",
                    "offsetInBeginSection": 116,
                    "offsetInEndSection": 312,
                    "text": "Thirteen patients with Wallenberg's lateral medullary syndrome were examined with conventional and echoplanar diffusion-weighted magnetic resonance (MR) imaging in a 1.5 T magnetic resonance unit.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35698705",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "text": "Lateral medullary syndrome (LMS), also known as Wallenberg syndrome, is a cerebrovascular event following ischemia of the lateral part of the medulla oblongata.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36993088",
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 503,
                    "text": "The most pathognomonic symptoms of LMS includes pain and temperature deficits on ipsilateral facial side and contralateral side of rest of the body, ipsilateral ataxia, vertigo, nystagmus, dysphagia, hoarseness, hiccups and Horner's syndrome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32539005",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 594,
                    "text": "Wallenberg syndrome, or lateral medullar syndrome, is the clinical presentation of the infarct in the territory of posterior inferior cerebellar artery. Its signs and symptoms include vertigo, nystagmus, diplopia, ipsilateral Horner syndrome, facial ruddiness and dry skin, dysphonia, dysphagia, dysarthria, ipsilateral loss of gag reflex, ipsilateral ataxia, ipsilateral impaired taste, ipsilateral facial pain and paresthesia, decreased ipsilateral blink reflex, contralateral hypoalgesia and thermoanaesthesia in the trunk and limbs; and ipsilateral facial hypoalgesia and thermoanaesthesia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7316726",
                    "offsetInBeginSection": 149,
                    "offsetInEndSection": 418,
                    "text": "The diagnosis of Wallenberg's syndrome is justified when the classic symptoms are apparent (Horner's syndrome, nystagmus, dysphonia and dysphagia, ataxia, ipsilateral sensory impairment of the face and contralateral elsewhere, and accompanying vegetative disturbances).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Please list the findings in lateral medullary (Wallenberg) syndrome",
            "type": "list",
            "id": "661bdc9148a2c27714000001",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/8661009",
                "http://www.ncbi.nlm.nih.gov/pubmed/15607899",
                "http://www.ncbi.nlm.nih.gov/pubmed/29170064",
                "http://www.ncbi.nlm.nih.gov/pubmed/25038992",
                "http://www.ncbi.nlm.nih.gov/pubmed/27238723",
                "http://www.ncbi.nlm.nih.gov/pubmed/28889264",
                "http://www.ncbi.nlm.nih.gov/pubmed/29308836",
                "http://www.ncbi.nlm.nih.gov/pubmed/22135851",
                "http://www.ncbi.nlm.nih.gov/pubmed/14579013",
                "http://www.ncbi.nlm.nih.gov/pubmed/19474728"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8661009",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "text": "A physiological role for paraoxonase (PON1) is still uncertain, but it catalyzes the hydrolysis of toxic organophosphates.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8661009",
                    "offsetInBeginSection": 123,
                    "offsetInEndSection": 228,
                    "text": "Evidence that the human genome contains two PON1-like genes, designated PON2 and PON3, is presented here.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8661009",
                    "offsetInBeginSection": 229,
                    "offsetInEndSection": 331,
                    "text": "Human PON1 and PON2 each have nine exons, and the exon/intron junctions occur at equivalent positions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8661009",
                    "offsetInBeginSection": 332,
                    "offsetInEndSection": 419,
                    "text": "PON1 and PON2 genes are both on chromosome 7 in human and on chromosome 6 in the mouse.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8661009",
                    "offsetInBeginSection": 840,
                    "offsetInEndSection": 1042,
                    "text": "The expanded number of PON genes will have important implications for future experiments designed to discover the individual functions, catalytic properties, and physiological roles of the paraoxonases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15607899",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "text": "Epidemiologic, genetic, and biochemical studies support an antiatherogenic role for paraoxonase (PON) 1.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15607899",
                    "offsetInBeginSection": 105,
                    "offsetInEndSection": 420,
                    "text": "While the precise mechanism by which PON1 protects against the development of atherosclerosis is unclear, in vitro studies and the results from PON1 knockout and transgenic mice suggest that this protective effect may be attributed to PON1's ability to attenuate the oxidative modification of lipoprotein particles.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15607899",
                    "offsetInBeginSection": 421,
                    "offsetInEndSection": 599,
                    "text": "The two other members of the PON gene family, namely, PON2 and PON3, have also been reported to possess antioxidant properties and may exhibit antiatherogenic capacities as well.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15607899",
                    "offsetInBeginSection": 864,
                    "offsetInEndSection": 1182,
                    "text": "While the physiological function of these proteins is unknown, studies currently underway using PON2 and PON3 knockout and transgenic mice should enable us to tease out the apparently redundant functions of these three proteins and yield clues as to their physiological function as well as their role in atherogenesis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29170064",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 752,
                    "text": "The paraoxonase (PON) gene family includes three proteins, PON1, PON2 and PON3. PON1 and PON3 are both associated with high-density lipoprotein (HDL) particles and exert anti-oxidant and anti-inflammatory properties. PON2 and PON3 are intracellular enzymes which modulate mitochondrial superoxide anion production and endoplasmic reticulum (ER) stress-induced apoptosis. The pleiotropic roles exerted by PONs have been mainly investigated in cardiovascular and neurodegenerative diseases. In recent years, overexpression of PON2 and PON3 has been observed in cancer cells and it has been proposed that both enzymes could be involved in tumor survival and stress resistance. Moreover, a lower activity of serum PON1 has been reported in cancer patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the function of the paraoxonase (PON) multigene family?",
            "type": "summary",
            "id": "661c03c848a2c27714000004",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26097168",
                "http://www.ncbi.nlm.nih.gov/pubmed/24479826",
                "http://www.ncbi.nlm.nih.gov/pubmed/21745147",
                "http://www.ncbi.nlm.nih.gov/pubmed/28991007",
                "http://www.ncbi.nlm.nih.gov/pubmed/26322933",
                "http://www.ncbi.nlm.nih.gov/pubmed/26091951",
                "http://www.ncbi.nlm.nih.gov/pubmed/32596478",
                "http://www.ncbi.nlm.nih.gov/pubmed/37719614",
                "http://www.ncbi.nlm.nih.gov/pubmed/37763239",
                "http://www.ncbi.nlm.nih.gov/pubmed/25888148"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26097168",
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 326,
                    "text": "Recent advances of targeted molecular therapies and high throughput screening have resulted in multiple drug therapies that target many important mutations in the CFTR protein.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26097168",
                    "offsetInBeginSection": 327,
                    "offsetInEndSection": 567,
                    "text": "In this review, we provide the latest results and current progress of CFTR modulators for the treatment of cystic fibrosis, focusing on potentiators of CFTR channel gating and Phe508del processing correctors for the Phe508del CFTR mutation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24479826",
                    "offsetInBeginSection": 775,
                    "offsetInEndSection": 952,
                    "text": "These developing therapies include CFTR gene therapy, CFTR pharmacotherapeutics, osmotically active agents and anti-inflammatory therapies, as well as novel inhaled antibiotics.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21745147",
                    "offsetInBeginSection": 540,
                    "offsetInEndSection": 1001,
                    "text": "Apart from gene therapy, several novel compounds have recently been discovered using high-throughput screening, which appear promising enough to develop effective drugs to cure the basic defect. This paper summarizes our current knowledge of gene and mutation-specific therapy and focuses on orally bioavailable potentiators and correctors, particularly suppressors of premature termination codons, including preclinical model systems and clinical trials in CF.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28991007",
                    "offsetInBeginSection": 875,
                    "offsetInEndSection": 1145,
                    "text": "Recently, new drugs are developed with the aim to treat the malfunction of the cystic fibrosis transmembrane conductance regulator gene. This potentiator/corrector therapy improves lung function and nutritional status and decreases the number of infective exacerbations.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26322933",
                    "offsetInBeginSection": 354,
                    "offsetInEndSection": 521,
                    "text": "Several innovative drugs recently approved by the Food and Drug Administration, termed genetic modulators, target the underlying disease by modulating the CFTR defect.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26091951",
                    "offsetInBeginSection": 539,
                    "offsetInEndSection": 970,
                    "text": "The marked success of ivacaftor both in clinical trials and in post-licensing evaluation studies in treating patients with G551D and other gating mutations has greatly encouraged the ongoing development of similar therapies that can directly target the underlying cause of CF. Other therapies, including a number of anti-infectives, anti-inflammatories and replacement pancreatic enzymes, are currently undergoing clinical studies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32596478",
                    "offsetInBeginSection": 936,
                    "offsetInEndSection": 1124,
                    "text": "A new triple therapy CFTR modulator, elexacaftor/tezacaftor/ivacaftor, is capable of treating 90% of patients with CF and has shown the greatest FEV1 improvement of any CFTR modulator yet.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37719614",
                    "offsetInBeginSection": 709,
                    "offsetInEndSection": 905,
                    "text": "Pharmacological management explores pancreatic enzyme replacement therapy (PERT), antimicrobial treatments, cystic fibrosis transmembrane regulator (CFTR) modulators, and promising gene therapies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37763239",
                    "offsetInBeginSection": 537,
                    "offsetInEndSection": 1132,
                    "text": "This review discusses the most current mainstay treatments and anticipated therapeutics in the CF drug development pipeline within the mechanisms of mucociliary clearance, anti-inflammatory and anti-infective therapies, restoration of the cystic fibrosis transmembrane conductance regulator (CFTR) protein (also known as highly effective modulator therapy (HEMT)), and genetic therapies. Ribonucleic acid (RNA) therapy, gene transfer, and gene editing are being explored in the hopes of developing a treatment and potential cure for people with CF, particularly for those not responsive to HEMT.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the new treatments for cystic fibrosis?",
            "type": "summary",
            "id": "6614fb7bfdcbea915f000044",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19574924",
                "http://www.ncbi.nlm.nih.gov/pubmed/19048626",
                "http://www.ncbi.nlm.nih.gov/pubmed/16226688",
                "http://www.ncbi.nlm.nih.gov/pubmed/21141419",
                "http://www.ncbi.nlm.nih.gov/pubmed/22549102",
                "http://www.ncbi.nlm.nih.gov/pubmed/25468258",
                "http://www.ncbi.nlm.nih.gov/pubmed/20680499",
                "http://www.ncbi.nlm.nih.gov/pubmed/21305335"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19574924",
                    "offsetInBeginSection": 133,
                    "offsetInEndSection": 293,
                    "text": "The aim of this analysis is to determine the cost-effectiveness of population-based screening for colorectal cancer (CRC) using CTC with a polyp size threshold.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19048626",
                    "offsetInBeginSection": 96,
                    "offsetInEndSection": 284,
                    "text": "In our study, we estimated the threshold costs for which CTC screening would be a cost-effective alternative to colonoscopy for colorectal cancer (CRC) screening in the general population.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19048626",
                    "offsetInBeginSection": 1122,
                    "offsetInEndSection": 1289,
                    "text": "For this strategy to be as cost-effective as colonoscopy screening, the costs must not exceed $285 or 43% of colonoscopy costs (range in sensitivity analysis: 39-47%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19048626",
                    "offsetInBeginSection": 1290,
                    "offsetInEndSection": 1388,
                    "text": "With 25% higher adherence than colonoscopy, CTC threshold costs could be 71% of colonoscopy costs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16226688",
                    "offsetInBeginSection": 533,
                    "offsetInEndSection": 952,
                    "text": "Before both tests can be promoted for population-based screening programs, several issues that have been detailed in this article must be addressed further, including technical improvements for improving accuracy, development of virtual preparation, test availability, patient and provider acceptability and cost-effectiveness for CTC, and identifying the optimal combination of molecular targets for stool DNA testing.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21141419",
                    "offsetInBeginSection": 1001,
                    "offsetInEndSection": 1175,
                    "text": "Cost-effectiveness and compliance in the general population, as well as radiation exposure and follow-up requirements with colonography for CRC screening, need further study.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22549102",
                    "offsetInBeginSection": 740,
                    "offsetInEndSection": 878,
                    "text": "It is unclear whether CTC screening is cost-effective and the impact of extracolonic findings, both medical and economic, remains unknown.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19574924",
                    "offsetInBeginSection": 1242,
                    "offsetInEndSection": 1492,
                    "text": "CTC with a 6 mm threshold for polypectomy is associated to a substantial cost reduction without significant loss of efficacy. Cost-effectiveness depends more on the AA prevalence or transition rate to CRC than on CTC accuracy or screening compliance.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25468258",
                    "offsetInBeginSection": 853,
                    "offsetInEndSection": 1398,
                    "text": "Based on the detection characteristics and acceptability of CTC screening, it might be a viable screening test. The potential disadvantage of radiation exposure is probably overemphasised, especially with newer technology. At this time-point, it is not entirely clear whether the detection of extracolonic findings at CTC is of net benefit and is cost effective, but with responsible handling, this may be the case. Future efforts will seek to further improve the technique, refine appropriate diagnostic algorithms and study cost-effectiveness.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20680499",
                    "offsetInBeginSection": 1151,
                    "offsetInEndSection": 1273,
                    "text": "Probably performing CTC without faecal tagging as second line test after a positive FOBT is not a cost-effective strategy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is liquid biopsy a cost-effective technique in general population screening for colorectal cancer?",
            "type": "yesno",
            "id": "65f77465c4010b4d78000028",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25104275",
                "http://www.ncbi.nlm.nih.gov/pubmed/31638247",
                "http://www.ncbi.nlm.nih.gov/pubmed/22882926",
                "http://www.ncbi.nlm.nih.gov/pubmed/35032595",
                "http://www.ncbi.nlm.nih.gov/pubmed/30414501",
                "http://www.ncbi.nlm.nih.gov/pubmed/21945273",
                "http://www.ncbi.nlm.nih.gov/pubmed/33123899",
                "http://www.ncbi.nlm.nih.gov/pubmed/18156813",
                "http://www.ncbi.nlm.nih.gov/pubmed/33059727",
                "http://www.ncbi.nlm.nih.gov/pubmed/18252063"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25104275",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 95,
                    "text": "Autosomal recessive polycystic kidney disease (ARPKD) is caused by mutations in the PKHD1 gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31638247",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 245,
                    "text": "Autosomal recessive polycystic kidney disease (ARPKD) is a hereditary fibrocystic disease that primarily involves the kidneys and hepatobiliary tract. The polycystic kidney and hepatic disease 1 (PKHD1) gene is the only gene implicated in ARPKD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22882926",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "text": "Autosomal recessive polycystic kidney disease (ARPKD) is a rare inherited disease, which is a disorder with multiple organ involvement, mainly the kidney and liver. It is caused by mutations in the PKHD1 gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35032595",
                    "offsetInBeginSection": 323,
                    "offsetInEndSection": 484,
                    "text": "Two genes have been shown to cause ARPKD when mutated, PKHD1, mutations in which lead to most of ARPKD cases and DZIP1L, which is associated with moderate ARPKD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30414501",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 422,
                    "text": "Autosomal Recessive Polycystic Kidney Disease (ARPKD) is a genetic disorder with an incidence of ~1:20,000 that manifests in a wide range of renal and liver disease severity in human patients and can lead to perinatal mortality. ARPKD is caused by mutations in PKHD1, which encodes the large membrane protein, Fibrocystin, required for normal branching morphogenesis of the ureteric bud during embryonic renal development.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21945273",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 291,
                    "text": "Autosomal recessive polycystic kidney disease (ARPKD), characterized by progressive cystic degeneration of the kidneys and congenital hepatic fibrosis (CHF), is the most common childhood onset ciliopathy, with an estimated frequency of 1 in 20,000 births. It is caused by mutations in PKHD1.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33123899",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "text": "PKHD1 mutations are generally considered to cause autosomal recessive polycystic kidney disease (ARPKD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18156813",
                    "offsetInBeginSection": 186,
                    "offsetInEndSection": 417,
                    "text": "The gene for ARPKD (PKHD1) is located on chromosome 6p12 and encodes a protein called fibrocystin/polyductin (FPC), 1 of many proteins that are normally present at the primary cilia of the renal tubules and intrahepatic bile ducts.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33059727",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 222,
                    "text": "Autosomal recessive polycystic kidney disease (ARPKD; MIM#263200) is one of the most frequent pediatric renal cystic diseases, with an incidence of 1:20,000. It is caused by mutations of the PKHD1 gene, on chromosome 6p12.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18252063",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "text": "Autosomal recessive polycystic kidney disease (ARPKD) is one of the most common hereditary renal cystic diseases, and is caused by mutations in the PKHD1 gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the cause of Autosomal Recessive Polycystic Kidney Disease?",
            "type": "factoid",
            "id": "661d6473eac11fad33000027",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19112830",
                "http://www.ncbi.nlm.nih.gov/pubmed/31752361",
                "http://www.ncbi.nlm.nih.gov/pubmed/26471458",
                "http://www.ncbi.nlm.nih.gov/pubmed/16957368",
                "http://www.ncbi.nlm.nih.gov/pubmed/29712715",
                "http://www.ncbi.nlm.nih.gov/pubmed/17507929",
                "http://www.ncbi.nlm.nih.gov/pubmed/27754357",
                "http://www.ncbi.nlm.nih.gov/pubmed/33321742",
                "http://www.ncbi.nlm.nih.gov/pubmed/28876213",
                "http://www.ncbi.nlm.nih.gov/pubmed/26582366"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19112830",
                    "offsetInBeginSection": 104,
                    "offsetInEndSection": 244,
                    "text": "Mature miRNA molecules associated with the RNA-induced silencing complex (RISC) guide specifically mRNA cleavage or inhibit the translation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31752361",
                    "offsetInBeginSection": 442,
                    "offsetInEndSection": 740,
                    "text": "All miRNAs are loaded into Argonaute proteins in the RNA-induced silencing complex (RISC) and act as post-transcriptional regulators by binding to the 3'- untranslated region (UTR) of mRNAs. This seed-dependent miRNA binding inhibits the translation and/or promotes the degradation of mRNA targets.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26471458",
                    "offsetInBeginSection": 283,
                    "offsetInEndSection": 384,
                    "text": "MiRNAs do not act alone, but exhibit their functions by forming RNA-induced silencing complex (RISC).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16957368",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 563,
                    "text": "Although initially believed to act exclusively as translational repressors, microRNAs (miRNAs) are now known to target complementary messenger RNA (mRNA) transcripts for either translational repression or cleavage via the RNA-induced silencing complex (RISC) ([1], reviewed in ref. 2). The current model postulates that mature miRNAs are incorporated into the RISC, bind target mRNAs based on complementarity, and guide cleavage of mRNA targets with perfect or nearly perfect complementarity and translational repression of targets with lower complementarity (2).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29712715",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 219,
                    "text": "MicroRNAs (miRNAs) repress translation of target mRNAs by associating with Argonaute (Ago) proteins to form the RNA-induced silencing complex (RISC), underpinning a powerful mechanism for fine-tuning protein expression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17507929",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "text": "MicroRNAs (miRNAs) are a class of small RNAs that act post-transcriptionally to regulate messenger RNA stability and translation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27754357",
                    "offsetInBeginSection": 729,
                    "offsetInEndSection": 866,
                    "text": "miRNAs act as post-transcriptional regulators of their messenger RNA (mRNA) targets via mRNA degradation and/or translational repression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33321742",
                    "offsetInBeginSection": 541,
                    "offsetInEndSection": 688,
                    "text": "The mature miRNAs are incorporated into the RNA-induced silencing complex (RISC) and drive the Argonaute (AGO) proteins towards their mRNA targets.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28876213",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "MicroRNAs (miRNAs) regulate gene expression by forming RNA-induced silencing complexes (RISCs) and have been considered as promising therapeutic targets.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28876213",
                    "offsetInBeginSection": 154,
                    "offsetInEndSection": 232,
                    "text": "MiRNA is an essential component of RISC for the modulation of gene expression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "By which method do micro RNAs (miRNAs) primarily aid in transcriptional and post-transcriptional regulation?",
            "type": "factoid",
            "id": "661c424588784bab31000001",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36351060",
                "http://www.ncbi.nlm.nih.gov/pubmed/37877814",
                "http://www.ncbi.nlm.nih.gov/pubmed/37861218",
                "http://www.ncbi.nlm.nih.gov/pubmed/35940259",
                "http://www.ncbi.nlm.nih.gov/pubmed/33203642",
                "http://www.ncbi.nlm.nih.gov/pubmed/31215500",
                "http://www.ncbi.nlm.nih.gov/pubmed/37627044",
                "http://www.ncbi.nlm.nih.gov/pubmed/35815644",
                "http://www.ncbi.nlm.nih.gov/pubmed/36864566",
                "http://www.ncbi.nlm.nih.gov/pubmed/25367186"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36351060",
                    "offsetInBeginSection": 473,
                    "offsetInEndSection": 628,
                    "text": "AMG 757 (tarlatamab), a half-life-extended bispecific T-cell engager (BiTE) immunotherapy that redirects CD3-positive T cells to kill DLL3-expressing cells",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37877814",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "text": "Tarlatamab, an investigational bispecific T-cell engager molecule that targets the cell surface protein delta-like ligand 3",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37861218",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "text": "Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously treated small-cell lung cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35940259",
                    "offsetInBeginSection": 717,
                    "offsetInEndSection": 865,
                    "text": "One BiTE molecule in development, AMG 757, is directed against delta-like ligand 3 (DLL3), which is expressed in small cell lung cancer tumor cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33203642",
                    "offsetInBeginSection": 185,
                    "offsetInEndSection": 286,
                    "text": "AMG 757, a half-life extended bispecific T-cell engager molecule targeting delta-like ligand 3 (DLL3)",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31215500",
                    "offsetInBeginSection": 442,
                    "offsetInEndSection": 1022,
                    "text": "Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand that is highly expressed in SCLC and other neuroendocrine tumors but minimally expressed in normal tissues. It is therefore being explored as a potential therapeutic target in SCLC. Here, we review the preclinical and clinical evidence for targeting DLL3 in SCLC and discuss several DLL3-specific therapies being developed for the treatment of SCLC: the antibody-drug conjugate rovalpituzumab tesirine, the bispecific T cell engager immuno-oncology therapy AMG 757, and the chimeric antigen receptor T cell therapy AMG 119.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37627044",
                    "offsetInBeginSection": 685,
                    "offsetInEndSection": 873,
                    "text": "The potential of targeting DLL3, a NOTCH ligand, through antibody-drug conjugates, bispecific T-cell engagers, and CAR T-cell therapy, has opened up new therapeutic options moving forward.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35815644",
                    "offsetInBeginSection": 227,
                    "offsetInEndSection": 367,
                    "text": "The bispecific DLL3/CD3 T-cell engager BI 764532 has been shown to induce complete tumor regression in a human T cell-engrafted mouse model.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36864566",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 298,
                    "text": "Bispecific antibodies are molecules with versatile modes of action and applications for therapy. They are commonly developed as T-cell engagers (TCE), which simultaneously target an antigen expressed by tumor cells and CD3 expressed by T-cells, thereby inducing T-cell-mediated target cell killing.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25367186",
                    "offsetInBeginSection": 120,
                    "offsetInEndSection": 452,
                    "text": "These molecules enhance the patient's immune response to tumors by retargeting T cells to tumor cells. BiTEs are constructed of two single-chain variable fragments (scFv) connected in tandem by a flexible linker. One scFv binds to a T-cell-specific molecule, usually CD3, whereas the second scFv binds to a tumor-associated antigen.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the targets of Tarlatamab?",
            "type": "list",
            "id": "65cf98431930410b1300000b",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36582623",
                "http://www.ncbi.nlm.nih.gov/pubmed/16908354",
                "http://www.ncbi.nlm.nih.gov/pubmed/10326294",
                "http://www.ncbi.nlm.nih.gov/pubmed/36130588",
                "http://www.ncbi.nlm.nih.gov/pubmed/36286200",
                "http://www.ncbi.nlm.nih.gov/pubmed/2907258",
                "http://www.ncbi.nlm.nih.gov/pubmed/35148313",
                "http://www.ncbi.nlm.nih.gov/pubmed/36851305",
                "http://www.ncbi.nlm.nih.gov/pubmed/37094206",
                "http://www.ncbi.nlm.nih.gov/pubmed/36415264"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36582623",
                    "offsetInBeginSection": 718,
                    "offsetInEndSection": 814,
                    "text": "Human monkeypox was first identified in 1970 in a child in the Democratic Republic of the Congo.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16908354",
                    "offsetInBeginSection": 82,
                    "offsetInEndSection": 184,
                    "text": "Human monkeypox was first identified in the Democratic Republic of the Congo (formerly Zaire) in 1970.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10326294",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 85,
                    "text": "Human monkeypox was first identified in 1970 in the Democratic Republic of the Congo.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36130588",
                    "offsetInBeginSection": 1802,
                    "offsetInEndSection": 1845,
                    "text": "Human monkeypox was first reported in 1970.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36286200",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 61,
                    "text": "Since the first case of human monkeypox was diagnosed in 1970",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2907258",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 336,
                    "text": "Human monkeypox is a zoonosis occurring sporadically in the tropical rain forest of western and central Africa. The exact incidence and geographical distribution are unknown, since many cases are not recognized. Special surveillance was established in three regions in Zaire in 1981 that led to a substantial increase in reported cases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35148313",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "text": "Monkeypox, a zoonotic disease caused by an orthopoxvirus, results in a smallpox-like disease in humans. Since monkeypox in humans was initially diagnosed in 1970 in the Democratic Republic of the Congo (DRC)",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36851305",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 74,
                    "text": "Human monkeypox is a rare viral zoonosis that was first identified in 1970",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37094206",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "Monkey pox is a rare zoonotic disease. It was first described in humans in Africa in 1970.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36415264",
                    "offsetInBeginSection": 179,
                    "offsetInEndSection": 291,
                    "text": "In September 1970, the first case of human monkeypox was identified in the Democratic Republic of Congo, Africa.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "When was the first case of human monkey pox diagnosed?",
            "type": "factoid",
            "id": "66165f2afdcbea915f000051",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35532252",
                "http://www.ncbi.nlm.nih.gov/pubmed/15131477",
                "http://www.ncbi.nlm.nih.gov/pubmed/21761152",
                "http://www.ncbi.nlm.nih.gov/pubmed/36604110",
                "http://www.ncbi.nlm.nih.gov/pubmed/36226007",
                "http://www.ncbi.nlm.nih.gov/pubmed/16568297",
                "http://www.ncbi.nlm.nih.gov/pubmed/8848770",
                "http://www.ncbi.nlm.nih.gov/pubmed/18695332",
                "http://www.ncbi.nlm.nih.gov/pubmed/36941816",
                "http://www.ncbi.nlm.nih.gov/pubmed/29531558"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35532252",
                    "offsetInBeginSection": 365,
                    "offsetInEndSection": 601,
                    "text": "Mucormycosis is an invasive fungal disease that primarily affects immunosuppressant patients, mainly caused by mold fungi of the genus mucor, rhizopus, rhizomucor, and absidia, which are in the zygomycetes class and the Mucorales order.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15131477",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 202,
                    "text": "Mucormycosis (zygomycosis) normally occurs among individuals with predisposing factors such as prematurity, use of broad spectrum antibiotics, metabolic acidosis or advanced stages of immunosuppression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21761152",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "text": "Mucormycosis (Zygomycosis) is a rare, invasive, opportunistic fungal infection of the paranasal sinuses, caused by a fungus of the order Mucorales.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36604110",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "text": "Zygomycosis is a fungal infection in humans caused by orders Mucorales and Entomophthorales.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36226007",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 91,
                    "text": "Mucormycosis is a rare, aggressive angioinvasive deep fungal infection caused by mucorales.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16568297",
                    "offsetInBeginSection": 529,
                    "offsetInEndSection": 766,
                    "text": "Patients with diabetes, malignancies, solid organ or bone marrow transplants, or iron overload and those receiving immunosuppressive agents, deferoxamine therapy, or broad-spectrum antimicrobial drugs are at highest risk for zygomycosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8848770",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 371,
                    "text": "Mucormycosis (zygomycosis) is an uncommon mycosis which can be contracted from the environment and which is responsible for rhino-orbital, pulmonary, gastrointestinal, cerebral or disseminated infections. Severe immunodepression, such as that caused by leukemia, lymphomata and organ graft, or treatment by desferrioxamine, may predispose to pulmonary and systemic forms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18695332",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 114,
                    "text": "Zygomycosis is an opportunistic fungal infection that seldom occurs in individuals with a competent immune system.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36941816",
                    "offsetInBeginSection": 343,
                    "offsetInEndSection": 457,
                    "text": "Mucormycosis is a fungal infection that invades the blood vessels and is caused by Mucormycetes, a group of fungi.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36941816",
                    "offsetInBeginSection": 567,
                    "offsetInEndSection": 789,
                    "text": "The reason behind the frequent development of opportunistic infections like mucormycosis is the use of steroids, oxygen masks, and antibiotics throughout the treatment of critically and severely ill patients with COVID-19.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What causes Mucormycosis?",
            "type": "factoid",
            "id": "65ef8502dffffb9b6b000003",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30189348",
                "http://www.ncbi.nlm.nih.gov/pubmed/31799598",
                "http://www.ncbi.nlm.nih.gov/pubmed/28800611",
                "http://www.ncbi.nlm.nih.gov/pubmed/29684067",
                "http://www.ncbi.nlm.nih.gov/pubmed/28580607",
                "http://www.ncbi.nlm.nih.gov/pubmed/36374245",
                "http://www.ncbi.nlm.nih.gov/pubmed/36107780",
                "http://www.ncbi.nlm.nih.gov/pubmed/31349852",
                "http://www.ncbi.nlm.nih.gov/pubmed/30540740",
                "http://www.ncbi.nlm.nih.gov/pubmed/37985205"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30189348",
                    "offsetInBeginSection": 281,
                    "offsetInEndSection": 377,
                    "text": "Recent studies indicate that heterochromatin can negatively affect Cas9 binding and functioning.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30189348",
                    "offsetInBeginSection": 490,
                    "offsetInEndSection": 613,
                    "text": "Nucleosomes, however, can completely block Cas9 access to DNA in cell-free assays and present a substantial hurdle in vivo.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31799598",
                    "offsetInBeginSection": 190,
                    "offsetInEndSection": 307,
                    "text": "One of the major challenges is that chromatin compaction inevitably limits the Cas9 protein access to the target DNA.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31799598",
                    "offsetInBeginSection": 624,
                    "offsetInEndSection": 809,
                    "text": "Our findings demonstrate that attenuation of HDAC1, HDAC2 activity, but not other HDACs, enhances CRISPR/Cas9-mediated gene knockout frequencies by NHEJ as well as gene knock-in by HDR.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31799598",
                    "offsetInBeginSection": 878,
                    "offsetInEndSection": 1083,
                    "text": "Furthermore, our study showed that attenuation of HDAC1, HDAC2 activity leads to an open chromatin state, facilitates Cas9 access and binding to the targeted DNA and increases the gene editing frequencies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800611",
                    "offsetInBeginSection": 363,
                    "offsetInEndSection": 497,
                    "text": "Besides the sequence features, local chromatin structures may have effects on CRISPR/Cas9 efficiency, which remain largely unexplored.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800611",
                    "offsetInBeginSection": 701,
                    "offsetInEndSection": 888,
                    "text": "To understand the effects of local chromatin structure on CRISPR/Cas9 efficiency in zebrafish, we first determined that CRISPR/Cas9 introduced genome editing mainly before the dome stage.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800611",
                    "offsetInBeginSection": 1083,
                    "offsetInEndSection": 1294,
                    "text": "Our study demonstrated that chromatin accessibility showed positive correlation with CRISPR/Cas9 efficiency, but we did not observe a clear correlation between nucleosome organization and CRISPR/Cas9 efficiency.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29684067",
                    "offsetInBeginSection": 104,
                    "offsetInEndSection": 215,
                    "text": "Recent studies indicate that the prokaryotic CRISPR-Cas9 system is affected by eukaryotic chromatin structures.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29684067",
                    "offsetInBeginSection": 652,
                    "offsetInEndSection": 950,
                    "text": "Using open access datasets generated from early developmental stages of the zebrafish, and guide RNAs selected from the CRISPRz database, we provide further evidence for an association between gene expression during early development and the success of CRISPR-Cas9 mutagenesis in zebrafish embryos.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Does chromatin accessibility affect CRISPR-Cas9 efficiency?",
            "type": "yesno",
            "id": "661c413f48a2c27714000006",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16915311",
                "http://www.ncbi.nlm.nih.gov/pubmed/17640391",
                "http://www.ncbi.nlm.nih.gov/pubmed/20098810",
                "http://www.ncbi.nlm.nih.gov/pubmed/31474720",
                "http://www.ncbi.nlm.nih.gov/pubmed/37774134",
                "http://www.ncbi.nlm.nih.gov/pubmed/28086259",
                "http://www.ncbi.nlm.nih.gov/pubmed/18155911",
                "http://www.ncbi.nlm.nih.gov/pubmed/7399922",
                "http://www.ncbi.nlm.nih.gov/pubmed/30983397",
                "http://www.ncbi.nlm.nih.gov/pubmed/35251925"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16915311",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 164,
                    "text": "Ehlers-Danlos syndrome is the most frequent heritable connective tissue disorder, and a differential diagnosis to known disorders of the muscle and skeletal system.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17640391",
                    "offsetInBeginSection": 1197,
                    "offsetInEndSection": 1417,
                    "text": "In childhood, coagulation disorders and Silverman's syndrome are the main differential diagnoses; in adulthood, the differential diagnosis includes other Ehlers-Danlos syndromes, Marfan syndrome and Loeys-Dietz syndrome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20098810",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 769,
                    "text": "There is an urgent need to increase the awareness on the Joint Hyper mobility Syndrome QHS). This is a congenital and prevalent emergent condition that is frequently undiagnosed and that causes significant health problems. Besides recurrent muscular-skeletal problems and signs and symptoms derived from tissue fragility, adolescents and young adults may develop osteoporosis, early osteoarthritis or dysautonomia, that are common in the disease, and deteriorate quality of life. Many JHS patients have signs and symptoms suggestive of fibromyalgia and are usually misdiagnosed. Physicians should be able to differentiate the less severe form of JHS from the Vascular Ehlers-Danlos Syndrome, to diagnose it before the appearance of serious complications and even death.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31474720",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 243,
                    "text": "Joint hypermobility syndrome (JHS) (also termed hypermobility type Ehlers-Danlos syndrome, hEDS) is a heritable connective tissue disorder that is characterized by generalized joint hypermobility, chronic pain, fatigue, and minor skin changes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37774134",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "The most common conditions with symptomatic joint hypermobility are hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28086259",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 516,
                    "text": "Joint hypermobility syndrome (JHS)/Ehlers-Danlos syndrome hypermobility type (EDS-HT) is the most common hereditary non-inflammatory disorder of connective tissue, characterized by a wide range of symptoms, mainly joint hyperextensibility and musculoskeletal symptoms. A majority of patients also experiences gastrointestinal (GI) symptoms. Furthermore, JHS/EDS-HT has specifically been shown to be highly prevalent in patients with functional GI disorders, such as functional dyspepsia and irritable bowel syndrome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18155911",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 795,
                    "text": "The kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VI) (OMIM 225400) is an inherited connective tissue disorder characterized by hypotonia and kyphoscoliosis at birth, joint hypermobility, and skin hyperelasticity and fragility. Biochemically, it is characterized by a deficiency of collagen lysyl hydroxylase (EC 1.14.11.4) due to mutations in PLOD1. This deficiency results in underhydroxylation of collagen lysyl residues and, hence, an abnormal pattern of lysyl pyridinoline (LP) and hydroxylysyl pyridinoline (HP) crosslinks excreted in the urine. Because of hypotonia and delay in gross motor development, a neuromuscular disease is usually suspected, and in most cases the diagnosis is considered only very late, after performing an invasive neuromuscular work-up with normal results.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7399922",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 479,
                    "text": "Progress in the experimental field and a deepened understanding of biological functional entities gave considerable impetus to connective tissue research. This was particularly true for the heritable connective tissue disorders, of which the Ehlers-Danlos-Syndrome is the best example. Its clinical and biochemical heterogeneity have allowed a classification of the disease into sub-groups, and the conditions for differential diagnosis and therapeutic trials were thus improved.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30983397",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1346,
                    "text": "In this review article, the authors summarize the clinical aspects of the novel classification of Ehlers-Danlos syndrome, which is a group of rare, hereditary connective tissue disorders. The leading symptom of the Ehlers-Danlos syndrome group is joint hypermobility, skin hyperextensibility and generalized tissue fragility. Ehlers-Danlos syndrome displays a high clinical and genetic heterogeneity and harbors many multidisciplinary properties. Certain subtypes only affect the quality of life, while other forms may lead to severe, even fatal vascular or intestinal complications. Last year, based on the data of various international genotype-phenotype correlation studies of large populations, a new classification of the syndrome's clinical subtypes was introduced. The novel international nosology of Ehlers-Danlos syndromes published in 2017 delineates 13 clinical subtypes, describes their genetic background and defines major and minor diagnostic criteria for each subtype. We gathered the complex, multidisciplinary symptoms of Ehlers-Danlos syndromes in a table to assist the diagnosis from a differential diagnostic point of view. In the clinical practice, the proper diagnosis of patients affected by the Ehlers-Danlos syndrome group is essential to give optimal clinical care and to prevent the development of severe complications.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35251925",
                    "offsetInBeginSection": 280,
                    "offsetInEndSection": 570,
                    "text": "Mild asymptomatic forms of Ehlers-Danlos syndrome seems to be under diagnosed and may have severe systemic complications mainly cardio vascular. Cartilaginous defects in the head and neck region increase the risk of Sleep-Disordered Breathing (SDB) especially Obstructive Sleep Apnea (OSA).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What diseases are included in the differential diagnosis of Ehlers-Danlos Syndrome?",
            "type": "list",
            "id": "661d51fdeac11fad3300001d",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35842249",
                "http://www.ncbi.nlm.nih.gov/pubmed/31449914",
                "http://www.ncbi.nlm.nih.gov/pubmed/34857395",
                "http://www.ncbi.nlm.nih.gov/pubmed/35412530",
                "http://www.ncbi.nlm.nih.gov/pubmed/34726262",
                "http://www.ncbi.nlm.nih.gov/pubmed/16129907"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35842249",
                    "offsetInBeginSection": 304,
                    "offsetInEndSection": 497,
                    "text": "Nemolizumab is a humanized monoclonal antibody that blocks the  subunit of the IL-31 receptor, modulates the neuroimmune response, and rapidly alleviates itching by directly blocking signaling.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31449914",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "text": "Nemolizumab targets the IL-31 receptor  subunit involved in atopic dermatitis (AD) pathogenesis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34857395",
                    "offsetInBeginSection": 907,
                    "offsetInEndSection": 1233,
                    "text": "Our results demonstrate that nemolizumab effectively decreases IL-31 responses in PN skin, leading to effective suppression of downstream inflammatory responses including T These data demonstrate a broad response to IL-31 receptor inhibition with nemolizumab and confirm the critical upstream role of IL-31 in PN pathogenesis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35412530",
                    "offsetInBeginSection": 277,
                    "offsetInEndSection": 464,
                    "text": "Nemolizumab is an anti-IL-31 receptor -chain (IL-31RA) monoclonal antibody agent that is efficacious in improving symptoms of AD in several phase II and phase III studies in recent years.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34726262",
                    "offsetInBeginSection": 159,
                    "offsetInEndSection": 305,
                    "text": "Nemolizumab, a humanized monoclonal antibody against IL-31 receptor A, reduced pruritus in patients with AD after a 16-week administration period.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16129907",
                    "offsetInBeginSection": 837,
                    "offsetInEndSection": 1047,
                    "text": "The administration of tocilizumab (a recombinant humanized anti-IL-6R monoclonal antibody) exerts its action by preventing the binding of IL-6 to its receptor and, therefore, preventing the activation of gp130.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the mechanism of action of Nemolizumab?",
            "type": "summary",
            "id": "65cfa70f1930410b1300000f",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29460462",
                "http://www.ncbi.nlm.nih.gov/pubmed/33517598",
                "http://www.ncbi.nlm.nih.gov/pubmed/10424821",
                "http://www.ncbi.nlm.nih.gov/pubmed/7713510",
                "http://www.ncbi.nlm.nih.gov/pubmed/31836684",
                "http://www.ncbi.nlm.nih.gov/pubmed/16953888",
                "http://www.ncbi.nlm.nih.gov/pubmed/28004033",
                "http://www.ncbi.nlm.nih.gov/pubmed/26059676",
                "http://www.ncbi.nlm.nih.gov/pubmed/30711802",
                "http://www.ncbi.nlm.nih.gov/pubmed/22921333"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29460462",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 103,
                    "text": "Cri du Chat syndrome (CdCS) is a genetic syndrome caused by deletions in the short arm of chromosome 5.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33517598",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 56,
                    "text": "Cri-du-chat (CdC) is a 5p chromosomal deletion syndrome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10424821",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 84,
                    "text": "Cri du chat syndrome is associated with a deletion on the short arm of chromosome 5.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7713510",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "The deletion of the short arm of chromosome 5 is associated with the cri-du-chat syndrome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31836684",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Cri du chat syndrome (CDCS) is a rare genetic disease that is caused by a deletion in the short arm of chromosome 5 (5p)",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16953888",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "text": "The Cri du Chat syndrome (CdCS) is a genetic disease resulting from a deletion of variable size occurring on the short arm of chromosome 5 (5p-).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28004033",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "text": "The Cri du Chat syndrome (CdC) is a rare genetic disorder caused by variable size deletions of the short arm of chromosome 5 (5p-)",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26059676",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 105,
                    "text": "The cri-du-chat syndrome is a rare genetic disorder caused by deletions in the short arm of chromosome 5.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30711802",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "text": "The Cri du Chat Syndrome (CdCS) is a genetic disease resulting from variable size deletion occurring on the short arm of chromosome 5.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22921333",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "text": "Cri du chat syndrome (CCS) is a genetic disorder resulting from the deletion of the short arm of chromosome 5.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is Cri du Chat syndrome (CdCS) a genetic syndrome caused by deletions in the long arm of chromosome 5",
            "type": "yesno",
            "id": "65f37aeac4010b4d7800000c",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36648121",
                "http://www.ncbi.nlm.nih.gov/pubmed/36382338"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36648121",
                    "offsetInBeginSection": 117,
                    "offsetInEndSection": 381,
                    "text": "A retrospective observational study (2017-2019) of children aged 18 years and younger presenting to a pediatric ED at a tertiary care children's hospital with fever, hypotension, or an infectious disease International Classification of Diseases (ICD)-10 diagnosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36648121",
                    "offsetInBeginSection": 512,
                    "offsetInEndSection": 651,
                    "text": "According to the Improving Pediatric Sepsis Outcomes Classification, confirmed by expert review, 191 patients met clinical sepsis criteria.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36648121",
                    "offsetInBeginSection": 835,
                    "offsetInEndSection": 995,
                    "text": "Machine learning methods reached a performance of up to 93% sensitivity and 84% specificity in identifying patients who received a hospital diagnosis of sepsis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36382338",
                    "offsetInBeginSection": 1098,
                    "offsetInEndSection": 1154,
                    "text": "Only one study evaluated pediatric patients exclusively.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is ICD-10 encoding sensitive for capturing paediatric sepsis?",
            "type": "yesno",
            "id": "661d2428eac11fad33000017",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37099816",
                "http://www.ncbi.nlm.nih.gov/pubmed/32001308",
                "http://www.ncbi.nlm.nih.gov/pubmed/12696479",
                "http://www.ncbi.nlm.nih.gov/pubmed/20369905",
                "http://www.ncbi.nlm.nih.gov/pubmed/8898453",
                "http://www.ncbi.nlm.nih.gov/pubmed/32982508",
                "http://www.ncbi.nlm.nih.gov/pubmed/2208563",
                "http://www.ncbi.nlm.nih.gov/pubmed/9177140",
                "http://www.ncbi.nlm.nih.gov/pubmed/29904156",
                "http://www.ncbi.nlm.nih.gov/pubmed/31891647"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37099816",
                    "offsetInBeginSection": 1414,
                    "offsetInEndSection": 1495,
                    "text": "The annual fecal immunochemical test was the most predominant screening strategy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32001308",
                    "offsetInBeginSection": 979,
                    "offsetInEndSection": 1081,
                    "text": "The most favorable intervention by net monetary benefit was flexible sigmoidoscopy ($3284 per person).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32001308",
                    "offsetInBeginSection": 1082,
                    "offsetInEndSection": 1163,
                    "text": "Flexible sigmoidoscopy, FOBT, and FIT all dominated the current standard of care.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12696479",
                    "offsetInBeginSection": 1111,
                    "offsetInEndSection": 1309,
                    "text": "Worldwide and Israeli results on colonoscopy in average-risk persons age 50-75, demonstrated a considerable prevalence of neoplasia, a low morbidity rate, no mortality and a high cost-effectiveness.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20369905",
                    "offsetInBeginSection": 704,
                    "offsetInEndSection": 927,
                    "text": "CTC screening offered every 10 years was cost saving compared with the current UK programme of biennial FOBT screening. This strategy also yielded greater health benefits (QALYs and life-years) than biennial FOBT screening.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8898453",
                    "offsetInBeginSection": 514,
                    "offsetInEndSection": 1092,
                    "text": "Periodic colorectal screening is therefore a cost-effective intervention and the Office of Technology Assessment of the Congress of the United States has concluded that colorectal cancer screening in average-risk adults beginning at age 50 is a relatively good investment for society. Flexible sigmoidoscopy and double contrast barium enema are the most cost-effective strategies but they both require colonoscopy if a lesion is identified. Colonoscopy at 10-yearly intervals is of comparable cost to flexible sigmoidoscopy every 5 years and less costly than FSIG every 3 years.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32982508",
                    "offsetInBeginSection": 736,
                    "offsetInEndSection": 2121,
                    "text": "The main outcome measures in this systematic review were the incremental cost-effectiveness ratio (ICER) of screening versus no-screening and then in comparison with other screening techniques. The ICER is defined by the difference in cost between two possible interventions, divided by the difference in their effect. Eight studies were identified and retained for the final analysis. In this study, when screening techniques were compared to no-screening, all CRC screening techniques showed to be cost-effective. The lowest ICER calculated was $PPP -16265/quality-adjusted life-year (QALY) (the negative ICERs were between purchasing power parity in US dollar ($PPP) -16265/QALY to $PPP -1988/QALY, whereas the positive ICERs were between $PPP 1257/QALY to $PPP 55987/QALY). For studies comparing various screening techniques, there was great heterogeneity in terms of the structures of the analyses, leading to diverse conclusions about their incremental cost-effectiveness. All CRC screening techniques were cost-effective, compared with the no-screening methods. The cost-effectiveness of the various screening techniques mainly was dependent on the context-specific parameters and highly affected by the framework of the cost-effectiveness analysis. In order to make the studies comparable, it is important to adopt a reference-based methodology for economic evaluation studies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2208563",
                    "offsetInBeginSection": 665,
                    "offsetInEndSection": 1260,
                    "text": "Flexible sigmoidoscopy and faecal occult blood tests are sufficiently acceptable to be included in case-finding among patients who are in the health care system. The results of current controlled trials involving more than 300,000 individuals for evaluating the impact of screening on mortality from colon cancer are needed before this approach can be recommended for general public health screening of the population. Further research is required to develop better screening tests, improve patient and physician compliance, and answer more definitively critical questions on cost-effectiveness.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9177140",
                    "offsetInBeginSection": 963,
                    "offsetInEndSection": 1151,
                    "text": "The American Cancer Society recommends a combination of FOBT and flexible sigmoidoscopy, but some experts believe that a one-time colonoscopy at age 60 may be a more cost-effective method.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29904156",
                    "offsetInBeginSection": 883,
                    "offsetInEndSection": 1108,
                    "text": "For commercial payers with a time horizon of ages 50-64, fecal occult blood testing (FOBT) and fecal immunochemical testing (FIT) were cost-effective (<$61,000/QALY gained), but colonoscopy was costly (>$185,000/QALY gained).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What type of colorectal cancer screening is the most cost-effective for general population?",
            "type": "factoid",
            "id": "65f774a4c4010b4d78000029",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16550145",
                "http://www.ncbi.nlm.nih.gov/pubmed/22249081",
                "http://www.ncbi.nlm.nih.gov/pubmed/26514053",
                "http://www.ncbi.nlm.nih.gov/pubmed/34929521",
                "http://www.ncbi.nlm.nih.gov/pubmed/21741216",
                "http://www.ncbi.nlm.nih.gov/pubmed/20194404",
                "http://www.ncbi.nlm.nih.gov/pubmed/18752109",
                "http://www.ncbi.nlm.nih.gov/pubmed/29079493",
                "http://www.ncbi.nlm.nih.gov/pubmed/23826212",
                "http://www.ncbi.nlm.nih.gov/pubmed/22526823"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16550145",
                    "offsetInBeginSection": 437,
                    "offsetInEndSection": 598,
                    "text": "The long-term evolution is marked by substantial excess mortality, a suicide rate of 10-20% and an overall decrease of approximately 10 years in life expectancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22249081",
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 304,
                    "text": "Patients with schizophrenia have two-fold to three-fold higher mortality rates compared with the general population, corresponding to a 10-25-year reduction in life expectancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22249081",
                    "offsetInBeginSection": 305,
                    "offsetInEndSection": 442,
                    "text": "Although the mortality rate from suicide is high, natural causes of death account for a greater part of the reduction in life expectancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26514053",
                    "offsetInBeginSection": 775,
                    "offsetInEndSection": 1351,
                    "text": "According to many reports from foreign countries, mortality rates associated with schizophrenia are two to three times higher than those of the general population, corresponding to a 10-25-year reduction in life expectancy. Natural deaths account for about 60% of the excess mortality of schizophrenia patients, and such patients are more likely to die from ischemic heart disease. Since it has been suggested that more than half of sudden deaths in schizophrenic patients have a cardiac origin, sudden cardiac deaths are chiefly responsible for their reduced life expectancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34929521",
                    "offsetInBeginSection": 632,
                    "offsetInEndSection": 728,
                    "text": "Life expectancy for men and women with schizophrenia was 52.8 years and 59.0 years respectively.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34929521",
                    "offsetInBeginSection": 729,
                    "offsetInEndSection": 867,
                    "text": "The overall PYLL of people with schizophrenia was 18.4 years, and suicide had the largest PYLL (31.2 years) among all causes of mortality.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21741216",
                    "offsetInBeginSection": 390,
                    "offsetInEndSection": 891,
                    "text": "Life-expectancy was 18.7 years shorter for schizophrenic men compared to men in the general population. Corresponding numbers for schizophrenic women was 16.3 years, for bipolar men 13.6 years, and for bipolar women 12.1 years. Life-expectancy was much shorter in persons with schizophrenia or bipolar disorder. Excess mortality from physical diseases and medical conditions exerts a far greater influence on the curtailed life-expectancy, when compared against the impact of death by external causes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20194404",
                    "offsetInBeginSection": 457,
                    "offsetInEndSection": 679,
                    "text": "During the five-year follow-up of 7,591 schizophrenia patients, 403 (5%) patients died. They had 4.45-fold higher mortality than the general population, and patients' mortality was significantly elevated in all age groups.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20194404",
                    "offsetInBeginSection": 817,
                    "offsetInEndSection": 873,
                    "text": "The largest single unnatural cause of death was suicide.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18752109",
                    "offsetInBeginSection": 657,
                    "offsetInEndSection": 859,
                    "text": "Part of the high death rates may be explained by long-lasting negative health habits, disease- and treatment-related metabolic disorders, and consequent increased frequencies of cardiovascular diseases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Mortality in schizophrenia.",
            "type": "summary",
            "id": "66168d7bfdcbea915f000056",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29861156",
                "http://www.ncbi.nlm.nih.gov/pubmed/29873684",
                "http://www.ncbi.nlm.nih.gov/pubmed/17214345",
                "http://www.ncbi.nlm.nih.gov/pubmed/21810511",
                "http://www.ncbi.nlm.nih.gov/pubmed/23204187",
                "http://www.ncbi.nlm.nih.gov/pubmed/20526097",
                "http://www.ncbi.nlm.nih.gov/pubmed/36252550",
                "http://www.ncbi.nlm.nih.gov/pubmed/33311791",
                "http://www.ncbi.nlm.nih.gov/pubmed/34364765",
                "http://www.ncbi.nlm.nih.gov/pubmed/17032196"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29861156",
                    "offsetInBeginSection": 1084,
                    "offsetInEndSection": 1590,
                    "text": "The addition of oxaliplatin provided an overall survival benefit for patients < 70 years (hazard ratio, 0.44; 95% confidence interval, 0.3-0.6; P < .0001) and for patients  70 years (hazard ratio, 0.64; 95% confidence interval, 0.5-0.9; P = .005). Despite a modestly increased rate of hospital admission and early chemotherapy cessation, we demonstrate a persistent survival benefit for the addition of oxaliplatin to a fluoropyrimidine as adjuvant treatment for stage III colon cancer in elderly patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29873684",
                    "offsetInBeginSection": 1720,
                    "offsetInEndSection": 1884,
                    "text": "The addition of oxaliplatin significantly improved DFS and OS in younger patients aged <60 years with advanced rectal cancer. Patients aged 70 years had no benefit.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29873684",
                    "offsetInBeginSection": 1575,
                    "offsetInEndSection": 1719,
                    "text": "The STEPP analysis revealed improved hazard ratios for DFS in patients aged 40-70 years compared with elderly patients treated with oxaliplatin.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29873684",
                    "offsetInBeginSection": 393,
                    "offsetInEndSection": 495,
                    "text": "We therefore investigated the impact of age on clinical outcome in the CAO/ARO/AIO-04 phase III trial.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29873684",
                    "offsetInBeginSection": 292,
                    "offsetInEndSection": 392,
                    "text": "The use of oxaliplatin as adjuvant treatment in elderly patients with colon cancer is controversial.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17214345",
                    "offsetInBeginSection": 369,
                    "offsetInEndSection": 497,
                    "text": "However, oxaliplatin-based chemotherapy has emerged as the new standard of care in adjuvant treatment of stage III colon cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21810511",
                    "offsetInBeginSection": 354,
                    "offsetInEndSection": 466,
                    "text": "A critical issue, which needs to be specifically addressed, is the role of adjuvant therapy in elderly patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21810511",
                    "offsetInBeginSection": 166,
                    "offsetInEndSection": 285,
                    "text": "Six months of oxaliplatin and fluoropyrimidine in combination is the standard adjuvant treatment in stage III patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204187",
                    "offsetInBeginSection": 1525,
                    "offsetInEndSection": 1719,
                    "text": "Therefore, for colon cancer patients aged 65, oxaliplatin, fluorouracil and leucovorin chemotherapy can be recommended as safe and effective adjuvant chemotherapy after curative surgery in Asia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204187",
                    "offsetInBeginSection": 1281,
                    "offsetInEndSection": 1524,
                    "text": "Adjuvant oxaliplatin, fluorouracil and leucovorin chemotherapy resulted in similar efficacy without significant increase in toxicity in older patients aged 65 when compared with younger patients with curatively resected Stage III colon cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Do very elderly stage III colorectal cancer patients present clinical benefit from oxaliplatin-based adjuvant chemotherapy?",
            "type": "yesno",
            "id": "65f7754ec4010b4d7800002b",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/34292533",
                "http://www.ncbi.nlm.nih.gov/pubmed/34565792",
                "http://www.ncbi.nlm.nih.gov/pubmed/37880647",
                "http://www.ncbi.nlm.nih.gov/pubmed/35983925",
                "http://www.ncbi.nlm.nih.gov/pubmed/35616682",
                "http://www.ncbi.nlm.nih.gov/pubmed/37878779",
                "http://www.ncbi.nlm.nih.gov/pubmed/34284994",
                "http://www.ncbi.nlm.nih.gov/pubmed/37870976",
                "http://www.ncbi.nlm.nih.gov/pubmed/34880698",
                "http://www.ncbi.nlm.nih.gov/pubmed/34913823"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34292533",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 274,
                    "text": "Amivantamab (amivantamab-vmjw; RybrevantTM), a bispecific monoclonal antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition factor (MET), is being developed by Janssen Biotech for the treatment of non-small cell lung cancer (NSCLC).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34292533",
                    "offsetInBeginSection": 275,
                    "offsetInEndSection": 533,
                    "text": "On 21 May 2021, amivantamab received its first approval in the USA for the treatment of adult patients with locally advanced or metastatic NSCLC harbouring EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34565792",
                    "offsetInBeginSection": 129,
                    "offsetInEndSection": 920,
                    "text": "Between 80-85% of all lung cancers are non-small cell lung cancer (NSCLC), and of these, between 2-3% have an EGFR exon 20 insertion, which is associated with increased cell proliferation, metastasis, and a lack of response to chemotherapy and epidermal growth factor receptor (EGFR) inhibitors. Until this year, there were no available targeted therapies for advanced NSCLC with this genetic subtype. However, in May 2021, the US Food and Drug Administration (FDA) granted accelerated approval for amivantamab-vmjw (Rybrevant), a bispecific monoclonal antibody, targeting activating and resistant EGFR and MET mutations and amplifications. This FDA approval was for adult patients with locally advanced metastatic NSCLC, with disease progression on or following platinum-based chemotherapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37880647",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Non-small cell lung cancer (NSCLC) patients with sensitizing oncogenic driver mutations benefit from targeted therapies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37880647",
                    "offsetInBeginSection": 430,
                    "offsetInEndSection": 662,
                    "text": "In May 2021, the US Federal Drug Administration (FDA) provided accelerated approval to amivantamab (Rybrevant) in adults with locally advanced or metastatic NSCLC with EGFR exon20ins after treatment with platinum-based chemotherapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37880647",
                    "offsetInBeginSection": 663,
                    "offsetInEndSection": 795,
                    "text": "Amivantamab was the first EGFR/MET bispecific antibody to be approved specifically for EGFR exon20ins where there was an unmet need.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35983925",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 348,
                    "text": "The U.S. Food and Drug Administration (FDA) first approved amivantamab, a monoclonal epidermal growth factor receptor (EGFR)-mesenchymal--epithelial transition factor (MET) bispecific antibody, in May 2021, to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with an insertion mutation in exon 20 of EGFR.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35616682",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 277,
                    "text": "Amivantamab was approved on May 21st, 2021, by United States food and drug administration with the brand name Rybervant, used particularly for adult patients with exon20 insertion of epithelial growth factor receptor with locally advanced metastatic non-small cell lung cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37878779",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 216,
                    "text": "Data from three phase III trials-PAPILLON, MARIPOSA, and MARIPOSA-2-highlight amivantamab, an EGFR-MET bispecific antibody, as a potential contender as a standard treatment for EGFR-mutant non-small cell lung cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34284994",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "Amivantamab is the only FDA-approved therapy for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is Amivantamab used for nonsmall-cell lung cancer?",
            "type": "yesno",
            "id": "65cf96ce1930410b1300000a",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20847697",
                "http://www.ncbi.nlm.nih.gov/pubmed/30063214",
                "http://www.ncbi.nlm.nih.gov/pubmed/7817181",
                "http://www.ncbi.nlm.nih.gov/pubmed/36706158"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20847697",
                    "offsetInBeginSection": 1600,
                    "offsetInEndSection": 1689,
                    "text": "No treatment for the underlying defect is presently available for Ehlers-Danlos syndrome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30063214",
                    "offsetInBeginSection": 227,
                    "offsetInEndSection": 494,
                    "text": "A recent international consortium proposed a revised Ehlers-Danlos syndrome classification, an update much needed since Villefranche nosology, in 1998. Hypermobile Ehlers-Danlos syndrome is the only subtype in these groups of syndromes with no known genetic cause(s).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7817181",
                    "offsetInBeginSection": 249,
                    "offsetInEndSection": 316,
                    "text": "Conservative treatment is first choice, unless complications occur.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36706158",
                    "offsetInBeginSection": 435,
                    "offsetInEndSection": 586,
                    "text": "To the best of our knowledge, this is the first report of the use of desmopressin during major obstetric hemorrhage in vascular Ehlers-Danlos syndrome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is there a specific cure for Ehlers-Danlos Syndrome?",
            "type": "yesno",
            "id": "661d56c0eac11fad3300001f",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/31098728",
                "http://www.ncbi.nlm.nih.gov/pubmed/35511871",
                "http://www.ncbi.nlm.nih.gov/pubmed/2541261",
                "http://www.ncbi.nlm.nih.gov/pubmed/8028099",
                "http://www.ncbi.nlm.nih.gov/pubmed/20688655",
                "http://www.ncbi.nlm.nih.gov/pubmed/25588013",
                "http://www.ncbi.nlm.nih.gov/pubmed/12910761",
                "http://www.ncbi.nlm.nih.gov/pubmed/25973622",
                "http://www.ncbi.nlm.nih.gov/pubmed/8667375",
                "http://www.ncbi.nlm.nih.gov/pubmed/2067060"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31098728",
                    "offsetInBeginSection": 91,
                    "offsetInEndSection": 274,
                    "text": "White-tailed deer (Odocoileus virginianus) are widely distributed in North America and deer densities are frequently high in unhunted areas, including most major metropolitan regions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35511871",
                    "offsetInBeginSection": 257,
                    "offsetInEndSection": 413,
                    "text": "Widely distributed in North America, the white-tailed deer (Odocoileus virginianus) has recreational, commercial, and food source value for many households.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2541261",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 314,
                    "text": "High white-tailed deer (Odocoileus virginianus) population densities and the occurrence of harsh environmental conditions are present on Anticosti Island, located in the Gulf of Saint-Lawrence (Quebec, Canada). This island is the northernmost region of white-tailed deer distribution in northeastern North America.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8028099",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 377,
                    "text": "We determined the antibody prevalence to Ehrlichia spp., in white-tailed deer (Odocoileus virginianus) and the geographic distribution of seropositive animals in 84 counties in Alabama, Arkansas, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland, Massachusetts, Mississippi, Missouri, North Carolina, South Carolina, Tennessee, Texas, Virginia, and West Virginia (USA).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20688655",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 272,
                    "text": "Individuals of three species of cervids, with varying degrees of alopecia, were examined for ectoparasites: Rocky Mountain elk (Cervus elaphus nelsoni) and mule deer (Odocoileus hemionus hemionus) in Colorado and white-tailed deer (Odocoileus virginianus) in South Dakota.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25588013",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 337,
                    "text": "The meningeal worm (Parelaphostrongylus tenuis) is a nematode parasite that commonly infects white-tailed deer (Odocoileus virginianus; WTD) throughout the deciduous forest biome and deciduous-coniferous ecotone of eastern and central North America; the species is not known to occur west of the grassland biome of central North America.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12910761",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 854,
                    "text": "Meningeal worm (Parelaphostrongylus tenuis), a common nematode parasite in white-tailed deer (Odocoileus virginianus) and pathogenic for several species of ungulates in eastern North America, is not known to occur in the west. Heads of 1,902 white-tailed deer were examined for adult meningeal worm to determine geographic distribution of the parasite in Saskatchewan and Manitoba (Canada) and North Dakota (USA). Finding the parasite in a deer in eastern Saskatchewan near the Manitoba border established the current northern and western limits in Canada. Prevalence of infection was < 1, 18.6, and 8.2% in Saskatchewan, Manitoba, and North Dakota, respectively. Infected deer occurred throughout southern Manitoba and eastern North Dakota. Distribution appears to have changed little since the last published survey for P. tenuis in the region in 1972.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25973622",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 586,
                    "text": "The meningeal worm (Parelaphostrongylus tenuis) is a parasite of white-tailed deer (Odocoileus virginianus) and is also a significant pathogen of moose (Alces alces) and other ungulates. Changes in climate or habitat may facilitate range expansion or increase the prevalence of meningeal worm infection in white-tailed deer, resulting in increased exposure to susceptible ungulates. We examined 3,730 white-tailed deer during 2002-05 to determine the prevalence and range of meningeal worm infection in North Dakota, US, and investigated whether these had changed since earlier surveys.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8667375",
                    "offsetInBeginSection": 495,
                    "offsetInEndSection": 767,
                    "text": "Its distribution appears to be expanding, and includes the state of Florida in the southeastern United States north to the provinces of Nova Scotia and Prince Edward Island, Canada, west to North and South Dakota, United States, and south to the state of Coahuila, Mexico.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2067060",
                    "offsetInBeginSection": 175,
                    "offsetInEndSection": 397,
                    "text": "The parasite is widely distributed and common in all or much of Arkansas, Kentucky, Louisiana, Maryland, North Carolina, Tennessee, Virginia and West Virginia. It is also common in the northern half of Alabama and Georgia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Where would Odocoileus virginianus be found?",
            "type": "factoid",
            "id": "660982eefdcbea915f000012",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [],
            "snippets": [],
            "body": "Should routine PET-CT scan be indicated in the initial evaluation of locally advanced rectal cancer patients?",
            "type": "yesno",
            "id": "65f774dec4010b4d7800002a",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26206099",
                "http://www.ncbi.nlm.nih.gov/pubmed/27454404",
                "http://www.ncbi.nlm.nih.gov/pubmed/16895565",
                "http://www.ncbi.nlm.nih.gov/pubmed/30245770",
                "http://www.ncbi.nlm.nih.gov/pubmed/30815041",
                "http://www.ncbi.nlm.nih.gov/pubmed/26096345",
                "http://www.ncbi.nlm.nih.gov/pubmed/25395294",
                "http://www.ncbi.nlm.nih.gov/pubmed/2187466",
                "http://www.ncbi.nlm.nih.gov/pubmed/35053435",
                "http://www.ncbi.nlm.nih.gov/pubmed/31538818"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26206099",
                    "offsetInBeginSection": 300,
                    "offsetInEndSection": 442,
                    "text": "The aim of this work is to discuss the rationale, evidence and perspectives of approaches combining target and immunotherapy against melanoma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27454404",
                    "offsetInBeginSection": 62,
                    "offsetInEndSection": 423,
                    "text": "Evidence that melanoma tumor cells are highly immunogenic and a better understanding of T-cell immune checkpoints have changed the therapeutic approach to advanced melanoma. Instead of targeting the tumor directly, immunotherapy targets and activates the immune response using checkpoint inhibitors, monoclonal antibodies, vaccines, and adoptive T cell therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16895565",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 358,
                    "text": "Immunotherapy has assumed increasing importance in the therapy of malignant melanoma. The main reason is the high immunogenicity of the tumor itself, so that an immune response against the tumor often exists even without immune stimulation. The goal of modern immunotherapeutic approaches is to augment these anti-tumoral immune reactions to fight the tumor.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30245770",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 369,
                    "text": "Immunotherapy is a treatment strategy that has demonstrated survival benefit for metastatic melanoma. Ipilimumab and nivolumab are examples of immunotherapy, in which monoclonal antibodies antagonize cytotoxic T-lymphocyte-associated protein 4 and programmed death-ligand 1 receptors, respectively, resulting in upregulation of the host immune response to cancer cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30815041",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "text": "The development of BRAF and MEK inhibitors (BRAFis and MEKis) and immune checkpoint inhibitors have changed the management of advanced stage melanoma and improved the outcomes of patients with this malignancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30815041",
                    "offsetInBeginSection": 498,
                    "offsetInEndSection": 732,
                    "text": "Preclinical and translational data have shown that BRAFis and MEKis alter the tumor microenvironment to make it more amenable to immunotherapy and have provided the scientific rationale for combing BRAFis and MEKis with immunotherapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26096345",
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 384,
                    "text": "The rationale of T1 use in cancer treatment stems from the consideration that tumor progression is favored by a failure of the immune response and in turn induces immune suppression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25395294",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 652,
                    "text": "There have been significant advances in the past several years with regard to targeted therapy and immunotherapy for cancer. This is highlighted in melanoma, where treatment with targeted therapy (against the BRAF oncoprotein) results in responses in the majority of patients, although the duration of response is limited. In contrast, treatment with immunotherapy results in a lower response rate, but one that tends to be more durable. Insights about mechanisms of response and potential synergy between these treatment strategies for melanoma are a focus of this review, with opportunities to extend these insights to the treatment of other cancers.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2187466",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 656,
                    "text": "Adoptive immunotherapy for the treatment of cancer has met with limited but, for some, encouraging success. A minority of malignant melanoma and renal cell carcinoma patients respond to therapy with interleukin 2 (IL-2) or IL-2 plus lymphokine-activated killer (LAK) cells. The mechanism of response, and the reasons for the variation within disease groups, is not clear. In this article, Giorgio Parmiani proposes that successful adoptive therapy is dependent on the recruitment of activated host antitumor T lymphocytes and suggests that this explains the greater efficacy of tumor-infiltrating lymphocytes in combating melanoma and renal cell carcinoma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35053435",
                    "offsetInBeginSection": 460,
                    "offsetInEndSection": 932,
                    "text": "The main fields of investigation include the identification of new immune checkpoint inhibitors (anti-LAG3, GITR agonist and anti-TIGIT), adoptive cell therapy, vaccines, engineered TCR therapy, IL-2 agonists, novel targets for targeted therapy (new MEK or RAF inhibitors, HDAC, IDO, ERK, Axl, ATR and PARP inhibitors), or combination strategies (antiangiogenetic agents plus immune checkpoint inhibitors, intra-tumoral immunotherapy in combination with systemic therapy).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the rationale behind treating melanoma with immunotherapy?",
            "type": "summary",
            "id": "65f868eac4010b4d78000056",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22752412",
                "http://www.ncbi.nlm.nih.gov/pubmed/21294944",
                "http://www.ncbi.nlm.nih.gov/pubmed/32684248",
                "http://www.ncbi.nlm.nih.gov/pubmed/22172152",
                "http://www.ncbi.nlm.nih.gov/pubmed/37925626",
                "http://www.ncbi.nlm.nih.gov/pubmed/19084436",
                "http://www.ncbi.nlm.nih.gov/pubmed/22227101",
                "http://www.ncbi.nlm.nih.gov/pubmed/37529329",
                "http://www.ncbi.nlm.nih.gov/pubmed/26060997",
                "http://www.ncbi.nlm.nih.gov/pubmed/27770493"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22752412",
                    "offsetInBeginSection": 105,
                    "offsetInEndSection": 291,
                    "text": "Recognized human infections have all resulted from a HeV infected horse that was unusually efficient in transmitting the virus and a person with a high exposure to infectious secretions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21294944",
                    "offsetInBeginSection": 1270,
                    "offsetInEndSection": 1373,
                    "text": "Human infection can occur via exposure to infectious urine, saliva or nasopharyngeal fluid from horses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32684248",
                    "offsetInBeginSection": 393,
                    "offsetInEndSection": 483,
                    "text": "The virus is transmitted from flying foxes to horses, horse to horse, and horse to humans.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22172152",
                    "offsetInBeginSection": 146,
                    "offsetInEndSection": 959,
                    "text": "Although the mode and critical control points of HeV spillover to horses from flying foxes, and the risk for transmission from infected horses to other horses and humans, are poorly understood, we successfully established systemic HeV disease in 3 horses exposed to Hendra virus/Australia/Horse/2008/Redlands by the oronasal route, a plausible route for natural infection. In 2 of the 3 animals, HeV RNA was detected continually in nasal swabs from as early as 2 days postexposure, indicating that systemic spread of the virus may be preceded by local viral replication in the nasal cavity or nasopharynx. Our data suggest that a critical factor for reducing HeV exposure risk to humans includes early consideration of HeV in the differential diagnosis and institution of appropriate infection control procedures.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37925626",
                    "offsetInBeginSection": 400,
                    "offsetInEndSection": 885,
                    "text": "More than 600 human infections have been reported in the literature, but information on viral shedding was only available for 40 case-patients. There is substantial evidence demonstrating person-to-person transmission of NiVB, and some evidence for NiVM. Less direct evidence is available about the risk for person-to-person transmission of HeV, but animals infected with HeV shed more virus in the respiratory tract than those infected with NiVM suggesting potential for transmission.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19084436",
                    "offsetInBeginSection": 284,
                    "offsetInEndSection": 480,
                    "text": "Both viruses emerged from their natural reservoir during the last decade of the 20th century, causing severe disease in humans, horses and swine, and infecting a number of other mammalian species.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22227101",
                    "offsetInBeginSection": 563,
                    "offsetInEndSection": 761,
                    "text": "While the initial human infection cases came from contact with infected pigs (NiV) or horses (HeV), in the more recent outbreaks of NiV both food-borne and human-to-human transmission were reported.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37529329",
                    "offsetInBeginSection": 1184,
                    "offsetInEndSection": 1374,
                    "text": "During the NiV-B outbreaks in Bangladesh, following initial spillover thought to be through the consumption of date palm sap, the spread of infection was largely human-to-human transmission.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26060997",
                    "offsetInBeginSection": 137,
                    "offsetInEndSection": 286,
                    "text": "To date, HeV has spilled over from flying-foxes to horses on 51 known occasions, and from infected horses to close-contact humans on seven occasions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27770493",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 274,
                    "text": "Hendra virus (HeV) causes potentially fatal respiratory and/or neurological disease in both horses and humans. Although Australian flying-foxes of the genus Pteropus have been identified as reservoir hosts, the precise mechanism of HeV transmission has yet to be elucidated.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the transmission mechanism of the Hendra virus in humans?",
            "type": "summary",
            "id": "65f846bfc4010b4d78000045",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36168114",
                "http://www.ncbi.nlm.nih.gov/pubmed/36537591",
                "http://www.ncbi.nlm.nih.gov/pubmed/36607374",
                "http://www.ncbi.nlm.nih.gov/pubmed/36252945",
                "http://www.ncbi.nlm.nih.gov/pubmed/37501758",
                "http://www.ncbi.nlm.nih.gov/pubmed/33741056",
                "http://www.ncbi.nlm.nih.gov/pubmed/34046042",
                "http://www.ncbi.nlm.nih.gov/pubmed/36549759",
                "http://www.ncbi.nlm.nih.gov/pubmed/34802545",
                "http://www.ncbi.nlm.nih.gov/pubmed/34802543"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36168114",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "text": "VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a newly recognised adult-onset multisystem autoinflammatory disease caused by a somatic mutation in the",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36537591",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 279,
                    "text": "VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently described, late-onset, acquired autoinflammatory disorder caused by mutations in the  This review describes the discovery of VEXAS, relevant genetic causes and immunopathology of the disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36607374",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 205,
                    "text": "VEXAS (vacuoles, E1 enzyme, X-LINKED, autoinflammatory, somatic) syndrome is a complex inflammatory disease associated with somatic mutations of the ubiquitin-like modifier activating enzyme 1 (UBA1) gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36252945",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "text": "VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is an adult-onset autoinflammatory disease caused by somatic UBA1 mutations first described in 2020.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37501758",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 325,
                    "text": "VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly defined refractory adult-onset autoinflammatory syndrome caused by somatic mutations in the ubiquitin-like modifier-activating enzyme 1 (UBA1) gene in hematopoietic stem and progenitor cells, resulting in a shift in UBA1 isoform expression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33741056",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 260,
                    "text": "VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly-described adult-onset inflammatory syndrome characterized by vacuoles in myeloid and erythroid precursor cells and somatic mutations affecting methionine-41 (p.Met41) in UBA1.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34046042",
                    "offsetInBeginSection": 224,
                    "offsetInEndSection": 419,
                    "text": "All patients had myeloid lineage-restricted somatic mutations in UBA1 affecting the Met41 residue of the protein and resulting in decreased cellular ubiquitylation activity and hyperinflammation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36549759",
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 219,
                    "text": "Patients with VEXAS syndrome have a somatic mutation in the UBA1 gene",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34802545",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 415,
                    "text": "VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently described autoinflammatory syndrome characterized by diffuse inflammatory manifestations, predisposition to hematological malignancy, and an association with a high rate of thrombosis. VEXAS is attributed to somatic mutations in the UBA1 gene in hematopoietic stem and progenitor cells with myeloid restriction in mature forms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34802543",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 190,
                    "text": "The identification of the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome as a myeloid-driven inflammatory disease resulting from somatic mutations in the UBA1 gene",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What mutation is associated with the VEXAS syndrome?",
            "type": "factoid",
            "id": "65cfa8f81930410b13000010",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16544441",
                "http://www.ncbi.nlm.nih.gov/pubmed/19198697",
                "http://www.ncbi.nlm.nih.gov/pubmed/30579233",
                "http://www.ncbi.nlm.nih.gov/pubmed/22890981",
                "http://www.ncbi.nlm.nih.gov/pubmed/7982465",
                "http://www.ncbi.nlm.nih.gov/pubmed/15838362",
                "http://www.ncbi.nlm.nih.gov/pubmed/26064237",
                "http://www.ncbi.nlm.nih.gov/pubmed/7509976",
                "http://www.ncbi.nlm.nih.gov/pubmed/26192308",
                "http://www.ncbi.nlm.nih.gov/pubmed/31004470"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16544441",
                    "offsetInBeginSection": 4,
                    "offsetInEndSection": 128,
                    "text": "Atrasentan (Xinlay(R)) is an anti-cancer drug from a new class of agents called selective endothelin-A receptor antagonists.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19198697",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 191,
                    "text": "Ambrisentan is the second selective endothelin-A receptor antagonist to be licensed in Europe, and the first in the United States, for the management of pulmonary arterial hypertension (PAH).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30579233",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 126,
                    "text": "Ambrisentan is a highly selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension (PAH).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22890981",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "text": "Sitaxentan sodium (Thelin) is a once daily, orally bioavailable, highly selective endothelin A receptor antagonist.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7982465",
                    "offsetInBeginSection": 46,
                    "offsetInEndSection": 153,
                    "text": "BQ-123 (cyclo(D-Trp-D-Asp-L-Pro-D-Val-L-Leu-), sodium salt), a selective endothelin ETA receptor antagonist",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15838362",
                    "offsetInBeginSection": 360,
                    "offsetInEndSection": 426,
                    "text": "Atrasentan (a selective endothelin-A receptor antagonist; 6 mg/kg)",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26064237",
                    "offsetInBeginSection": 689,
                    "offsetInEndSection": 753,
                    "text": "Zibotentan or Atrasentan, two selective ETA receptor antagonists",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7509976",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 555,
                    "text": "Until recently, a role for endothelin-1 (ET-1) in the development and/or maintenance of hypertension has been based solely on indirect findings, e.g., elevated circulating levels of peptide. However, with the development of specific ET-1 receptor antagonists it is now possible to examine this relationship directly. The present study describes the hemodynamic effects of systemic infusions of BQ-123, a selective endothelin (ETA)-receptor antagonist, in conscious, freely moving spontaneously hypertensive (SHRs) and normotensive Wistar-Kyoto (WKY) rats.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26192308",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 161,
                    "text": "Endothelin A (ET-A) receptor antagonists including zibotentan and atrasentan, have been suggested as a treatment for castration-resistant prostate cancer (CRPC).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31004470",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "text": "Clazosentan is a selective endothelin A receptor antagonist in development for the prevention and treatment of vasospasm postsubarachnoid hemorrhage.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Please list the selective endothelin A receptor antagonists",
            "type": "list",
            "id": "65f03163dffffb9b6b000005",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33067531"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33067531",
                    "offsetInBeginSection": 295,
                    "offsetInEndSection": 586,
                    "text": "After excluding upd(14)pat and an epimutation (hypermethylation) and a deletion affecting the maternally derived 14q32.2 imprinted region, we performed whole-genome sequencing, revealing that the translocation was generated between noncoding region at 2q11.2 and intron 6 of MEG3 at 14q32.2.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is Kagami-Ogata associated with a deletion in chromosome 14",
            "type": "yesno",
            "id": "660812b4fdcbea915f000006",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37987848",
                "http://www.ncbi.nlm.nih.gov/pubmed/10626556",
                "http://www.ncbi.nlm.nih.gov/pubmed/36515769",
                "http://www.ncbi.nlm.nih.gov/pubmed/9401540",
                "http://www.ncbi.nlm.nih.gov/pubmed/23700380",
                "http://www.ncbi.nlm.nih.gov/pubmed/32555988",
                "http://www.ncbi.nlm.nih.gov/pubmed/24737477",
                "http://www.ncbi.nlm.nih.gov/pubmed/23295077",
                "http://www.ncbi.nlm.nih.gov/pubmed/14749005",
                "http://www.ncbi.nlm.nih.gov/pubmed/22903639"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37987848",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "text": "Prader-Willi syndrome (PWS) is a rare genetic disorder caused by the loss of imprinted gene expression on the paternal chromosome 15q11-q13.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10626556",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 247,
                    "text": "Prader-Willi syndrome is a multigenic disorder with developmental and neurobehavioural abnormalities. There are multiple genetic causes, although all ultimately involve the loss of paternally derived gene expression of chromosome region 15q11-q13.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36515769",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 210,
                    "text": "Prader-Willi syndrome is a complex neurodevelopmental genetic disorder due to lack of paternal expression of critical imprinted genes in the 15q11.2-q13.1 chromosomal region, generally from a paternal deletion.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9401540",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1243,
                    "text": "The genetic basis of Prader-Willi syndrome involves imprinted genes on the proximal long arm of chromosome 15. The basic defect appears to be the absence of function of genes that are normally expressed in a monoallelic fashion only from the paternal chromosome. In 60-70% of patients with Prader-Willi syndrome, the genetic defect is a deletion in the area of 15q11-13 on the paternal chromosome. A further 25-30% of patients with Prader-Willi syndrome do not have paternal deletions, the defect being due to uniparental disomy (UPD) for maternal chromosome 15. Paternal deletions and maternal UPD are functionally equivalent, as they both result in the absence of a paternal contribution to the genome in the 15q11-13 region. The SNRPN (small nuclear ribonucleoprotein-associated polypeptide N) gene has a critical role in the 15q11-13 region, as it is probably part of the putative imprinting centre that regulates the expression of several genes in the Prader-Willi syndrome transcriptional domain. Two further rare causes of Prader-Willi syndrome are imprinting mutations, which are microdeletions or point mutations in the putative imprinting control region, and translocations with their breakpoints in the Prader-Willi syndrome region.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23700380",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 154,
                    "text": "Prader-Willi syndrome (PWS) is caused by the loss of RNA expression from an imprinted region on chromosome 15 that includes SNRPN, SNORD115, and SNORD116.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32555988",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "text": "Prader-Willi syndrome (PWS) is a genetic disorder caused by the absence of gene expression in the 15q11.2-q13 paternal chromosome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24737477",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 300,
                    "text": "Prader-Willi syndrome (PWS) is caused by the lack of expression of genes located on paternal chromosome 15q11-q13. This lack of gene expression may be due to a deletion in this chromosomal segment, to maternal uniparental disomy of chromosome 15, or to a defect in the imprinting center on 15q11-q13.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23295077",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "text": "Prader-Willi syndrome (PWS), most recognized for the hallmark hyperphagia and food preoccupations, is caused by the absence of expression of the paternally active genes in the q11-13 region of chromosome 15.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14749005",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "text": "Prader-Willi syndrome (PWS) is an example of a human genetic disorder that involves imprinting genes on the proximal long arm of chromosome 15 and SNRPN gene as a candidate gene for this syndrome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22903639",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 301,
                    "text": "Prader-Willi syndrome is caused by the lack of paternal contribution for the imprinted 15q11-q13 region that originates through a number of mechanisms such as paternal deletion of 15q11-q13, maternal uniparental disomy, or by an imprinting defect due to epimutations in the paternal imprinting center.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the cause of Prader-Willi Syndrome?",
            "type": "factoid",
            "id": "661d5c97eac11fad33000021",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37256976",
                "http://www.ncbi.nlm.nih.gov/pubmed/37543694",
                "http://www.ncbi.nlm.nih.gov/pubmed/36508589",
                "http://www.ncbi.nlm.nih.gov/pubmed/35671774",
                "http://www.ncbi.nlm.nih.gov/pubmed/32220884",
                "http://www.ncbi.nlm.nih.gov/pubmed/32359497",
                "http://www.ncbi.nlm.nih.gov/pubmed/37803350",
                "http://www.ncbi.nlm.nih.gov/pubmed/35398754",
                "http://www.ncbi.nlm.nih.gov/pubmed/34518313",
                "http://www.ncbi.nlm.nih.gov/pubmed/31836609"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37256976",
                    "offsetInBeginSection": 255,
                    "offsetInEndSection": 1646,
                    "text": "In a phase 3, randomized, double-blind trial, we enrolled eligible pre-, peri-, and postmenopausal women and men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer who had had a relapse or disease progression during or after treatment with an aromatase inhibitor, with or without previous cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor therapy. Patients were randomly assigned in a 1:1 ratio to receive capivasertib plus fulvestrant or placebo plus fulvestrant. The dual primary end point was investigator-assessed progression-free survival assessed both in the overall population and among patients with AKT pathway-altered ( Overall, 708 patients underwent randomization; 289 patients (40.8%) had AKT pathway alterations, and 489 (69.1%) had received a CDK4/6 inhibitor previously for advanced breast cancer. In the overall population, the median progression-free survival was 7.2 months in the capivasertib-fulvestrant group, as compared with 3.6 months in the placebo-fulvestrant group (hazard ratio for progression or death, 0.60; 95% confidence interval [CI], 0.51 to 0.71; P<0.001). In the AKT pathway-altered population, the median progression-free survival was 7.3 months in the capivasertib-fulvestrant group, as compared with 3.1 months in the placebo-fulvestrant group (hazard ratio, 0.50; 95% CI, 0.38 to 0.65; P<0.001).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37543694",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 237,
                    "text": "Combining the selective AKT inhibitor, capivasertib, and SERD, fulvestrant improved PFS in a Phase III clinical trial (CAPItello-291), treating HR+ breast cancer patients following aromatase inhibitors, with or without CDK4/6 inhibitors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36508589",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 380,
                    "text": "In the phase III CAPItello-291 study, the combination of fulvestrant and capivasertib more than doubled progression-free survival compared with fulvestrant alone in patients with hormone receptor-positive, HER2-negative breast cancer who have developed resistance to aromatase inhibitors and CDK4/6 inhibitors. The AKT inhibitor could become a treatment option for these patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35671774",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 230,
                    "text": "Capivasertib, an AKT inhibitor, added to fulvestrant, was previously reported to improve progression-free survival in women with aromatase inhibitor-resistant oestrogen receptor (ER)-positive, HER2-negative advanced breast cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35671774",
                    "offsetInBeginSection": 2636,
                    "offsetInEndSection": 2891,
                    "text": "Updated median progression-free survival was 103 months (95% CI 50-134) in the group receiving fulvestrant plus capivasertib compared with 48 months (31-79) for fulvestrant plus placebo (adjusted hazard ratio [HR] 056 [95% CI 038-081]; two-sided p=00023).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35671774",
                    "offsetInBeginSection": 2892,
                    "offsetInEndSection": 3070,
                    "text": "Median overall survival in the capivasertib versus placebo groups was 293 months (95% CI 237-390) versus 234 months (187-327; adjusted HR 066 [95% CI 045-097]; two-sided p=0035).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32220884",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 272,
                    "text": "AZD5363/capivasertib is a pan-AKT catalytic inhibitor with promising activity in combination with paclitaxel in triple-negative metastatic breast cancer harboring PI3K/AKT-pathway alterations and in estrogen receptor-positive breast cancer in combination with fulvestrant.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32359497",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 59,
                    "text": "Fulvestrant plus capivasertib for metastatic breast cancer.",
                    "beginSection": "title",
                    "endSection": "title"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37803350",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "text": "Triple negative breast cancer (TNBC) is a particularly aggressive and difficult-to-treat subtype of breast cancer that requires the development of novel therapeutic strategies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37803350",
                    "offsetInBeginSection": 1210,
                    "offsetInEndSection": 1411,
                    "text": "Combinations of miR-4649-5p upregulation and PIP5K1C or AKT inhibition, using the pharmacologic inhibitors UNC3230 and capivasertib, respectively, showed additive growth-reducing effects in TNBC cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can capivasertib be used for breast cancer?",
            "type": "yesno",
            "id": "65cfe1d21930410b1300002a",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19153567",
                "http://www.ncbi.nlm.nih.gov/pubmed/32884221",
                "http://www.ncbi.nlm.nih.gov/pubmed/26897480",
                "http://www.ncbi.nlm.nih.gov/pubmed/30963399",
                "http://www.ncbi.nlm.nih.gov/pubmed/26206642",
                "http://www.ncbi.nlm.nih.gov/pubmed/23112544",
                "http://www.ncbi.nlm.nih.gov/pubmed/23739201",
                "http://www.ncbi.nlm.nih.gov/pubmed/29594111",
                "http://www.ncbi.nlm.nih.gov/pubmed/36464124",
                "http://www.ncbi.nlm.nih.gov/pubmed/28435398"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19153567",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 158,
                    "text": "The timing of surgery in rectal cancer treatment after neoadjuvant chemoradiotherapy is debated, mainly because of downsizing and repopulation of tumor cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19153567",
                    "offsetInBeginSection": 159,
                    "offsetInEndSection": 480,
                    "text": "The retrospective analysis of prospectively collected data from a series of patients with locally advanced rectal cancer by Lim et al. has tried to evaluate whether timing of surgery after neoadjuvant chemoradiotherapy has any effect on tumor regression, sphincter preservation, local recurrence rate or overall survival.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19153567",
                    "offsetInBeginSection": 481,
                    "offsetInEndSection": 626,
                    "text": "The study included 397 patients who had received chemoradiotherapy and surgery with different time intervals between the use of these modalities.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32884221",
                    "offsetInBeginSection": 1745,
                    "offsetInEndSection": 1918,
                    "text": "A longer time interval to surgery after neoadjuvant therapy may improve the pCR rate and DFS but has little impact on postoperative complications and sphincter preservation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26897480",
                    "offsetInBeginSection": 983,
                    "offsetInEndSection": 1238,
                    "text": "After adjusting for patient demographic, clinical, tumor, and treatment characteristics, our model determined an inflection point at 56 days after end of radiotherapy associated with the highest likelihood of complete resection and pathologic downstaging.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26897480",
                    "offsetInBeginSection": 1566,
                    "offsetInEndSection": 1806,
                    "text": "This study objectively determined the optimal time for surgery after completion of nCRT for rectal cancer based on completeness of resection and tumor downstaging. Eight weeks appears to be the critical threshold for optimal tumor response.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30963399",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "text": "Increasing the interval from completion of neoadjuvant therapy to surgery beyond 8 weeks is associated with increased response of rectal cancer to neoadjuvant therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30963399",
                    "offsetInBeginSection": 296,
                    "offsetInEndSection": 509,
                    "text": "Patients who presented with a tumor within 15 cm of the anal verge in 2009-2015 were grouped according to the interval between completion of neoadjuvant therapy and surgery: < 8 weeks, 8-12 weeks, and 12-16 weeks.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26206642",
                    "offsetInBeginSection": 1074,
                    "offsetInEndSection": 1735,
                    "text": "An nCRT-surgery interval time >8 weeks was associated with higher odds of pCR (odds ratio [OR] 1.12, 95% CI 1.01 to 1.25) and tumor downstaging (OR 1.11, 95% CI 1.02 to 1.25). The longer time delay was also associated with lower odds of 30-day readmission (OR 0.82, 95% CI 0.70 to 0.92). An nCRT-surgery interval time >8 weeks results in increased odds of pCR, with no evidence of associated increased surgical complications compared with an interval of 6 to 8 weeks. These data support implementation of a lengthened interval after nCRT to optimize the chances of pCR and perhaps add to the possibility of ultimate organ preservation (nonoperative management).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23112544",
                    "offsetInBeginSection": 622,
                    "offsetInEndSection": 802,
                    "text": "Optimal time of surgery after neoadjuvant treatment remained unclear and prospective randomized controlled trial is ongoing. Traditionally, 6-8 wk waiting period was commonly used.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the optimal timing of surgical resection after a neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients?",
            "type": "factoid",
            "id": "65f777d7c4010b4d78000032",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24665290",
                "http://www.ncbi.nlm.nih.gov/pubmed/31088692",
                "http://www.ncbi.nlm.nih.gov/pubmed/32940341",
                "http://www.ncbi.nlm.nih.gov/pubmed/18256988",
                "http://www.ncbi.nlm.nih.gov/pubmed/30229853",
                "http://www.ncbi.nlm.nih.gov/pubmed/26387071",
                "http://www.ncbi.nlm.nih.gov/pubmed/25085837",
                "http://www.ncbi.nlm.nih.gov/pubmed/26979097",
                "http://www.ncbi.nlm.nih.gov/pubmed/30258022",
                "http://www.ncbi.nlm.nih.gov/pubmed/22810605"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665290",
                    "offsetInBeginSection": 140,
                    "offsetInEndSection": 266,
                    "text": "A total of 4% to 5% of MS population are pediatric. Pediatric MS is defined as the appearance of MS before the age of sixteen.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31088692",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 271,
                    "text": "Multiple Sclerosis (MS) is the commonest among inflammatory demyelinating diseases. While the disease prevalence is high in adults, frequency of pediatric onset multiple sclerosis (POMS) is very low in children and particularities in this population have been identified.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32940341",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 374,
                    "text": "Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease of the central nervous system that mostly affects younger adults. However, the first symptoms of MS can appear in children and adolescents before the age of 18, and we call this paediatric MS (PMS). It is estimated that paediatric MS accounts for 3-5% of the general population of patients with MS.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18256988",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 84,
                    "text": "Multiple sclerosis (MS) is being increasingly diagnosed in children and adolescents.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30229853",
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 423,
                    "text": "The incidence of pediatric MS is relatively rare, affecting 0.2 to 0.64/100,000 subjects; cases with MS onset before age 10-12 years, account for less than 1% of all MS cases, while 2.7 to 10.5% of all MS cases worldwide are seen in children <18 years of age, with a strong female preponderance.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26387071",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 124,
                    "text": "Multiple sclerosis (MS) is a demyelinating disease of the CNS occurring in young adults and even in children in 5% of cases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25085837",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1120,
                    "text": "The first episode of central nervous system (CNS) symptoms with a presumed inflammatory demyelinating cause is defined as clinically isolated syndrome (CIS) according to the 2007 consensus of the International Pediatric Multiple Sclerosis Study Group, which developed diagnostic criteria for CNS demyelination disease in children. Using this definition of CIS, we attempted to identify the natural course of pediatric patients with CIS in a single Korean institution and to determine the factors affecting their prognosis. We retrospectively reviewed the medical records of all pediatric patients (age <18 years old) who presented with clinical symptoms of CNS events between 1997 and 2008. We identified 32 patients with CIS. Their mean age with standard deviation was 10.04.1 years. The most common type of presentation of CIS was optic neuritis (ON). Sixteen (16/32, 50%) patients experienced a second demyelinating event. The mean interval between the first event and the recurrent episode was 2120 months. The mean follow-up was 6.11.6 years. Eleven (34%) patients developed childhood onset multiple sclerosis (MS).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26979097",
                    "offsetInBeginSection": 630,
                    "offsetInEndSection": 897,
                    "text": "Out of 4536 multiple sclerosis patients referred to the authors' center, 221 patients (4.8%) had multiple sclerosis starting at the age of 16 or less (11 true-childhood multiple sclerosis vs 210 juvenile-onset multiple sclerosis); the female to male ratio was 4.81:1.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30258022",
                    "offsetInBeginSection": 1085,
                    "offsetInEndSection": 1396,
                    "text": "Depending on the administrative case definition used, in 2014, the annual age-standardized annual incidence of MS in the pediatric population ranged from 0.99 to 1.24 per 100,000 population, and the age-standardized prevalence ranged from 4.03 to 6.8 per 100,000 population. The prevalence of MS rose over time.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22810605",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "text": "Multiple sclerosis (MS) onset in childhood occurs in a small proportion of individuals with the disease, although the precise incidence of pediatric MS is unknown.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Are children affected by multiple sclerosis?",
            "type": "factoid",
            "id": "6614f672fdcbea915f000042",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/38035006",
                "http://www.ncbi.nlm.nih.gov/pubmed/38017349",
                "http://www.ncbi.nlm.nih.gov/pubmed/37568516",
                "http://www.ncbi.nlm.nih.gov/pubmed/35622206",
                "http://www.ncbi.nlm.nih.gov/pubmed/30918097",
                "http://www.ncbi.nlm.nih.gov/pubmed/28964591",
                "http://www.ncbi.nlm.nih.gov/pubmed/37714122",
                "http://www.ncbi.nlm.nih.gov/pubmed/37635789"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38035006",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 107,
                    "text": "Trofinetide is the first drug approved by the FDA to treat Rett Syndrome in children aged 2 years or above.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38017349",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 111,
                    "text": "Trofinetide is the first drug to be approved for the treatment of Rett syndrome, a neurodevelopmental disorder.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37568516",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 369,
                    "text": "Rett syndrome (RTT) is a rare disability causing female-oriented pediatric neurodevelopmental unmet medical need. RTT was recognized in 1966. However, over the past 56 years, the United States Food and Drug Administration (USFDA) has authorized no effective treatment for RTT. Recently, Trofinetide was approved by the USFDA on 10 March 2023 as the first RTT treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35622206",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 220,
                    "text": "Trofinetide, a synthetic analog of tripeptide glycine-proline-glutamate, is an investigational agent for the treatment of Rett syndrome, a neurodevelopmental disorder with affected individuals requiring lifelong support.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30918097",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 269,
                    "text": "To determine safety, tolerability, and pharmacokinetics of trofinetide and evaluate its efficacy in female children/adolescents with Rett syndrome (RTT), a debilitating neurodevelopmental condition for which no pharmacotherapies directed at core features are available.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28964591",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 274,
                    "text": "This study aimed to determine the safety and tolerability of trofinetide and to evaluate efficacy measures in adolescent and adult females with Rett syndrome, a serious and debilitating neurodevelopmental condition for which no therapies are available for its core features.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37714122",
                    "offsetInBeginSection": 997,
                    "offsetInEndSection": 1230,
                    "text": "There are drugs in the research phase such as oxytocin, vasopressin and even some developed for specific entities related to autism such as arbaclofen in Fragile X and Trofinetide that has just been approved for use in Rett syndrome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37635789",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 230,
                    "text": "The Rett Syndrome Behaviour Questionnaire (RSBQ), which is completed by the caregiver, is one of the most widely used efficacy measures in clinical studies of Rett syndrome (RTT) due to its specificity to the core features of RTT.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37635789",
                    "offsetInBeginSection": 964,
                    "offsetInEndSection": 1187,
                    "text": "In LAVENDER, the FDA-approved drug trofinetide significantly improved the RSBQ total score over placebo in girls and women with RTT and change from baseline for all RSBQ subscores were directionally in favor of trofinetide.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What disease can be treated with Trofinetide?",
            "type": "factoid",
            "id": "65d134bd1930410b13000037",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35962648",
                "http://www.ncbi.nlm.nih.gov/pubmed/32184665",
                "http://www.ncbi.nlm.nih.gov/pubmed/25575824",
                "http://www.ncbi.nlm.nih.gov/pubmed/31070668",
                "http://www.ncbi.nlm.nih.gov/pubmed/36382087",
                "http://www.ncbi.nlm.nih.gov/pubmed/36232827",
                "http://www.ncbi.nlm.nih.gov/pubmed/37217357"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35962648",
                    "offsetInBeginSection": 353,
                    "offsetInEndSection": 933,
                    "text": "Following curative-intent surgery for cancer, the presence of ctDNA is highly predictive of early disease recurrence, while in metastatic cancer an early decline in ctDNA following the initiation of treatment is predictive of good outcome. Compared with protein biomarkers, ctDNA provides greater cancer specificity and sensitivity for detecting early recurrent/metastatic disease. Thus, in patients with surgically resected colorectal cancer, multiple studies have shown that ctDNA is superior to carcinoembryonic antigen (CEA) in detecting residual disease and early recurrence.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32184665",
                    "offsetInBeginSection": 1710,
                    "offsetInEndSection": 2049,
                    "text": "Our data demonstrate that the genomic profile obtained from ctDNA is comparable with the genomic profile obtained from metastatic liver tumors. Furthermore, our study also show that pre-surgery ctDNA levels are positively correlated with tumor burden. In addition, pre-surgery ctDNA, cfDNA and CEA levels have predictive value for relapse.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25575824",
                    "offsetInBeginSection": 1165,
                    "offsetInEndSection": 1405,
                    "text": "The multiplexed SCODA mutation enrichment and detection method can be applied to mutation profiling and quantitation of ctDNA, and is likely to have particular utility in the metastatic setting, including patients undergoing metastatectomy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31070668",
                    "offsetInBeginSection": 1325,
                    "offsetInEndSection": 1420,
                    "text": "Positive ctDNA preceded radiologic and clinical evidence of recurrence by a median of 3 months.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31070668",
                    "offsetInBeginSection": 1421,
                    "offsetInEndSection": 1569,
                    "text": "Of the 45 patients with negative ctDNA throughout follow-up, none (0%; 95% CI, 0%-7.9%) experienced a relapse, with a median follow-up of 49 months.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36382087",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 186,
                    "text": "Identification of circulating tumor DNA (ctDNA) following curative intent therapies is a surrogate for microscopic residual disease for patients with metastatic colorectal cancer (mCRC).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36232827",
                    "offsetInBeginSection": 1393,
                    "offsetInEndSection": 1541,
                    "text": "Our results indicate that MRD detection using the tissue CGP-informed ctDNA assay is prognostic of survival outcomes in patients with resected mCRC.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36382087",
                    "offsetInBeginSection": 519,
                    "offsetInEndSection": 771,
                    "text": "Patients with liver-limited, MSS mCRC and with detected ctDNA after complete resection of all known tumors and standard-of-care therapy were treated with 1200 mg of BA intravenously every 14 days for six doses. The primary endpoint was ctDNA clearance.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36382087",
                    "offsetInBeginSection": 1084,
                    "offsetInEndSection": 1119,
                    "text": "None of the patients cleared ctDNA.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36382087",
                    "offsetInBeginSection": 1467,
                    "offsetInEndSection": 1695,
                    "text": "Treatment with BA in patients with ctDNA-detected, liver-limited mCRC did not clear ctDNA and was associated with large-volume recurrence, highlighting the potential context-specific complexity of dual TGF- and PD-L1 inhibition.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which is the most reliable liquid biopsy technique after complete resection of  colorectal cancer metastases?",
            "type": "factoid",
            "id": "65f7789dc4010b4d78000034",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22056174",
                "http://www.ncbi.nlm.nih.gov/pubmed/28659681",
                "http://www.ncbi.nlm.nih.gov/pubmed/30574000",
                "http://www.ncbi.nlm.nih.gov/pubmed/19461343",
                "http://www.ncbi.nlm.nih.gov/pubmed/22016280",
                "http://www.ncbi.nlm.nih.gov/pubmed/2426317",
                "http://www.ncbi.nlm.nih.gov/pubmed/22007570",
                "http://www.ncbi.nlm.nih.gov/pubmed/16552022",
                "http://www.ncbi.nlm.nih.gov/pubmed/500878",
                "http://www.ncbi.nlm.nih.gov/pubmed/26588334"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22056174",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "text": "The trichilemmal cyst, also called pilar cyst, is a dermal epithelial cyst originating from the pilar follicle. It usually occurs in the scalp.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28659681",
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 181,
                    "text": "These cysts are observed on the scalp most commonly in females.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30574000",
                    "offsetInBeginSection": 349,
                    "offsetInEndSection": 436,
                    "text": "Pilar cysts are adnexal skin lesions most commonly found in the scalp of elderly women.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19461343",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 81,
                    "text": "Trichilemmal cyst (TC) is an adnexal skin tumor that usually occurs on the scalp.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22016280",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 124,
                    "text": "Proliferating trichilemmal (pilar) cysts, also known as pilar tumors, are most commonly found on the scalp of elderly women.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2426317",
                    "offsetInBeginSection": 152,
                    "offsetInEndSection": 259,
                    "text": "Proliferating trichilemmal cysts characteristically occur on the scalp and occasionally on the upper trunk.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22007570",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 105,
                    "text": "Malignant proliferating trichilemmal cyst is a rare tumour usually located on the scalp of elderly women.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16552022",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "text": "Proliferating trichilemmal cysts, also known as pilar tumors, are slow-growing lobulated masses most commonly found on the scalp of elderly women.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/500878",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "text": "Proliferating pilar cysts are rare tumors which occur most commonly on the scalp of elderly women.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26588334",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 78,
                    "text": "Pilar cysts are common squamous-lined cysts that typically occur on the scalp.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Where is the tumor of follicular infundibulum usually found?",
            "type": "factoid",
            "id": "65f59e46c4010b4d78000015",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15057263",
                "http://www.ncbi.nlm.nih.gov/pubmed/20151201",
                "http://www.ncbi.nlm.nih.gov/pubmed/30864096",
                "http://www.ncbi.nlm.nih.gov/pubmed/35854334",
                "http://www.ncbi.nlm.nih.gov/pubmed/25375236",
                "http://www.ncbi.nlm.nih.gov/pubmed/7584088",
                "http://www.ncbi.nlm.nih.gov/pubmed/22348550",
                "http://www.ncbi.nlm.nih.gov/pubmed/14728985",
                "http://www.ncbi.nlm.nih.gov/pubmed/23910161",
                "http://www.ncbi.nlm.nih.gov/pubmed/33055427"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15057263",
                    "offsetInBeginSection": 274,
                    "offsetInEndSection": 1322,
                    "text": "Here, we show that a liver-directed PAH gene transfer brought about long-term correction of hyperphenylalaninemia and behavioral improvement in a mouse model of PKU. A recombinant adeno-associated virus (AAV) vector carrying the murine PAH cDNA was constructed and administered to PAH-deficient mice (strain PAH(enu2)) via the portal vein. Within 2 weeks of treatment, the hyperphenylalaninemic phenotype improved and completely normalized in the animals treated with higher vector doses. The therapeutic effect persisted for 40 weeks in male mice, while serum phenylalanine concentrations in female animals gradually returned to pretreatment levels. Notably, this long-term correction of hyperphenylalaninemia was associated with a reversal of hypoactivity observed in PAH(enu2) mice. While locomotory activity over 24 h and exploratory behavior were significantly decreased in untreated PAH(enu2) mice compared with the age-matched controls, these indices were completely normalized in 12-month-old male PKU mice with lowered serum phenylalanine.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20151201",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1396,
                    "text": "Current therapy for phenylketonuria (PKU) consists of life-long dietary restriction of phenylalanine (Phe), which presents problems of adherence for patients. Alternative therapies under investigation include, among others, the use of gene therapy to provide copies of wild-type, non-mutant, phenylalanine hydroxylase (PAH) enzyme. Expression of PAH in both liver (the usual metabolic source of this enzyme) and skeletal muscle is under investigation. Liver gene therapy, using a viral vector based on the adeno-associated viruses (AAVs), provided effective clearance of serum Phe that was sustained for 1 year in some mice. In order for PAH expression to be effective in skeletal muscle, the essential metabolic cofactor, tetrahydrobiopterin (BH(4)), must also be provided, either by supplementation or gene therapy. Both these approaches were effective. When transgenic PKU mice that constitutively expressed PAH in muscle were given intraperitoneal supplementation with BH(4), this produced (transient) effective clearance of Phe to normal levels. In addition, use of an AAV vector containing the genes for PAH, and for two key synthetic enzymes for BH(4), provided substantial and long-lasting correction (more than 1 year) of blood Phe levels when injected into skeletal muscle of PKU mice. These two strategies provide promising treatment alternatives for the management of PKU in patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30864096",
                    "offsetInBeginSection": 870,
                    "offsetInEndSection": 1772,
                    "text": "For over four decades the only available treatment was a very restrictive low phenylalanine diet. This changed in 2007 with the approval of cofactor therapy which is effective in up to 55% of patients depending on the population. Cofactor therapy typically is more effective in patients with milder forms of the disease and less effective in classical PKU. A new therapy has just been approved that can be effective in all patients with PAH deficiency regardless of their degree of enzyme deficiency or the severity of their phenotype. This article reviews the mainstay therapy, adjunct enzyme cofactor therapy, and the newly available enzyme substitution therapy for hyperphenylalaninemia. It also provides an outlook on emerging approaches for hyperphenylalaninemia treatment such as recruiting the microbiome into the therapeutic endeavor as well as therapies under development such as gene therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35854334",
                    "offsetInBeginSection": 1303,
                    "offsetInEndSection": 1965,
                    "text": "Additional treatments include the casein glycomacropeptide (GMP), which contains very limited aromatic amino acids and may improve immunological function, and large neutral amino acid (LNAA) supplementation to prevent plasma Phe transport into the brain. The synthetic BH4 analog, sapropterin hydrochloride (i.e., Kuvan, BioMarin), is another potential treatment that activates residual PAH, thus decreasing Phe concentrations in the blood of PKU patients. Moreover, daily subcutaneous injection of pegylated Phe ammonia-lyase (i.e., pegvaliase; PALYNZIQ, BioMarin) has promised gene therapy in recent clinical trials, and mRNA approaches are also being studied.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25375236",
                    "offsetInBeginSection": 383,
                    "offsetInEndSection": 1005,
                    "text": "Additions to treatment include new, more palatable foods based on glycomacropeptide that contains very limited amount of aromatic amino acids, the administration of large neutral amino acids to prevent phenylalanine entry into the brain or tetrahydropterina cofactor capable of increasing residual activity of phenylalanine hydroxylase. Moreover, human trials have recently been performed with subcutaneous administration of phenylalanine ammonia-lyase, and further efforts are underway to develop an oral therapy containing phenylanine ammonia-lyase. Gene therapy also seems to be a promising approach in the near future.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7584088",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "text": "Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer.",
                    "beginSection": "title",
                    "endSection": "title"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7584088",
                    "offsetInBeginSection": 172,
                    "offsetInEndSection": 881,
                    "text": "A recombinant adenoviral vector containing the human PAH cDNA was constructed and administered to PAH-deficient mice (strain PAHenu2). The hyperphenylalaninemic phenotype of these animals was completely normalized within 1 week of treatment. Although this therapeutic effect did not persist, analysis of the relationship between hepatic PAH activity and serum phenylalanine levels indicated that only 10-20% of normal enzymatic activity in the mouse liver is sufficient to restore normal serum phenylalanine levels. These results demonstrate that PKU and other metabolic disorders secondary to hepatic deficiencies can be completely corrected by gene therapy when more persistent vector systems are developed.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22348550",
                    "offsetInBeginSection": 590,
                    "offsetInEndSection": 1437,
                    "text": "We explored a gene therapy approach aimed at long-term correction of the pathologic phenotype of BTBR-PahEnu2 mice, a mouse model of PKU. To this aim, we developed a helper-dependent adenoviral (HD-Ad) vector expressing phenylalanine hydroxylase and administered it to 3-week-old PKU mice. This resulted in complete normalization of Phe and Tyr levels and reversal of coat hypopigmentation that lasted throughout the observation period of six months. The spatial learning deficits observed in PKU mice were also reversed and hippocampus levels of the N-methyl-D-Aspartate and 2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl) propanoic acid receptor subunits returned to normal. Long-term potentiation, which is impaired in PKU mice, was also restored by treatment. Therefore, HD-Ad vector-mediated gene therapy is a promising approach to PKU treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14728985",
                    "offsetInBeginSection": 639,
                    "offsetInEndSection": 902,
                    "text": "Here we summarize past present nonviral and viral gene transfer approaches, both in vitro studies and preclinical animal trials, to delivering the PAH gene into liver or other organs as potential alternatives to life-long phenylalanine-restricted dietary therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23910161",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 577,
                    "text": "Low phenylalanine diet has been the key treatment of phenylketonuria for more than 50years, allowing efficient management of thousands of PKU patients to date. However, non-compliance exists, mainly after adolescence. A medication for PKU received approval in Europe in 2009 (sapropterine dihydrochloride or Kuvan()) and can benefit to patients responsive to this drug. Other treatment options are available in some countries (glycomacropeptides, large neutral amino acids) or are currently under investigation (phenylalanine ammonia lyase, chaperones molecules, gene therapy).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the current approaches for gene therapy for Phenylketonuria (PKU)?",
            "type": "list",
            "id": "661d4aa3eac11fad33000019",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15070486",
                "http://www.ncbi.nlm.nih.gov/pubmed/17874730",
                "http://www.ncbi.nlm.nih.gov/pubmed/22106023",
                "http://www.ncbi.nlm.nih.gov/pubmed/20236870",
                "http://www.ncbi.nlm.nih.gov/pubmed/31333401",
                "http://www.ncbi.nlm.nih.gov/pubmed/10542899",
                "http://www.ncbi.nlm.nih.gov/pubmed/20473347",
                "http://www.ncbi.nlm.nih.gov/pubmed/31362710",
                "http://www.ncbi.nlm.nih.gov/pubmed/27491552",
                "http://www.ncbi.nlm.nih.gov/pubmed/12112735"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15070486",
                    "offsetInBeginSection": 176,
                    "offsetInEndSection": 306,
                    "text": "The majority of cases of sporadic Rett syndrome are caused by mutations in the gene encoding methyl-CpG-binding protein 2 (MeCP2).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17874730",
                    "offsetInBeginSection": 285,
                    "offsetInEndSection": 582,
                    "text": "Rett syndrome is the first pervasive developmental disorder with a known genetic cause. The majority of cases are caused by de novo mutations in an X-linked MECP2 gene. Its product, methyl-CpG-binding protein 2, plays an important role in the regulation of gene expression and chromatin structure.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22106023",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "Rett syndrome is a rare neurological disorder affecting girls and usually caused by a mutation on the MECP2 gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20236870",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "Rett syndrome, a neurodevelopmental disorder affecting mainly females, is caused by a mutation of the MeCP2 gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31333401",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "text": "Rett syndrome (RTT) is an X-linked neurodevelopmental disorder caused mainly by mutations in the",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10542899",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "text": "Rett's syndrome is a neurodevelopmental disorder which is caused by a mutation on the x-chromosome",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20473347",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "text": "Rett syndrome is an X-linked autism-spectrum disorder caused by mutations in MECP2, encoding methyl CpG-binding protein 2.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31362710",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 95,
                    "text": "Rett syndrome is a neurodevelopmental disorder caused by a mutation in the X-linked MECP2 gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27491552",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 91,
                    "text": "Rett syndrome is a rare neurodevelopmental disorder caused by a mutation in the MECP2 gene.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12112735",
                    "offsetInBeginSection": 308,
                    "offsetInEndSection": 449,
                    "text": "Recent studies have shown that mutations in the X-linked methyl CpG binding protein 2 gene (MeCP2) cause most typical cases of Rett syndrome.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the cause of Rett Syndrome?",
            "type": "factoid",
            "id": "661d4c2eeac11fad3300001a",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36250361",
                "http://www.ncbi.nlm.nih.gov/pubmed/24829543",
                "http://www.ncbi.nlm.nih.gov/pubmed/25083060",
                "http://www.ncbi.nlm.nih.gov/pubmed/26528001",
                "http://www.ncbi.nlm.nih.gov/pubmed/35431513",
                "http://www.ncbi.nlm.nih.gov/pubmed/34631603",
                "http://www.ncbi.nlm.nih.gov/pubmed/35145413",
                "http://www.ncbi.nlm.nih.gov/pubmed/12643225",
                "http://www.ncbi.nlm.nih.gov/pubmed/34093447",
                "http://www.ncbi.nlm.nih.gov/pubmed/21537962"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36250361",
                    "offsetInBeginSection": 142,
                    "offsetInEndSection": 301,
                    "text": "The etiology of IBS is multifactorial, including abnormal gut-brain interactions, visceral hypersensitivity, altered colon motility, and psychological factors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24829543",
                    "offsetInBeginSection": 280,
                    "offsetInEndSection": 639,
                    "text": "The pathophysiology of IBS is poorly understood and is currently thought to represent a complex interplay among the gut microbiota, low-grade inflammation, impaired mucosal barrier function, visceral hypersensitivity, gut motility, and alterations in the gut-brain axis. In any individual patient, 1 or more of these factors may interact to generate symptoms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25083060",
                    "offsetInBeginSection": 362,
                    "offsetInEndSection": 721,
                    "text": "Alteration in neurohumoral mechanisms and psychological factors, bacterial overgrowth, genetic factors, gut motility, visceral hypersensitivity, and immune system factors are currently believed to influence the pathogenesis of IBS. It is possible that there is an interaction of one or more of these etiologic factors leading to heterogeneous symptoms of IBS.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26528001",
                    "offsetInBeginSection": 156,
                    "offsetInEndSection": 624,
                    "text": "The mechanisms underlying the symptoms of this condition are poorly understood. Considered initially as the consequence of abnormal gut motility, visceral hypersensitivity, psychosocial factors and brain-gut axis dysfunction, IBS is now acknowledged as a multifactorial disorder. Specific peripheral mechanisms are involved, including mucosal immune activation, increased intestinal permeability, entero-endocrine cell products, an excess of bile acids, gut dysbiosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35431513",
                    "offsetInBeginSection": 556,
                    "offsetInEndSection": 752,
                    "text": "Proposed mechanisms involved in its pathogenesis include increased intestinal permeability, changes in the immune system, visceral hypersensitivity, impaired gut motility, and emotional disorders.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35431513",
                    "offsetInBeginSection": 753,
                    "offsetInEndSection": 979,
                    "text": "Recently, accumulating evidence has highlighted the important role of the gut microbiota in the development of IBS. Microbial dysbiosis within the gut is thought to contribute to all aspects of its multifactorial pathogenesis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34631603",
                    "offsetInBeginSection": 291,
                    "offsetInEndSection": 378,
                    "text": "Gut microbiota and its metabolites are proposed as possible etiological factors of IBS.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34631603",
                    "offsetInBeginSection": 621,
                    "offsetInEndSection": 825,
                    "text": "Metabolites-focused research has identified multiple microbial targets relevant to IBS patients, important roles of microbiota-derived metabolites in the development of IBS symptoms have been established.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35145413",
                    "offsetInBeginSection": 463,
                    "offsetInEndSection": 812,
                    "text": "These disorders are heterogeneous and are intertwined with several proposed pathophysiological mechanisms, such as altered gut motility, intestinal barrier dysfunction, gut immune dysfunction, visceral hypersensitivity, altered GI secretion, presence and degree of bile acid malabsorption, microbial dysbiosis, and alterations to the gut-brain axis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12643225",
                    "offsetInBeginSection": 198,
                    "offsetInEndSection": 1078,
                    "text": "Visceral hypersensitivity has been recognized as a characteristic of patients with FGD, especially in patients with irritable bowel syndrome (IBS). Visceral afferent input is modulated by a variety of mechanisms, operating between the gastrointestinal tract and the brain. Dysfunction of these regulatory mechanisms could distort gastrointestinal perceptions. Recent findings suggest that in the majority of cases of IBS the primary abnormality may be at the periphery with alterations of the motor and secretory sensory activity. Although imaging techniques indicate that there are also differences in cortical activation. Furthermore, selective serotonin reuptake inhibitors may benefit FGD. Recent pharmacological studies suggest that 5-HT3 antagonist such as alosetron and cilansetron, and 5-HT4 agonist such as legaserod and prucalopride may also have a potential use in FGD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Mechanisms that explain irritable bowel syndrome.",
            "type": "summary",
            "id": "6616576afdcbea915f000050",
            "ideal_answer": ""
        }
    ]
}